internal_id,abstract_title,session_title,session_type,keywords.diseases,keywords.indications,keywords.drug_classes,keywords.primary_drugs,keywords.secondary_drugs,keywords.comparator_drugs,keywords.firms,keywords.patient_subgroups,keywords.nct_and_acronyms,priority,Comment - SD/AS
13,Moderator,ctDNA Guiding Treatment of Colorectal Cancer: Ready for Primetime?,Case-Based Panel,['colorectal cancer'],['colorectal cancer'],[],[],[],[],[],[],,Low,1
14,Translational Researcher Perspective,ctDNA Guiding Treatment of Colorectal Cancer: Ready for Primetime?,Case-Based Panel,['colorectal cancer'],['colorectal cancer'],[],[],[],[],[],[],,Low,1
15,Medical Oncologist Perspective,ctDNA Guiding Treatment of Colorectal Cancer: Ready for Primetime?,Case-Based Panel,['colorectal cancer'],['colorectal cancer'],[],[],[],[],[],[],,Low,1
16,Hematologist-Oncologist Perspective,ctDNA Guiding Treatment of Colorectal Cancer: Ready for Primetime?,Case-Based Panel,['colorectal cancer'],['colorectal cancer'],[],[],[],[],[],[],,Low,1
17,Panel Question and Answer,ctDNA Guiding Treatment of Colorectal Cancer: Ready for Primetime?,Case-Based Panel,['colorectal cancer'],['colorectal cancer'],[],[],[],[],[],[],,Low,1
58,Dosing decitabine and venetoclax for terminal differentiation to improve outcomes in TP53 mutant MDS and AML.,"Hematologic Malignancies - Leukemia, Myelodysplastic Syndromes, and Allotransplant",Rapid Oral Abstract Session,"['myelodysplastic syndrome', 'acute myeloid leukemia']","['tp53 mutant myelodysplastic syndrome', 'tp53 mutant acute myeloid leukemia']","['dnmt inhibitor', 'bcl2 inhibitor']","['decitabine', 'venetoclax']",[],[],[],[],,High,1
74,"Empowering young-onset colorectal cancer patients with an accessible, self-navigable online platform for universal germline testing.",Quality Care/Health Services Research,Oral Abstract Session,['colorectal cancer'],['young onset colorectal cancer'],[],[],[],[],[],['young'],,Low,1
75,"Real-world social determinants of health (SDOH) and outcomes of early-onset colorectal cancer (EO-CRC): An analysis of a large, nationally representative US community oncology network.",Quality Care/Health Services Research,Oral Abstract Session,['colorectal cancer'],['early onset colorectal cancer'],[],[],[],[],[],['early onset'],,Low,1
76,"Too Soon, Too Fast: Let's Tackle Early-Onset Colorectal Cancer at Last",Quality Care/Health Services Research,Oral Abstract Session,['colorectal cancer'],['early onset colorectal cancer'],[],[],[],[],[],['early onset'],,Low,1
110,"Phase I study of iza-bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with driver genomic alterations (GA) outside of classic EGFR mutations.",Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology,Oral Abstract Session,['non-small cell lung cancer'],['locally advanced/metastatic non-small cell lung cancer'],['egfr/her3 antibody drug conjugate'],['iza-bren'],[],[],"['systimmune', 'baili-bio pharmaceutical']","['metastatic', 'locally advanced']",,Low,1
130,A phase II study of asandeutertinib (TY-9591) in advanced NSCLC patients with EGFR-positive mutations and brain metastases.,Central Nervous System Tumors,Oral Abstract Session,"['secondary brain cancer', 'non-small cell lung cancer']","['brain metastases', 'egfr-positive mutant advanced non-small cell lung cancer']",['egfr inhibitor'],['asandeutertinib'],[],[],['tyk medicines'],['advanced'],,Low,1
131,"Patritumab deruxtecan (HER3-DXd) in active brain metastases (BM) from metastatic breast (mBC) and non‚Äìsmall cell lung cancers (aNSCLC), and leptomeningeal disease (LMD) from advanced solid tumors: Results from the TUXEDO-3 phase II trial.",Central Nervous System Tumors,Oral Abstract Session,"['secondary brain cancer', 'leptomeningeal disease', 'non-small cell lung cancer', 'breast cancer']","['advanced non-small cell lung cancer', 'leptomeningeal disease', 'brain metastases', 'metastatic breast cancer']",['her3 antibody drug conjugate'],['patritumab deruxtecan'],[],[],['daiichi sankyo'],"['advanced', 'metastatic']",,Low,1
149,First-line encorafenib + cetuximab + mFOLFOX6 in BRAF V600E-mutant metastatic colorectal cancer (BREAKWATER): Progression-free survival and updated overall survival analyses.,Gastrointestinal Cancer - Colorectal and Anal,Oral Abstract Session,['colorectal cancer'],['first-line braf v600e-mutant metastatic colorectal cancer'],"['egfr inhibitor', 'braf inhibitor']","['cetuximab', 'mfolfox6', 'encorafenib']",[],[],"['merck', 'pfizer', 'ono pharmaceutical', 'eli lilly']","['braf v600e-mutant', 'first-line', 'metastatic']",,Low,1
150,Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) or NIVO monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Expanded analyses from CheckMate 8HW.,Gastrointestinal Cancer - Colorectal and Anal,Oral Abstract Session,['colorectal cancer'],['microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer'],"['pd1 inhibitor', 'ctla4 inhibitor']","['nivolumab', 'ipilimumab']",[],['nivolumab'],"['bristol-myers squibb', 'ono pharmaceutical']","['dmmr', 'msi-h', 'metastatic']",,Low,1
159,Long-term safety and efficacy of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreaK 101 (phase 1b).,Gastrointestinal Cancer - Colorectal and Anal,Oral Abstract Session,['colorectal cancer'],['previously treated kras g12c-mutant metastatic colorectal cancer'],"['kras g12c inhibitor', 'nucleoside metabolic inhibitor', 'folic acid analog', 'egfr inhibitor', 'top1 inhibitor']","['folfiri', 'sotorasib', 'panitumumab']",[],[],['amgen'],"['kras g12c-mutant', 'previously treated', 'metastatic']",,High,1
152,Precision Oncology in the First-Line Setting of Colorectal Cancer,Gastrointestinal Cancer - Colorectal and Anal,Oral Abstract Session,['colorectal cancer'],['first-line colorectal cancer'],[],[],[],[],[],['first-line'],,Low,1
153,Panel Question and Answer,Gastrointestinal Cancer - Colorectal and Anal,Oral Abstract Session,"['anal cancer', 'colorectal cancer']","['colorectal cancer', 'anal cancer']",[],[],[],[],[],[],,Low,1
155,Tissue-free circulating tumor DNA assay and patient outcome in a phase III trial of FOLFOX-based adjuvant chemotherapy (Alliance N0147).,Gastrointestinal Cancer - Colorectal and Anal,Oral Abstract Session,"['colorectal cancer', 'anal cancer']","['colorectal cancer', 'anal cancer']","['folic acid analog', 'nucleoside metabolic inhibitor', 'dna synthesis inhibitor']",['folfox'],[],[],['guardant health'],[],,Low,1
157,Refining Perioperative Selection and Treatment,Gastrointestinal Cancer - Colorectal and Anal,Oral Abstract Session,"['anal cancer', 'colorectal cancer']","['colorectal cancer', 'anal cancer']",[],[],[],[],[],[],,Low,1
158,Panel Question and Answer,Gastrointestinal Cancer - Colorectal and Anal,Oral Abstract Session,"['anal cancer', 'colorectal cancer']","['colorectal cancer', 'anal cancer']",[],[],[],[],[],[],,Low,1
160,"Efficacy and safety of olomorasib, a second-generation KRAS G12C inhibitor, plus cetuximab in KRAS G12C-mutant advanced colorectal cancer.",Gastrointestinal Cancer - Colorectal and Anal,Oral Abstract Session,['colorectal cancer'],['kras g12c-mutant advanced colorectal cancer'],"['kras g12c inhibitor', 'egfr targeted therapy']","['olomorasib', 'cetuximab']",[],[],"['eli lilly', 'merck sharp & dohme']","['kras g12c-mutant', 'advanced']",,High,1
161,The KRAS G12C inhibitor MK-1084 for KRAS G12C‚Äìmutated advanced colorectal cancer (CRC): Results from KANDLELIT-001.,Gastrointestinal Cancer - Colorectal and Anal,Oral Abstract Session,['colorectal cancer'],['kras g12c-mutated advanced colorectal cancer'],['kras g12c inhibitor'],['mk-1084'],[],[],['merck'],"['kras g12c-mutant', 'advanced']",,High,1
162,KRAS G12C: From First to Next Generation,Gastrointestinal Cancer - Colorectal and Anal,Oral Abstract Session,"['anal cancer', 'colorectal cancer']","['colorectal cancer', 'anal cancer']",[],[],[],[],[],[],,High,1
251,Efficacy and safety of first-line ibrutinib plus venetoclax in patients with mantle cell lymphoma (MCL) who were older or had TP53 mutations in the SYMPATICO study.,Hematologic Malignancies - Lymphoma and Chronic Lymphocytic Leukemia,Rapid Oral Abstract Session,['mantle cell lymphoma'],['elderly first line tp53-mutant mantle cell lymphoma'],"['btk inhibitor', 'bcl2 inhibitor']","['venetoclax', 'ibrutinib']",[],[],"['abbvie', 'johnson & johnson']","['elderly', 'first-line', 'tp53-mutated']",,High,1
163,Panel Question and Answer,Gastrointestinal Cancer - Colorectal and Anal,Oral Abstract Session,"['anal cancer', 'colorectal cancer']","['colorectal cancer', 'anal cancer']",[],[],[],[],[],[],,Low,1
189,Let's Talk Toxicity: The Role of Shared Decision-Making in Front-Line Treatment Selection for Patients With Metastatic EGFR+ Non‚ÄìSmall Cell Lung Cancer,Tough Choices: Front-Line Treatment Dilemmas in EGFR Metastatic Non‚ÄìSmall Cell Lung Cancer,Education Session,['non-small cell lung cancer'],['front-line metastatic egfr-positive non-small cell lung cancer'],[],[],[],[],[],['metastatic'],,Low,1
190,Debate: Osimertinib Alone as Front-Line Therapy for a Patient With Metastatic EGFR Non‚ÄìSmall Cell Lung Cancer,Tough Choices: Front-Line Treatment Dilemmas in EGFR Metastatic Non‚ÄìSmall Cell Lung Cancer,Education Session,['non-small cell lung cancer'],['frontline metastatic egfr mutant non-small cell lung cancer'],['egfr inhibitor'],['osimertinib'],[],[],[],"['egfr mutated', 'metastatic', 'frontline']",,Low,1
191,Debate: Combination Approaches as Front-Line Therapy for a Patient With Metastatic EGFR Non‚ÄìSmall Cell Lung Cancer,Tough Choices: Front-Line Treatment Dilemmas in EGFR Metastatic Non‚ÄìSmall Cell Lung Cancer,Education Session,['non-small cell lung cancer'],['frontline metastatic egfr mutant non-small cell lung cancer'],[],[],[],[],[],"['egfr mutated', 'metastatic', 'frontline']",,Low,1
192,Panel Question and Answer,Tough Choices: Front-Line Treatment Dilemmas in EGFR Metastatic Non‚ÄìSmall Cell Lung Cancer,Education Session,['non-small cell lung cancer'],['frontline metastatic egfr mutant non-small cell lung cancer'],[],[],[],[],[],"['egfr mutated', 'metastatic', 'frontline']",,Low,1
222,SNF-CLIMEDIN: A HECOG prospective randomized trial of digital support and intervention in patients with advanced non-small cell lung cancer (NSCLC)‚ÄîFinal results.,Care Delivery/Models of Care,Rapid Oral Abstract Session,['non-small cell lung cancer'],['advanced non small cell lung cancer'],[],[],[],[],[],['advanced'],,Low,1
226,Economic modelling to inform pricing for LMICs of immune checkpoint inhibitors in advanced PD-L1-high non-small cell lung cancer.,Care Delivery/Models of Care,Rapid Oral Abstract Session,['non-small cell lung cancer'],['advanced non-small cell lung cancer'],['immune checkpoint inhibitor'],[],[],[],[],['advanced'],,Low,1
228,"Effect of broad-based genomic sequencing on survival outcomes in advanced non-small cell lung cancer: A national cohort study, 2011-2023.",Care Delivery/Models of Care,Rapid Oral Abstract Session,['non-small cell lung cancer'],['advanced non small cell lung cancer'],[],[],[],[],[],['advanced'],,Low,1
239,Association between wildfire-dominated PM2.5 exposure and non-small cell lung cancer survival in California.,"Prevention, Risk Reduction, and Genetics",Rapid Oral Abstract Session,['non-small cell lung cancer'],['non-small cell lung cancer'],[],[],[],[],[],[],,Low,1
278,MYC amplification and protein expression as prognostic markers in pediatric and young adult osteosarcoma.,Pediatric Oncology,Poster Session,['osteosarcoma'],"['paediatric osteosarcoma', 'young adult osteosarcoma']",[],[],[],[],[],"['young adult', 'paediatric']",,High,1
280,MYC amplification as a prognostic biomarker in osteosarcoma: A report from the Children‚Äôs Oncology Group.,Pediatric Oncology,Poster Session,['osteosarcoma'],['myc amplified osteosarcoma'],[],[],[],[],[],['myc-amplified'],,High,1
381,"Dual targeting of VEGF and PD-1: A phase I/II trial of ivonescimab, a novel bispecific antibody, in recurrent glioblastoma.",Central Nervous System Tumors,Poster Session,['glioblastoma'],['recurrent glioblastoma'],['pd1/vegf bispecific antibody'],['ivonescimab'],[],[],['summit therapeutics sub'],['recurrent'],,High,1
312,Effect of CD4+PD-1+CXCR6+ T cells on the response of immune checkpoint inhibitor therapy in brain metastases of NSCLC.,Central Nervous System Tumors,Poster Session,"['secondary brain cancer', 'non-small cell lung cancer']","['non-small cell lung cancer', 'brain metastasis']",['immune checkpoint inhibitor'],[],[],[],[],[],,Low,1
313,"IT-IO: Intrathecal administration of nivolumab and ipilimumab in combination with systemic combination of nivolumab and ipilimumab in patients with non-small cell lung cancer or melanoma and newly diagnosed leptomeningeal metastasis, a multicentric phase I study.",Central Nervous System Tumors,Poster Session,"['melanoma', 'non-small cell lung cancer', 'neoplastic meningitis']","['non small cell lung cancer', 'melanoma', 'newly diagnosed leptomeningeal metastasis']","['pd1 inhibitor', 'ctla4 inhibitor']","['nivolumab', 'ipilimumab']",[],[],[],['newly diagnosed'],,Low,1
369,"A multicenter, randomized, controlled, pivotal trial of microbubble-enhanced transcranial focused ultrasound for patients with NSCLC brain metastases (LIMITLESS).",Central Nervous System Tumors,Poster Session,"['secondary brain cancer', 'non-small cell lung cancer']","['brain metastases', 'non-small cell lung cancer']",[],[],[],[],['insightec'],[],,Low,1
416,"Biomarkers of emergent resistance to sotorasib plus panitumumab in KRAS G12C-mutated metastatic colorectal cancer (mCRC) from the randomized, phase 3 CodeBreaK 300 study.",Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['kras g12c-mutant metastatic colorectal cancer'],"['kras inhibitor', 'egfr targeted therapy']","['sotorasib', 'panitumumab']",[],[],['amgen'],"['kras g12c-mutant', 'metastatic']",,High,1
403,Monitoring botensilimab- and balstilimab-induced T-cell dynamics in refractory mismatch repair proficient metastatic colorectal cancer.,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['refractory mismatch repair proficient metastatic colorectal cancer'],"['pd1 targeted therapy', 'ctla4 targeted therapy']","['botensilimab', 'balstilimab']",[],[],['agenus'],"['refractory', 'metastatic']",,Low,1
405,Risk factors associated with de novo metastatic colorectal cancer in early onset colorectal cancer.,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],"['de novo metastatic colorectal cancer', 'early onset colorectal cancer']",[],[],[],[],[],"['early onset', 'metastatic']",,Low,1
406,Survival impact of NeoRAS wild-type metastatic colorectal cancer: A SCRUM-Japan GOZILA substudy.,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['neoras wild type metastatic colorectal cancer'],[],[],[],[],[],['metastatic'],,Low,1
408,Predicting pathologic complete response in colorectal cancer patients after immunotherapy based on endoscopic biopsy and deep learning approach.,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['colorectal cancer'],[],[],[],[],[],[],,Low,1
409,Metastatic site pattern as predictor of outcome of first-line alternating oxaliplatin-based chemotherapy and nivolumab for patients with microsatellite-stable (MSS) colorectal cancer (CRC).,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['microsatellite stable colorectal cancer'],"['pd1 inhibitor', 'dna synthesis inhibitor']","['nivolumab', 'oxaliplatin']",[],[],[],['microsatellite stable'],,Low,1
410,Open-label phase Ib/II study of cetuximab (CET) plus LY3214996 with or without abemaciclib in patients (pts) with anti-EGFR-refractory metastatic colorectal cancer (mCRC).,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['anti-egfr refractory metastatic colorectal cancer'],"['anti-egfr', 'egfr inhibitor', 'erk1/2 inhibitor']","['cetuximab', 'ly3214996']",['abemaciclib'],[],[],"['refractory', 'metastatic']",,Low,1
413,The prognostic and predictive role of HER2 amplification/overexpression and HER2 mutations in metastatic colorectal cancer treated with first-line chemotherapy plus bevacizumab/anti-EGFRs: An individual patient data pooled analysis of eight randomized trials.,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['first-line her2 amplified/overexpressing/her2 mutant metastatic colorectal cancer'],"['vegf inhibitor', 'egfr targeted therapy']",['bevacizumab'],[],[],['takeda'],"['first-line', 'her2-mutated', 'her2-amplified', 'metastatic']",,Low,1
573,PYNNACLE phase 2 clinical trial of rezatapopt in patients with advanced solid tumors harboring a TP53 Y220C mutation.,Sarcoma,Poster Session,['solid tumor'],['tp53 y220c-mutant advanced solid tumor'],['tp53 targeted therapy'],['rezatapopt'],[],[],"['merck', 'pmv pharmaceuticals']",['advanced'],,High,1
678,Clinico-molecular characteristics and enhanced efficacy of immune checkpoint inhibitors in TP53-mutated advanced biliary tract cancer.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Poster Session,['biliary tract cancer'],['tp53-mutated advanced biliary tract cancer'],['immune checkpoint inhibitor'],[],[],[],[],"['advanced', 'tp53-mutated']",,High,1
417,Safety and efficacy of anti-CEA CAR-T cells to prolong relapse-free survival of colorectal cancer liver metastases patients after radical resection.,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,"['colorectal cancer', 'secondary liver cancer']","['colorectal cancer', 'liver metastases']","['car t cell therapy', 'cea targeted therapy']",['cea-targeted car-t cell'],[],[],[],[],,Low,1
418,"Preliminary safety, pharmacokinetics, and clinical activity of RG6344 in patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC).",Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['braf v600e-mutant metastatic colorectal cancer'],['braf inhibitor'],['rg-6344'],[],[],['roche'],"['braf v600e-mutant', 'metastatic']",,Low,1
419,Impact of anti-EGFR and anti-VEGF antibodies on survival in BRAFV600E mutated metastatic colorectal cancer: A pooled analysis of eight clinical trials performed in the first-line treatment of mCRC (German AIO Study Group).,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['first line braf v600e-mutant metastatic colorectal cancer'],"['egfr targeted antibody', 'vegf targeted antibody']",[],[],[],[],"['braf v600e-mutant', 'first-line', 'metastatic']",,Low,1
420,Circulating tumor DNA (ctDNA) dynamics in liver-limited metastatic colorectal cancer (mCRC) patients resected after first-line systemic treatment.,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['first line liver limited metastatic colorectal cancer'],[],[],[],[],['tempus'],"['first-line', 'metastatic']",,Low,1
713,Use of an ultra-sensitive sequencing platform to detect mutant KRAS in the whole blood of pancreatic cancer patients.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Poster Session,['pancreatic cancer'],['kras mutant pancreatic cancer'],[],[],[],[],[],['kras mutant'],,High,
422,Prognostic and predictive role of HLA supertypes in pMMR mCRC patients receiving FOLFOXIRI/bev ¬± atezolizumab in the AtezoTRIBE study.,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['pmmr metastatic colorectal cancer'],"['nucleoside metabolic inhibitor', 'folic acid analog', 'dna synthesis inhibitor', 'top1 inhibitor']",['folfoxiri'],['atezolizumab'],[],['roche'],['metastatic'],,Low,1
423,Impact of Medicare Advantage (MA) on timely initiation of pembrolizumab among dMMR/MSI-h metastatic colorectal cancer patients.,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['dmmr/msi-h metastatic colorectal cancer'],['pd1 inhibitor'],['pembrolizumab'],[],[],[],"['dmmr', 'msi-h', 'metastatic']",,Low,1
424,Outcomes of young-onset colorectal cancer vs late-onset colorectal cancer patients on phase 1 matched and non-matched therapies.,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],"['late onset colorectal cancer', 'young onset colorectal cancer']",[],[],[],[],[],"['young', 'late onset']",,Low,1
425,Amivantamab treatment and intra-tumoral gene expression and immune cell changes in refractory metastatic colorectal cancer (mCRC): Whole transcriptome RNA-sequencing analysis from the OrigAMI-1 study.,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['refractory metastatic colorectal cancer'],"['egfr targeted therapy', 'met targeted therapy']",['amivantamab'],[],[],['johnson & johnson'],"['refractory', 'metastatic']",,Low,1
426,"Phase 1 dose escalation results of the WEE1 inhibitor, azenosertib (A), in combination with encorafenib (E) and cetuximab (C) in patients (pts) with previously treated BRAF V600E mutant metastatic colorectal cancer (mCRC).",Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['previously treated braf v600e mutant metastatic colorectal cancer'],"['wee1 inhibitor', 'egfr targeted therapy', 'braf inhibitor']","['cetuximab', 'azenosertib', 'encorafenib']",[],[],"['zentalis pharmaceuticals', 'pfizer']","['braf v600e-mutant', 'previously treated', 'metastatic']",,Low,1
427,Low-pass whole methylome sequencing‚Äìbased liquid biopsy for metastatic colorectal cancer monitoring in the VALENTINO trial.,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['metastatic colorectal cancer'],[],[],[],[],[],['metastatic'],,Low,1
428,"Vilastobart (XTX101), a tumor-activated, Fc-enhanced anti‚ÄìCTLA-4 monoclonal antibody, in combination with atezolizumab in patients with MSS CRC.",Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['microsatellite stable colorectal cancer'],"['ctla4 targeted therapy', 'pdl1 inhibitor']","['atezolizumab', 'vilastobart']",[],[],"['xilio therapeutics', 'roche']",['microsatellite stable'],,Low,1
429,mFOLFIRINOX efficacy as rescue regimen for patients with metastatic refractory colorectal cancer: The RE-PLAY trial.,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['metastatic refractory colorectal cancer'],"['thymidylate synthetase inhibitor', 'nucleoside metabolic inhibitor', 'dna synthesis inhibitor', 'top1 inhibitor']",['mfolfirinox'],[],[],[],"['refractory', 'metastatic']",,Low,1
431,Analysis of mutational profiles and their correlation with organ-specific metastases in MSS and BRAFwt colorectal cancer (mCRC).,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],"['braf wild type-mutant metastatic colorectal cancer', 'mss mutant metastatic colorectal cancer']",[],[],[],[],[],"['braf wild-type', 'metastatic']",,Low,1
432,Patterns of immunotherapy use in dMMR/MSI-H metastatic CRC.,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['dmmr/msi-h metastatic colorectal cancer'],[],[],[],[],[],"['dmmr', 'msi-h', 'metastatic']",,Low,1
433,Colorectal cancer with gene fusions: Navigating the genomic landscape and treatment selection in a phase I unit.,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['colorectal cancer'],[],[],[],[],[],[],,Low,1
434,"The efficacy of watch and wait strategy or surgery after neoadjuvant immunotherapy for locally advanced colorectal cancer with dMMR/MSI-H guided by ctDNA dynamic monitoring (WINDOW): A single-center, open-label, prospective, phase II study.",Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['locally advanced colorectal cancer'],[],[],[],[],[],['locally advanced'],,Low,1
777,A phase 1b/2 trial of onvansertib in combination with NALIRIFOX for first line treatment of advanced pancreatic cancer (PANCONVA trial).,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Poster Session,['pancreatic cancer'],['first line advanced pancreatic cancer'],"['nucleoside metabolic inhibitor', 'plk1 inhibitor', 'folic acid analog', 'dna synthesis inhibitor', 'top1 inhibitor']","['nalirifox', 'onvansertib']",[],[],['cardiff oncology'],['first-line advanced'],,High,
438,A medically tailored meal (MTM) delivery program to reduce nutritional decline and improve treatment tolerance in patients with colorectal cancer (CRC): A pilot study.,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['colorectal cancer'],[],[],[],[],['merck'],[],,Low,1
439,"Relapse patterns, risk factors, re-resectability and survival after curative treatment for metastatic colorectal cancer (mCRC): A RAXO substudy.",Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['metastatic colorectal cancer'],[],[],[],[],[],['metastatic'],,Low,1
440,Single-slide histology-based deep learning model for mismatch repair deficiency prediction in colorectal cancer.,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['mismatch repair deficiency colorectal cancer'],[],[],[],[],[],['dmmr'],,Low,1
441,Time to treatment initiation (TTI) in patients with colorectal cancer and liver metastases.,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,"['colorectal cancer', 'secondary liver cancer']","['colorectal cancer', 'liver metastases']",[],[],[],[],[],[],,Low,1
442,Comparison of MET genomic alterations (GA) identified in colorectal cancer (CRC) vs gastric cancer (GCA).,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,"['colorectal cancer', 'gastric cancer']","['met altered gastric cancer', 'met altered colorectal cancer']",[],[],[],[],['foundation medicine'],[],,Low,1
443,The role of gut microbiome composition in the IBD-CRC pathway: A retrospective study of 428 patients.,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,"['colorectal cancer', 'inflammatory bowel disease']","['colorectal cancer', 'inflammatory bowel disease']",[],[],[],[],[],[],,Low,1
444,Clinicogenomic landscape and outcomes of metastatic colorectal cancer patients with pathogenic GNAS variants.,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['metastatic colorectal cancer'],[],[],[],[],['tempus'],['metastatic'],,Low,1
445,Clinicopathologic features of complement activation signatures in colorectal cancer.,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['colorectal cancer'],[],[],[],[],[],[],,Low,1
446,Impact of SARS-CoV-2 mRNA-BNT162b2 vaccination on survival outcomes in metastatic colorectal cancer patients treated with bevacizumab-based therapy.,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,"['colorectal cancer', 'infection']","['sars-cov-2 infection', 'metastatic colorectal cancer']","['mrna vaccine', 'vegf inhibitor']","['bnt162b2', 'bevacizumab']",[],[],[],['metastatic'],,Low,1
447,Effect of race/ethnicity on clinical outcomes for metastatic colorectal cancer (mCRC) patients in phase 1 trials: A dual institution experience.,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['metastatic colorectal cancer'],[],[],[],[],[],['metastatic'],,Low,1
448,Understanding and addressing unmet needs in colorectal cancer: Findings from the Colorectal Cancer Alliance‚Äôs Patient and Survivor survey.,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['colorectal cancer'],[],[],[],[],[],[],,Low,1
449,Drivers of homologous recombination deficiency (HRD) in metastatic colorectal cancer (mCRC).,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['metastatic colorectal cancer'],[],[],[],[],[],['metastatic'],,Low,1
450,Real-world efficacy of trifluridine/tipiracil and bevacizumab combination according to baseline prognostic factors: The BeTAS study.,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,"['colorectal cancer', 'anal cancer']","['colorectal cancer', 'anal cancer']","['vegf inhibitor', 'thymidine analog']","['bevacizumab', 'tipiracil/trifluridine']",[],[],['stem cell therapeutics'],[],,Low,1
451,Safety and efficacy of ADG126 (an anti-CTLA-4 masking antibody) in combination with pembrolizumab: Updated results of phase 1b/2 study in advanced MSS CRC.,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['advanced microsatellite instability colorectal cancer'],"['pd1 targeted therapy', 'ctla4 targeted therapy']","['pembrolizumab', 'adg126']",[],[],"['merck', 'adagene']","['advanced', 'microsatellite instability']",,Low,1
452,Real-world treatment patterns and outcomes with trifluridine/tipiracil monotherapy or in combination with bevacizumab in metastatic colorectal cancer.,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['metastatic colorectal cancer'],"['nucleoside analog', 'dna synthesis inhibitor']",['tipiracil/trifluridine'],['bevacizumab'],[],['taiho oncology'],['metastatic'],,Low,1
453,A phase 1 dose-escalation study of GCC19CART: A novel CAR T-cell therapy for metastatic colorectal cancer in the United States.,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['metastatic colorectal cancer'],['car t cell therapy'],['gcc19cart'],[],[],['innovative cellular therapeutics'],['metastatic'],,Low,1
454,Impact of obesity and lifestyle-associated risk factors on outcomes of early-onset colorectal cancer in patients younger than 50 years old: A propensity-matched analysis.,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['early onset colorectal cancer'],[],[],[],[],[],['early onset'],,Low,1
455,Colorectal cancer mortality dynamics: Uncovering critical disparities in U.S. population health (2018‚Äì2023).,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['colorectal cancer'],[],[],[],[],[],[],,Low,1
457,Cell-free DNA 5-hydroxymethylcytosine profiling for the assessment of colorectal cancer biology and treatment response in blood.,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['blood colorectal cancer'],[],[],[],[],[],[],,Low,1
458,"Sintilimab plus bevacizumab, oxaliplatin, and capecitabine as perioperative therapy in microsatellite-stable, resectable colorectal cancer liver metastases: An open-label, single-arm, phase II trial.",Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],"['microsatellite stable resectable colorectal cancer', 'liver metastasis']","['nucleoside metabolic inhibitor', 'vegf inhibitor', 'dna synthesis inhibitor']","['capecitabine', 'bevacizumab', 'oxaliplatin']",[],[],[],"['microsatellite stable', 'resectable', 'metastatic']",,Low,1
461,"Single-incision laparoscopic surgery vs conventional laparoscopic surgery for colorectal cancer: Short-term outcomes of a multi-center, randomized, controlled trial.",Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['colorectal cancer'],[],[],[],[],[],[],,Low,1
462,The association of ctDNA with recurrence in patients with stage II-IV colorectal cancer: The Íûµ-CORRECT study.,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['recurrent stage ii/iii colorectal cancer'],[],[],[],[],['exact sciences'],"['stage ii', 'recurrent']",,Low,1
463,Biologic correlates of circulating tumor DNA (ctDNA) shedding in the INTERCEPT colorectal cancer (CRC) study.,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['colorectal cancer'],[],[],[],[],['axsome therapeutics'],[],,Low,1
465,Clinical and immunopathological evaluation and its comparison with consensus molecular subtypes of colorectal cancer.,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['colorectal cancer'],[],[],[],[],[],[],,Low,1
467,Performance of a targeted enzymatic methylation-based early detection test by different colorectal cancer subgroups.,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['colorectal cancer'],[],[],[],[],[],[],,Low,1
468,ctDNA dynamics and targeted therapies associated with genetic mutations in patients with colorectal cancer.,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['colorectal cancer'],[],[],[],[],['natera'],[],,Low,1
470,Neoadjuvant mFOLFOXIRI chemotherapy with or without cadonilimab versus mFOLFOX6 alone in locally advanced colorectal cancer: A randomized phase II study (OPTICAL2).,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['locally advanced colorectal cancer'],"['nucleoside metabolic inhibitor', 'folic acid analog', 'dna synthesis inhibitor', 'top1 inhibitor']",['mfolfoxiri'],['cadonilimab'],[],[],['locally advanced'],,Low,1
474,Enhancing colorectal cancer precision medicine through multi-omics and clinical data integration with artificial intelligence.,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['colorectal cancer'],[],[],[],[],[],[],,Low,1
476,A novel active chromatin cell-free DNA (cfDNAac) assay for early detection of colorectal cancer.,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['early onset colorectal cancer'],[],[],[],[],['aqtual'],['early onset'],,Low,1
477,Analysis of early onset colorectal cancer: Implications for research and clinical practice.,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['early onset colorectal cancer'],[],[],[],[],[],['early onset'],,Low,1
480,Exploring transcriptomic regulation of the tissue-associated microbiome in oncogenic progression of colorectal cancer.,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['progressive colorectal cancer'],[],[],[],[],[],['progressive'],,Low,1
483,Development and validation of machine learning risk prediction models for detection of early-onset colorectal cancer: Data from 30 health systems in the United States.,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['early onset colorectal cancer'],[],[],[],[],[],['early onset'],,Low,1
484,Use and benefit of adjuvant chemotherapy in early- vs average-onset colorectal cancer.,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],"['early onset colorectal cancer', 'average onset colorectal cancer']",[],[],[],[],[],['early onset'],,Low,1
485,Detection of early-stage colorectal cancer using multiplexed extracellular vesicle proteomic biomarkers.,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['early stage colorectal cancer'],[],[],[],[],['nexosome oncology'],['early-stage'],,Low,1
486,An early colorectal cancer screening programme based on bisulfite-free sequencing of methylated circulating tumor DNA.,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['early onset colorectal cancer'],[],[],[],[],['jiangsu mole bioscience'],['early onset'],,Low,1
489,Reassessing colorectal cancer recurrence in solid organ transplant recipients: Implications for revised management guidelines.,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['recurrent colorectal cancer'],[],[],[],[],[],['recurrent'],,Low,1
490,Impact of COVID-19 on the stage at diagnosis and mortality of colorectal cancer.,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,"['colorectal cancer', 'coronavirus infection']","['colorectal cancer', 'covid-19']",[],[],[],[],[],[],,Low,1
491,Leveraging EHRs and a phenome-wide association study to identify pre-diagnostic clinical markers in early-onset colorectal cancer.,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['early onset colorectal cancer'],[],[],[],[],[],['early onset'],,Low,1
492,Colorectal cancer screening and detection following USPSTF recommendations for ages 45-49: Insights from a large EHR cohort.,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['elderly colorectal cancer'],[],[],[],[],[],['elderly'],,Low,1
494,Comprehensive analysis of outcomes of patients with colorectal cancer in a racially diverse cohort.,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['colorectal cancer'],[],[],[],[],[],[],,Low,1
496,Characterizing clinical outcomes and DNA co-alterations of ERBB2-amplified colorectal cancer.,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['erbb2-amplified colorectal cancer'],[],[],[],[],[],[],,Low,1
497,Effects of marital status on survival in patients with colorectal cancer.,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['colorectal cancer'],[],[],[],[],[],[],,Low,1
498,Clinicopathological features of colorectal cancer in adolescents and young adults (AYA) at a tertiary referral centre in Nigeria.,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],"['adolescent colorectal cancer', 'young adult colorectal cancer']",[],[],[],[],[],"['young adult', 'adolescent']",,Low,1
499,Adherence to repeat screening for colorectal cancer using the multi-target stool DNA test: Real-world analysis of patients from federally qualified health centers.,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['colorectal cancer'],[],[],[],[],['exact sciences'],[],,Low,1
500,Quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) analysis of pembrolizumab (pembro) versus chemotherapy (chemo) in microsatellite instability‚Äìhigh (MSI-H)/mismatch repair‚Äìdeficient (dMMR) metastatic colorectal cancer (mCRC) in the KEYNOTE-177 trial.,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer'],['pd1 inhibitor'],['pembrolizumab'],[],[],['merck'],"['dmmr', 'msi-h', 'metastatic']",,Low,1
501,Association between fine particulate matter exposure and colorectal cancer mortality by age at diagnosis: Insights from county-level analysis in the United States.,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['colorectal cancer'],[],[],[],[],[],[],,Low,1
503,"Alliance A022101/NRG-GI009: A pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer-Evaluating radiation, ablation, and surgery (ERASur).",Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['limited metastatic colorectal cancer'],[],[],[],[],[],['metastatic'],,Low,1
504,"Telisotuzumab adizutecan (ABBV-400; Temab-A) monotherapy vs trifluridine/tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer with increased c-Met protein expression: An open-label, randomized, phase 3 trial.",Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['refractory metastatic colorectal cancer'],"['cmet targeted therapy', 'vegf targeted therapy']",['telisotuzumab adizutecan'],[],['bevacizumab'],['abbvie'],"['refractory', 'metastatic']",,Low,1
778,"Trial in progress: RASolute 302-A phase 3, multicenter, global, open-label, randomized study of daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor, versus standard of care chemotherapy in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).","Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Poster Session,['pancreatic ductal adenocarcinoma'],['previously treated metastatic pancreatic ductal adenocarcinoma'],['ras(on) multi selective inhibitor'],['daraxonrasib'],[],[],['revolution medicines'],"['previously treated', 'metastatic']",,High,
506,An observational/translational study to conduct real-world evidence and develop biomarkers of fruquintinib for patients with metastatic colorectal cancer (mCRC): FruBLOOM trial (JACCRO CC-19).,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['metastatic colorectal cancer'],['vegfr inhibitor'],['fruquintinib'],[],[],[],['metastatic'],,Low,1
1016,Skewed offspring distribution of TP53 pathogenic variants in Israeli Li-Fraumeni syndrome families.,"Prevention, Risk Reduction, and Genetics",Poster Session,['li-fraumeni syndrome'],['li-fraumeni syndrome'],[],[],[],[],[],[],,High,1
1020,Clinical characteristics and cancer spectrum among breast cancer patients with TP53 germline mutation from a single institution.,"Prevention, Risk Reduction, and Genetics",Poster Session,['breast cancer'],['tp53 germline mutant breast cancer'],[],[],[],[],[],[],,High,1
511,Combining low-dose regorafenib with pembrolizumab as a front-line therapy for patients with MSI-H colorectal cancer: REGPEM-CRC-01.,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['front-line microsatellite instability-high colorectal cancer'],"['pd1 targeted therapy', 'multi inhibitor']","['regorafenib', 'pembrolizumab']",[],[],['bayer'],['msi-h'],,Low,1
512,Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-NORTH AMERICA): NRG-GI008.,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,"['colorectal cancer', 'anal cancer']","['colorectal cancer', 'anal cancer']",[],[],[],[],['natera'],[],,Low,1
514,"mFOLFOX6 + bevacizumab + PD-1 monoclonal antibody vs. mFOLFOX6 in locally advanced pMMR/MSS CRC: A multicenter, randomized controlled phase III study (BASKETIII).",Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['locally advanced pmmr/mss colorectal cancer'],"['nucleoside metabolic inhibitor', 'vegf targeted therapy', 'folic acid analog', 'dna synthesis inhibitor']","['bevacizumab', 'mfolfox6']",[],['mfolfox6'],[],['locally advanced'],,Low,1
1053,Lipid metabolic gene expression and association with decreased overall survival and immunogenicity in KRAS-STK11 NSCLC.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['kras-stk11 non-small cell lung cancer'],[],[],[],[],['tempus'],[],,High,
672,Deep learning-based contouring of Couinaud segments on CT: Utility for volumetric analysis of future liver remnant.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Poster Session,"['gastro-esophageal cancer', 'pancreatic cancer', 'hepatobiliary cancer']","['gastroesophageal cancer', 'pancreatic cancer', 'hepatobiliary cancer']",[],[],[],[],[],[],,Low,1
1058,Spatial transcriptomic profiling of the tumor microenvironment in EGFR and KRAS mutant non-small cell lung cancer.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['egfr/kras mutant non-small cell lung cancer'],[],[],[],[],[],['kras mutant'],,High,
679,Genomic and outcome analysis of recurrent versus de novo metastatic pancreatic ductal adenocarcinoma (PDAC) receiving systemic therapy: Results from the Australian MoST and CaSP screening programs.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Poster Session,['pancreatic ductal adenocarcinoma'],['recurrent/de novo metastatic pancreatic ductal adenocarcinoma'],[],[],[],[],[],"['recurrent', 'metastatic']",,Low,1
706,Development of a cfDNA-based protein-informed epigenetic signature (PEp-sig) to enable biomarker-based risk stratification for pancreatic ductal adenocarcinoma (PDA).,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Poster Session,['pancreatic ductal adenocarcinoma'],['pancreatic ductal adenocarcinoma'],[],[],[],[],[],[],,Low,1
707,"Development of a comprehensive cfDNA methylation signature for prognostic, predictive, and diagnostic applications in pancreatic ductal adenocarcinoma (PDA).","Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Poster Session,['pancreatic ductal adenocarcinoma'],['pancreatic ductal adenocarcinoma'],[],[],[],[],[],[],,Low,1
708,DNA methylation signatures as predictive biomarkers for chemotherapy (CT) resistance and survival in pancreatic ductal adenocarcinoma (PDA).,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Poster Session,['pancreatic ductal adenocarcinoma'],['pancreatic ductal adenocarcinoma'],[],[],[],[],[],[],,Low,1
709,A phase I trial of binimetinib plus hydroxychloroquine in patients with previously treated metastatic pancreatic cancer.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Poster Session,['pancreatic cancer'],['previously treated metastatic pancreatic cancer'],"['mek inhibitor', 'antimalarial']","['binimetinib', 'hydroxychloroquine']",[],[],['merck'],"['previously treated', 'metastatic']",,Low,1
1107,Impact of standard vs reduced dosing of sotorasib on efficacy and toxicity in KRAS G12C‚Äìmutated advanced non-small cell lung cancer: A systematic review and meta-analysis.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['kras g12c-mutated advanced non-small cell lung cancer'],['kras g12c inhibitor'],['sotorasib'],[],[],[],"['kras g12c-mutant', 'advanced']",,High,
712,Functional role of GLI2 in cancer-associated fibroblasts for modulation of the fibrotic tumor microenvironment within pancreatic cancer.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Poster Session,['pancreatic cancer'],['pancreatic cancer'],[],[],[],[],[],[],,Low,1
1117,MK-1084 for KRAS G12C-mutated (mut) metastatic non‚Äìsmall-cell lung cancer (mNSCLC): Results from KANDLELIT-001.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['kras g12c-mutated metastatic non-small cell lung cancer'],['kras g12c inhibitor'],['mk-1084'],[],[],['merck'],"['kras g12c-mutant', 'metastatic']",,High,
714,"Efficacy and safety of surufatinib (S) plus KN046 (K) and chemotherapy in first line (1L) advanced pancreatic cancer (PC): A single-arm, phase 1b/2 trial.","Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Poster Session,['pancreatic cancer'],['first line advanced pancreatic cancer'],"['vegfr inhibitor', 'ctla4/pdl1 bispecific antibody']","['surufatinib', 'kn-046']",[],[],[],['first-line advanced'],,Low,1
715,"Early treatment ctDNA dynamics to predict response to chemotherapy in patients with metastatic pancreatic cancer: A prospective, observational pilot study.","Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Poster Session,['pancreatic cancer'],['metastatic pancreatic cancer'],[],[],[],[],[],['metastatic'],,Low,1
716,"TQB2868 combined with anlotinib and nab-paclitaxel plus gemcitabine as first-line treatment for metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase 2 study.","Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Poster Session,['pancreatic cancer'],['first line metastatic pancreatic cancer'],"['nucleoside metabolic inhibitor', 'multi kinase inhibitor', 'microtubule inhibitor']","['gemcitabine', 'anlotinib', 'nab-paclitaxel']",[],[],['chia tai tianqing pharmaceutical'],"['first-line', 'metastatic']",,Low,1
717,Phase II trial of serplulimab combined with gemcitabine plus nab-paclitaxel (GnP) and SBRT for metastatic pancreatic cancer as the first-line treatment.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Poster Session,['pancreatic cancer'],['first line metastatic pancreatic cancer'],"['nucleoside analog', 'nab targeted therapy', 'microtubule stabilizing agent', 'cd47 targeted therapy']","['gemcitabine', 'serplulimab', 'nab-paclitaxel']",[],[],[],"['first-line', 'metastatic']",,Low,1
718,"First-line treatment with surufatinib, camrelizumab, nab-paclitaxel, and S-1 in locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC): A phase Ib/II randomized study.","Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Poster Session,['pancreatic ductal adenocarcinoma'],['locally advanced/metastatic pancreatic ductal adenocarcinoma'],"['pd1 inhibitor', 'microtubule stabilizing agent', 'vegfr inhibitor', 'thymidylate synthase inhibitor']","['surufatinib', 'nab-paclitaxel', 'camrelizumab']",[],[],[],"['metastatic', 'locally advanced']",,Low,1
719,First-line serplulimab and bevacizumab combined with nab-paclitaxel/gemcitabine followed by mFOLFOX in advanced pancreatic cancer: A phase II trial.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Poster Session,['pancreatic cancer'],['advanced pancreatic cancer'],"['taxane', 'vegf targeted therapy', 'cd274 targeted therapy', 'alkylating agent', 'antimetabolite']","['serplulimab', 'gemcitabine', 'bevacizumab', 'nab-paclitaxel']",[],[],[],['advanced'],,Low,1
720,AI-based predictive tool for detection of ctDNA in pancreatic adenocarcinoma using nationwide comprehensive genomic profiling data.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Poster Session,['pancreatic adenocarcinoma'],['pancreatic adenocarcinoma'],[],[],[],[],[],[],,Low,1
721,Using live true single-circulating tumor cell comprehensive genomics to show clonal evolution and tumor heterogeneity in pancreatic cancer management.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Poster Session,['pancreatic cancer'],['pancreatic cancer'],[],[],[],[],['onecell dx'],[],,Low,1
722,Homologous recombination deficiency (HRD) profiling in Chinese pancreatic ductal adenocarcinoma: Implications for platinum-based chemotherapy.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Poster Session,['pancreatic ductal adenocarcinoma'],['pancreatic ductal adenocarcinoma'],[],[],[],[],[],[],,Low,1
723,The differential effect of stromal genes on gemcitabine/nab-paclitaxel (GN) and GN/cisplatin (GCN) outcomes in advanced pancreatic adenocarcinoma (aPDAC).,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Poster Session,['pancreatic ductal adenocarcinoma'],['advanced pancreatic ductal adenocarcinoma'],"['microtubule stabilizing agent', 'nucleoside analog', 'alkylating agent']","['gemcitabine', 'paclitaxel', 'cisplatin']",[],[],['caris life sciences'],['advanced'],,Low,1
724,"CheMo4METPANC: Combination chemotherapy (gemcitabine and nab-paclitaxel), chemokine (C-X-C) motif receptor 4 inhibitor (motixafortide), and immune checkpoint blockade (cemiplimab) in metastatic treatment-na√Øve pancreatic adenocarcinoma‚ÄîUpdated clinical and translational findings.","Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Poster Session,['pancreatic ductal adenocarcinoma'],['metastatic treatment naive pancreatic ductal adenocarcinoma'],"['nucleoside analog', 'cd25 targeted therapy', 'cxc motif receptor 4 inhibitor', 'microtubule destabilising agent']","['gemcitabine', 'cemiplimab', 'nab-paclitaxel']",[],[],"['bioline rx', 'regeneron']",['metastatic'],,Low,1
725,"Phase 1/2 study of nivolumab and ipilimumab combined with gemcitabine, nab-paclitaxel, and adaptive stereotactic body radiotherapy in bordeline resectable, locally advanced or metastatic pancreatic cancer (LAPTOP).","Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Poster Session,['pancreatic cancer'],['resectable locally advanced/metastatic pancreatic cancer'],"['pd1 inhibitor', 'nucleoside analog', 'cd86 targeted therapy', 'top1 inhibitor', 'cd80 targeted therapy']","['nivolumab', 'ipilimumab']",[],[],[],"['resectable', 'metastatic', 'locally advanced']",,Low,1
726,Clinico-genomic characterization of PALB2-mutated pancreatic adenocarcinoma.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Poster Session,['pancreatic adenocarcinoma'],['palb2-mutated pancreatic adenocarcinoma'],[],[],[],[],[],['palb2 mutated'],,Low,1
727,Prognostic and predictive impact of next-generation sequencing in metastatic pancreatic ductal adenocarcinoma.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Poster Session,['pancreatic ductal adenocarcinoma'],['metastatic pancreatic ductal adenocarcinoma'],[],[],[],[],[],['metastatic'],,Low,1
728,Interpretable artificial intelligence-driven selection of doublet chemotherapy regimens as second-line treatment in patients with advanced pancreatic cancer.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Poster Session,['pancreatic cancer'],['second line advanced pancreatic cancer'],[],[],[],[],[],"['second-line', 'advanced']",,Low,1
729,Circulated T-cell exhausted subtypes to predict response in PDAC patients.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Poster Session,['pancreatic ductal adenocarcinoma'],['pancreatic ductal adenocarcinoma'],[],[],[],[],[],[],,Low,1
730,USP22 as promoter of Treg cell infiltration and modulator of immunotherapy efficacy through the PIAS1/P65/CCL22 pathway in pancreatic cancer.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Poster Session,['pancreatic cancer'],['pancreatic cancer'],[],[],[],[],[],[],,Low,1
731,"NAPOLI 3, a phase 3 study of NALIRIFOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Final overall survival (OS) analysis and characteristics of the long-term survivors.","Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Poster Session,['pancreatic ductal adenocarcinoma'],['metastatic pancreatic ductal adenocarcinoma'],"['nucleoside metabolic inhibitor', 'folic acid analog', 'dna synthesis inhibitor', 'top1 inhibitor']",['nalirifox'],[],[],['ipsen'],['metastatic'],,Low,1
732,Biomarkers of response to immunotherapy in pancreatic ductal adenocarcinoma (PDAC) with homologous recombination deficiency (HRD).,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Poster Session,"['pancreatic ductal adenocarcinoma', 'deficiency']",['homology deficient pancreatic ductal adenocarcinoma'],[],[],[],[],['caris life sciences'],[],,Low,1
733,Interim open-label phase 1 results of misetionamide (GP-2250): A small molecule antineoplastic targeting three major transcription factors.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Poster Session,"['cancer', 'gastro-esophageal cancer', 'pancreatic cancer']","['hepatobilliary cancer', 'gastroesophageal cancer', 'pancreatic cancer']",['checkpoint inhibitor'],['misetionamide'],[],[],[],[],,Low,1
734,"Concurrent mutations in DNA damage repair genes BRCA1, POLE, ATM and FANCA to predict overall and progression-free survival for patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with chemotherapy in combination with dual checkpoint inhibition in the CCTG randomized PA.7 trial.","Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Poster Session,['pancreatic ductal adenocarcinoma'],['metastatic pancreatic ductal adenocarcinoma'],[],[],[],[],['astrazeneca'],['metastatic'],,Low,1
735,Clinical outcomes and molecular characteristics of patients with metastatic pancreatic ductal adenocarcinoma according to involved metastatic sites.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Poster Session,['pancreatic ductal adenocarcinoma'],['metastatic pancreatic ductal adenocarcinoma'],[],[],[],[],[],['metastatic'],,Low,1
736,Pancreatic cancer mortality trends (2018-2023): Exposing racial inequities in Michigan's cancer burden.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Poster Session,['pancreatic cancer'],['pancreatic cancer'],[],[],[],[],[],[],,Low,1
737,Multimodal machine learning predictions of treatment response and survival in advanced pancreatic cancer from the COMPASS trial.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Poster Session,['pancreatic cancer'],['advanced pancreatic cancer'],[],[],[],[],[],['advanced'],,Low,1
738,Integrative analysis of tumor microenvironment in advanced pancreatic cancer: Unraveling genomic and immune landscape for targeted therapies.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Poster Session,['pancreatic cancer'],['advanced pancreatic cancer'],[],[],[],[],[],['advanced'],,Low,1
739,BRCA1/2 and PALB2 short variants (SVs) contributed by clonal hematopoiesis (CH) in liquid biopsies (LBx) from patients with advanced pancreatic cancer (PC).,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Poster Session,['pancreatic cancer'],['advanced pancreatic cancer'],[],[],[],[],['foundation medicine'],['advanced'],,Low,1
740,"5-FU + Naliri, gemcitabine plus nab-paclitaxel or both regimens given sequentially for first line treatment of metastatic pancreatic ductal adenocarcinoma: A randomized phase II comparative study (FUNGEMAX-PRODIGE 61).","Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Poster Session,['pancreatic ductal adenocarcinoma'],['first line metastatic pancreatic ductal adenocarcinoma'],"['glucocorticoid agonist', 'microtubule inhibitor', 'alkylating agent', 'microtubule stabilizing agent', 'top2 inhibitor', 'antimetabolite']","['gemcitabine', 'nab-paclitaxel', '5-fluorouracil']",[],[],[],"['first-line', 'metastatic']",,Low,1
741,Machine learning and statistical prediction of overall survival (OS) from pre-dose plasma biomarkers in a randomized phase 2 trial (1801 Part 3B) of the GSK-3 inhibitor elraglusib in metastatic pancreatic ductal adenocarcinoma (mPDAC): Application toward patient enrichment.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Poster Session,['pancreatic ductal adenocarcinoma'],['metastatic pancreatic ductal adenocarcinoma'],['gsk3 inhibitor'],['elraglusib'],[],[],['actuate therapeutics'],['metastatic'],,Low,1
742,Real-world predictors of adverse clinical outcomes in pancreatic cancer using a machine-learning framework.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Poster Session,['pancreatic cancer'],['pancreatic cancer'],[],[],[],[],[],[],,Low,1
743,"A PBMC and machine learning based biomarker signature to predict second line chemotherapy success in advanced PDAC: Translational data of the PREDICT trial‚ÄîA prospective, multicenter, trial of the AIO Pancreatic Cancer Group (AIO-PAK-0216).","Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Poster Session,['pancreatic ductal adenocarcinoma'],['second-line pancreatic ductal adenocarcinoma'],[],[],[],[],['servier'],['second-line'],,Low,1
744,Neo-adjuvant chemo-immunotherapy in pancreatic cancer: Results of the Australasian Gastrointestinal Trials Group (AGITG) NEO-IMPACT pilot trial.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Poster Session,['pancreatic cancer'],['pancreatic cancer'],[],[],[],[],[],[],,Low,1
745,NeoOPTIMIZE: Phase II trial of adaptive switching of neoadjuvant FOLFIRINOX (FFX) to gemcitabine/nab-paclitaxel (GA) resectable/borderline resectable (BR)/locally advanced (LA) pancreatic adenocarcinoma (PDAC).,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Poster Session,['pancreatic ductal adenocarcinoma'],['resectable/borderline resectable locally advanced pancreatic ductal adenocarcinoma'],"['thymidylate synthetase inhibitor', 'nucleoside metabolic inhibitor', 'alkylating agent', 'microtubule stabilizing agent', 'dna synthesis inhibitor', 'top1 inhibitor', 'antimetabolite']","['gemcitabine', 'folfirinox', 'nab-paclitaxel']",[],[],[],"['resectable', 'borderline resectable', 'locally advanced']",,Low,1
746,Development and prospective validation of a novel cfDNA-based diagnostic model for the early detection of pancreatic cancer.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Poster Session,['pancreatic cancer'],['pancreatic cancer'],[],[],[],[],['nanjing geneseeq technology'],[],,Low,1
747,Prognostic value of postoperative circulating tumor DNA and tumor markers in resected pancreatic adenocarcinoma (PAAD): An interim analysis of a prospective observational study.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Poster Session,['pancreatic adenocarcinoma'],['resectable pancreatic adenocarcinoma'],[],[],[],[],['genecast biotechnology'],['resectable'],,Low,1
748,Five-year outcomes of perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (the NEONAX trial): A randomized phase II trial of the AIO pancreatic cancer group.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Poster Session,['pancreatic cancer'],['resectable pancreatic cancer'],"['nucleoside metabolic inhibitor', 'microtubule inhibitor']","['gemcitabine', 'nab-paclitaxel']",[],[],['celgene'],['resectable'],,Low,1
750,Association of neighborhood-level factors with access to genetic testing in patients with resectable pancreatic ductal adenocarcinoma.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Poster Session,['pancreatic ductal adenocarcinoma'],['resectable pancreatic ductal adenocarcinoma'],[],[],[],[],[],['resectable'],,Low,1
776,"An open-label, dose-finding, phase Ib study to assess the safety, tolerability of nesuparib (JPI-547), a dual inhibitor of PARP/TNKS, in combination with modified FOLFIRINOX (mFOLFIRINOX) and gemcitabine-nab-paclitaxel (GemAbraxane) in patients with locally advanced and metastatic pancreatic cancer.","Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Poster Session,['pancreatic cancer'],['locally advanced and metastatic pancreatic cancer'],"['thymidylate synthetase inhibitor', 'nucleoside metabolic inhibitor', 'glucocorticoid', 'top inhibitor', 'alkylating agent', 'parp/tnks inhibitor', 'microtubule destabilising agent', 'dna synthesis inhibitor', 'top1 inhibitor', 'antimetabolite']","['mfolfirinox', 'nesuparib', 'methylprednisolone']",[],[],['onconic therapeutics'],"['metastatic', 'locally advanced']",,Low,1
1141,Safety and efficacy of ifebemtinib (IN10018) combined with garsorasib (D-1553) in KRAS G12C mutant solid tumors from a phase Ib/II study: Results from single-arm of non-small-cell lung cancer (NSCLC) and randomized part of colorectal cancer (CRC).,Lung Cancer - Non - Small Cell Metastatic,Poster Session,"['solid tumor', 'non-small cell lung cancer']","['kras g12c-mutant solid tumor', 'non-small cell lung cancer']","['kras inhibitor', 'erk inhibitor']","['ifebemtinib', 'garsorasib']",[],[],"['inventisbio', 'inxmed (shanghai)']",['kras g12c-mutant'],,High,
1159,"Onkoras-101: A phase 1a/1b open-label study evaluating the safety, tolerability, pharmacokinetics, and efficacy of BBO-8520 in subjects with advanced KRASG12C mutant non-small-cell lung cancer.",Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['advanced krasg12c mutant non-small cell lung cancer'],['kras g12c inhibitor'],['bbo-8520'],[],[],['bridgebio'],"['kras g12c-mutant', 'advanced']",,High,
779,"A phase 2 study of botensilimab and AGEN1423, an anti-CD73-TGFŒ≤-trap bifunctional antibody, with or without chemotherapy in subjects with advanced pancreatic cancer.","Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Poster Session,['pancreatic cancer'],['advanced pancreatic cancer'],"['cd73 tgf beta targeted antibody', 'ctla4 antibody']","['botensilimab', 'agen1423']",[],[],['agenus'],['advanced'],,Low,1
780,Adaptive organoid-based precision therapy study in pancreatic cancer (ADOPT): A phase II single-arm study to evaluate the efficacy of patient-derived organoid (PDO)-directed therapy in advanced pancreatic ductal adenocarcinoma (PDAC).,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Poster Session,['pancreatic ductal adenocarcinoma'],['advanced pancreatic ductal adenocarcinoma'],[],[],[],[],[],['advanced'],,Low,1
781,Phase I trial of MK2 inhibitor in combination with mFOLFIRINOX for untreated metastatic pancreatic ductal adenocarcinoma.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Poster Session,['pancreatic ductal adenocarcinoma'],['untreated metastatic pancreatic ductal adenocarcinoma'],"['thymidylate synthetase inhibitor', 'nucleoside metabolic inhibitor', 'dna synthesis inhibitor', 'top1 inhibitor', 'mk2 inhibitor']",['mfolfirinox'],[],[],['aclaris therapeutics'],"['untreated', 'metastatic']",,Low,1
782,"An open-label, phase 1 trial with expansion cohort of botensilimab (AGEN1181) + balstilimab (AGEN2034) + nab-paclitaxel + gemcitabine + cisplatin + chloroquine + celecoxib in adult patients with previously untreated metastatic pancreatic cancer.","Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Poster Session,['pancreatic cancer'],['previously untreated adult metastatic pancreatic cancer'],"['alkylating agent', 'cd4 targeted therapy', 'microtubule destabilising agent', 'antimetabolite']","['botensilimab', 'chloroquine', 'gemcitabine', 'cisplatin', 'nab-paclitaxel']",[],[],['agenus'],"['previously untreated', 'adult', 'metastatic']",,Low,1
783,A supervised prehabilitation program for patients with pancreatic cancer.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Poster Session,['pancreatic cancer'],['pancreatic cancer'],[],[],[],[],[],[],,Low,1
840,Assessment of survival benefit with immunotherapy in combination with adjuvant chemoradiation in pathologic stage II-IIIB non-small cell lung cancer.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Poster Session,['non-small cell lung cancer'],['stage ii-iiib non-small cell lung cancer'],[],[],[],[],[],['stage ii'],,Low,1
841,Real world characteristics of stages II-III NSCLC patients (pts) who initiate neoadjuvant chemo-immunotherapy (NACT-I) and do not undergo surgical resection.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Poster Session,['non-small cell lung cancer'],['stage ii-iii non-small cell lung cancer'],[],[],[],[],[],['stage ii'],,Low,1
842,Adjuvant icotinib of 12 months versus observation as adjuvant therapy for completely resected EGFR-mutated stage IB non-small-cell lung cancer: 5-year update from CORIN (GASTO1003).,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Poster Session,['non-small cell lung cancer'],['resectable egfr-mutated stage ib non-small cell lung cancer'],['egfr inhibitor'],['icotinib'],[],[],[],"['egfr mutated', 'resectable', 'stage ib']",,Low,1
843,IMpower010: Genomic profiling and clinical outcomes with adjuvant atezolizumab in early-stage non-small cell lung cancer (eNSCLC).,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Poster Session,['non-small cell lung cancer'],['early stage non small cell lung cancer'],['pdl1 inhibitor'],['atezolizumab'],[],[],"['genentech', 'roche']",['early-stage'],,Low,1
845,"Ensartinib as postoperative adjuvant therapy in patients with ALK-positive non-small cell lung cancer (NSCLC): A registered, retrospective, real-world study.",Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Poster Session,['non-small cell lung cancer'],['alk-positive non-small cell lung cancer'],['alk inhibitor'],['ensartinib'],[],[],[],['alk-positive'],,Low,1
846,Molecular profiling of neoadjuvant immunochemotherapy and identification of residual cancer cells in pCR NSCLC: A single-cell analysis of CTONG 1804 clinical trial.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Poster Session,['non-small cell lung cancer'],['non-small cell lung cancer'],[],[],[],[],['bristol-myers squibb'],[],,Low,1
847,Molecular profiling and survival in oncogene-addicted resected stage IIIAN2 non-small cell lung cancer (NSCLC): A study from the Lung ART IFCT 0503 trial.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Poster Session,['non-small cell lung cancer'],['oncogene addicted resectable stage iiian2 non-small cell lung cancer'],[],[],[],[],[],['resectable'],,Low,1
848,"An international, multicenter, prospective randomized trial of adjuvant chemotherapy for stage Ia-IIa non-small cell lung cancer identified as high-risk by a 14-gene molecular assay.",Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Poster Session,['non-small cell lung cancer'],['stage ia-iia non-small cell lung cancer'],[],[],[],[],[],['stage ia'],,Low,1
850,Genomic characterization of STAS in stage 1 EGFR-mutated NSCLC and prognostic implications.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Poster Session,['non-small cell lung cancer'],['stage 1 egfr-mutant non-small cell lung cancer'],[],[],[],[],[],"['egfr mutated', 'stage i']",,Low,1
852,Association of 8-gene signature with early recurrence in resected non-small cell lung cancer.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Poster Session,['non-small cell lung cancer'],['early onset recurrent resectable non-small cell lung cancer'],[],[],[],[],[],"['resectable', 'early onset', 'recurrent']",,Low,1
855,Actionable gene alterations in resected non-small cell lung cancer (AGA-R study).,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Poster Session,['non-small cell lung cancer'],['resectable non-small cell lung cancer'],[],[],[],[],[],['resectable'],,Low,1
858,Longitudinal EGFR assessment in plasma and tissue samples in early non‚Äìsmall cell lung cancer (NSCLC).,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Poster Session,['non-small cell lung cancer'],['early onset non small cell lung cancer'],[],[],[],[],[],['early onset'],,Low,1
860,A window of opportunity study for preoperative brigatinib in resectable anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC): WILDERNESS trial.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Poster Session,['small-cell lung cancer'],['resectable anaplastic lymphoma kinase-positive non-small-cell lung cancer'],['tyrosine kinase inhibitor'],['brigatinib'],[],[],[],"['resectable', 'alk-positive']",,Low,1
861,Genomic landscape of NSCLC with no targetable driver mutation among different races: An exploratory analysis of the AACR Project GENIE Database.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Poster Session,['non-small cell lung cancer'],['non-small cell lung cancer'],[],[],[],[],[],[],,Low,1
863,Safety and efficacy of radiotherapy combined with anlotinib in locally advanced non-small cell lung cancer patients intolerant to concurrent chemoradiotherapy: Preliminary result of a phase II clinical trial.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Poster Session,['non-small cell lung cancer'],['locally advanced non-small cell lung cancer'],['multi kinase inhibitor'],['anlotinib'],[],[],['chia tai tianqing pharmaceutical'],['locally advanced'],,Low,1
865,Neoadjuvant immunotherapy and surgery in patients with stage IIIB-IIIC (N3) non-small cell lung cancer.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Poster Session,['non-small cell lung cancer'],['stage iiib-iiic non-small cell lung cancer'],[],[],[],[],[],['stage iiib'],,Low,1
866,Neoadjuvant durvalumab (D) + chemotherapy (CT) + novel anticancer agents and adjuvant D ¬± novel agents in resectable non-small-cell lung cancer (NSCLC): Updated outcomes from NeoCOAST-2.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Poster Session,['non-small cell lung cancer'],['resectable non-small cell lung cancer'],['pdl1 inhibitor'],['durvalumab'],[],[],['astrazeneca'],['resectable'],,Low,1
867,"A prospective, single-arm, phase II study to evaluate the efficacy and safety of perioperative tislelizumab in resectable non-small-cell lung cancer (NSCLC).",Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Poster Session,['non-small cell lung cancer'],['resectable non-small cell lung cancer'],['pd1 inhibitor'],['tislelizumab'],[],[],['beigene'],['resectable'],,Low,1
869,"Impact of lymph node characteristics on clinical outcomes in clinical N2 non-small cell lung cancer patients treated with chemoradiotherapy: Single- vs. multiple-stations, bulky vs. non-bulky and discrete vs. infiltrative.",Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Poster Session,['non-small cell lung cancer'],['n2 non-small cell lung cancer'],[],[],[],[],[],[],,Low,1
870,Outcomes with neoadjuvant chemotherapy and/or osimertinib in patients with EGFR-mutant resectable non-small cell lung cancers.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Poster Session,['non-small cell lung cancer'],['egfr-mutant resectable non-small cell lung cancer'],['egfr inhibitor'],['osimertinib'],[],[],[],"['egfr mutated', 'resectable']",,Low,1
872,Survival impact of lymphocytopenia during chemoradiation in locally advanced NSCLC patients treated with adjuvant durvalumab.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Poster Session,['non-small cell lung cancer'],"['locally advanced non-small cell lung cancer', 'lymphocytenia']",['pdl1 inhibitor'],['durvalumab'],[],[],[],['locally advanced'],,Low,1
875,ImmunoDriver-1: Driver alterations (dAlts) and their immunological implications in early and metastatic non-small cell lung cancer (NSCLC).,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Poster Session,['non-small cell lung cancer'],"['early onset non small cell lung cancer', 'metastatic non small cell lung cancer']",[],[],[],[],['tempus'],"['early onset', 'metastatic']",,Low,1
876,Unique mutational landscape and therapeutic implications in non-small cell lung cancer with comorbid fibrotic interstitial lung disease.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Poster Session,"['interstitial lung disease', 'non-small cell lung cancer']","['fibrotic interstitial lung disease', 'non-small cell lung cancer']",[],[],[],[],[],[],,Low,1
877,Differential prognostic significance of distant and locoregional recurrence on survival in surgically resected non-small cell lung cancer post-chemotherapy: Multicenter dynamic prediction with landmark model.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Poster Session,['non-small cell lung cancer'],['resectable non-small cell lung cancer'],[],[],[],[],[],['resectable'],,Low,1
878,Neoadjuvant hypofractionated radiotherapy plus tislelizumab with anlotinib followed by adjuvant tislelizumab with anlotinib in patients with resectable non-small cell lung cancer (NSCLC): Preliminary analysis of a phase II trial (NEO-PIONEER).,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Poster Session,['non-small cell lung cancer'],['resectable non-small cell lung cancer'],"['pd1 targeted therapy', 'multi kinase inhibitor']","['tislelizumab', 'anlotinib']",[],[],[],['resectable'],,Low,1
880,Initial results of a screening trial for evaluating oncogenic drivers in Japanese patients with surgically resected early-stage non-small cell lung cancer: LC-SCRUM-Advantage.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Poster Session,['non-small cell lung cancer'],['resectable early stage non small cell lung cancer'],[],[],[],[],[],"['early-stage', 'resectable']",,Low,1
883,Racial and ethnic disparities in receipt of guideline concordant treatment for early-stage non-small cell lung cancer in Los Angeles County.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Poster Session,['non-small cell lung cancer'],['early stage non small cell lung cancer'],[],[],[],[],[],['early-stage'],,Low,1
884,Impact of time to neoadjuvant treatment initiation (TTI) for resectable non-small cell lung cancer (NSCLC) on clinical outcomes.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Poster Session,['non-small cell lung cancer'],['resectable non-small cell lung cancer'],[],[],[],[],[],['resectable'],,Low,1
886,Real-world (rw) study to identify disparities in outcomes for patients (pts) with early-stage resected NSCLC who received biomarker-targeted adjuvant treatment (BTRx).,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Poster Session,['non-small cell lung cancer'],['early stage resectable non-small cell lung cancer'],[],[],[],[],['astrazeneca'],"['early-stage', 'resectable']",,Low,1
888,Sequential versus concurrent strategy of immunotherapy and radiotherapy in advanced non-small-cell lung cancer: A territory-wide multicenter study (OCEANUS study).,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Poster Session,['non-small cell lung cancer'],['advanced non-small cell lung cancer'],[],[],[],[],[],['advanced'],,Low,1
889,EMBER-Lung: Electronic medical record boosting molecular testing in early stage NSCLC.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Poster Session,['non-small cell lung cancer'],['early stage non-small cell lung cancer'],[],[],[],[],['advion biosciences'],['early-stage'],,Low,1
890,A retrospective study of induction immunochemotherapy followed by definitive chemoradiotherapy and consolidation immunotherapy in unresectable locally advanced non-small cell lung cancer.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Poster Session,['non-small cell lung cancer'],['unresectable locally advanced non-small cell lung cancer'],[],[],[],[],[],"['locally advanced', 'unresectable']",,Low,1
891,Association of radiomic features with disease-free survival following neoadjuvant chemoimmunotherapy in resectable NSCLC.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Poster Session,['non-small cell lung cancer'],['resectable non-small cell lung cancer'],[],[],[],[],[],['resectable'],,Low,1
892,Real-world surgical and treatment patterns after neoadjuvant checkpoint inhibition in US patients with stage II/III non-small cell lung cancer.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Poster Session,['non-small cell lung cancer'],['stage ii/stage iii non-small cell lung cancer'],[],[],[],[],['astrazeneca'],"['stage ii', 'stage iii']",,Low,1
894,Radiomic signatures as predictors of pathological response to neoadjuvant chemoimmunotherapy in surgically resected NSCLC.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Poster Session,['non-small cell lung cancer'],['resectable non-small cell lung cancer'],[],[],[],[],[],['resectable'],,Low,1
923,Comparing impact of treatment before or after surgery in patients with stage II-IIIb resectable non-small cell lung cancer (NSCLC; Alliance A082304-SWOG S2402).,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Poster Session,['NSCLC'],['stage ii-iiib resectable non-small cell lung cancer'],[],[],[],[],[],"['stage ii', 'resectable']",,Low,1
924,GEMINI-NSCLC study: Integrated longitudinal multi-omic biomarker profiling study of non-small cell lung cancer (NSCLC) patients.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Poster Session,['non-small cell lung cancer'],['non-small cell lung cancer'],[],[],[],[],"['tempus', 'astrazeneca']",[],,Low,1
925,KEYMAKER-U01E: A phase 2 umbrella study with rolling arms of investigational agents with or without chemotherapy plus pembrolizumab for resectable stage II‚ÄìIIIB (N2) non‚Äìsmall-cell lung cancer (NSCLC).,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Poster Session,['non-small cell lung cancer'],['resectable stage iia-iiia non-small cell lung cancer'],['pd1 inhibitor'],['pembrolizumab'],[],[],"['daiichi sankyo', 'merck']","['resectable', 'stage iia']",,Low,1
926,A randomized study of neoadjuvant REGN7075 + cemiplimab + chemotherapy (chemo) vs cemiplimab + chemo in patients (pts) with resectable non-small cell lung cancer (NSCLC).,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Poster Session,['non-small cell lung cancer'],['resectable non-small cell lung cancer'],"['pd1 inhibitor', 'cd3 targeted therapy', 'alkylating agent']","['regn7075', 'cemiplimab']",[],['cemiplimab'],['regeneron pharmaceuticals'],['resectable'],,Low,1
927,Phase 2 peri-operative study of fianlimab + cemiplimab + chemotherapy versus cemiplimab + chemotherapy in resectable early-stage non-small cell lung cancer (NSCLC).,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Poster Session,['non-small cell lung cancer'],['resectable early stage non small cell lung cancer'],"['pd1 inhibitor', 'lag3 inhibitor']","['fianlimab', 'cemiplimab']",[],['cemiplimab'],['regeneron pharmaceuticals'],"['early-stage', 'resectable']",,Low,1
928,"Safety, efficacy, and tumor immune microenvironment changes with neoadjuvant chemotherapy and cemiplimab with or without alirocumab in stage 1B-3A non-small cell lung cancer.",Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Poster Session,['non-small cell lung cancer'],['stage ib-stage iiia non small cell lung cancer'],['pd1 inhibitor'],['cemiplimab'],['alirocumab'],[],['regeneron pharmaceuticals'],"['stage iiia', 'stage ib']",,Low,1
929,Neoadjuvant lazertinib with or without chemotherapy for patients with epidermal growth factor receptor (EGFR)-mutated resectable non-small cell lung cancer (NSCLC): NeoLazer trial.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Poster Session,['non-small cell lung cancer'],['epidermal growth factor receptor-mutated resectable non-small cell lung cancer'],['egfr inhibitor'],['lazertinib'],[],[],[],['resectable'],,Low,1
930,Neotrace: A multicenter phase II study of neoadjuvant sacituzumab govitecan plus zimberelimab followed by adjuvant zimberelimab with or without sacituzumab govitecan in patients with resectable non-small cell lung cancer.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Poster Session,['non-small cell lung cancer'],['resectable non-small cell lung cancer'],"['pd1 targeted therapy', 'top1 inhibitor']","['zimberelimab', 'sacituzumab govitecan']",['sacituzumab govitecan'],[],[],['resectable'],,Low,1
942,The effect of metformin exposure on colorectal cancer incidence according to tumor sidedness.,"Prevention, Risk Reduction, and Genetics",Poster Session,['colorectal cancer'],['colorectal cancer'],['biguanide'],['metformin'],[],[],[],[],,Low,1
944,Colonoscopy quality indicators for colorectal cancer precursors: Sessile serrated lesion and adenoma detection rates from a large clinical study of a blood-based test for CRC screening.,"Prevention, Risk Reduction, and Genetics",Poster Session,['colorectal cancer'],"['colorectal cancer', 'sessile serrated lesion']",[],[],[],[],['freenome'],[],,Low,1
964,Impact of 2021 United States cancer screening guideline changes on racial and ethnic differences in patient-reported adherence to age-appropriate colorectal cancer screening.,"Prevention, Risk Reduction, and Genetics",Poster Session,['colorectal cancer'],['colorectal cancer'],[],[],[],[],[],[],,Low,1
966,Global burden and trend of pancreatic cancer in high-income countries: A 30-year analysis of disease dynamics.,"Prevention, Risk Reduction, and Genetics",Poster Session,['pancreatic cancer'],['pancreatic cancer'],[],[],[],[],[],[],,Low,1
979,Epidemiology of MET gene mRNA expression in metastatic colorectal cancer: Analyses of a real-world clinicogenomic database.,"Prevention, Risk Reduction, and Genetics",Poster Session,['colorectal cancer'],['met expressing colorectal cancer'],[],[],[],[],['abbvie'],[],,Low,1
988,Histopathologic and demographic features of non-small cell lung cancer in patients with BRCA pathogenic germline variants.,"Prevention, Risk Reduction, and Genetics",Poster Session,['non-small cell lung cancer'],['brca pathogenic germline variant non-small cell lung cancer'],[],[],[],[],[],[],,Low,1
994,Mainstreaming the diagnosis of Lynch syndrome (LS) in colorectal cancer (CRC) patients: The ItaLynch study.,"Prevention, Risk Reduction, and Genetics",Poster Session,"['colorectal cancer', 'lynch syndrome']","['colorectal cancer', 'lynch syndrome']",[],[],[],[],[],[],,Low,1
1004,Clinical significance of germline CFTR mutations in pancreatic cancer.,"Prevention, Risk Reduction, and Genetics",Poster Session,['pancreatic cancer'],['pancreatic cancer'],[],[],[],[],[],[],,Low,1
1007,Germline genetic testing among patients with pancreatic cancer (PC): A Pancreatic Cancer Action Network (PanCAN) patient survey.,"Prevention, Risk Reduction, and Genetics",Poster Session,['pancreatic cancer'],['pancreatic cancer'],[],[],[],[],[],[],,Low,1
1165,"Krascendo 2: A phase III study of divarasib and pembrolizumab vs pembrolizumab and chemotherapy in patients with previously untreated, advanced or metastatic, KRAS G12C-mutated non-small cell lung cancer (NSCLC).",Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['previously untreated advanced/metastatic kras g12c-mutated non-small cell lung cancer'],"['pd1 inhibitor', 'kras g12c inhibitor']","['pembrolizumab', 'divarasib']",[],['pembrolizumab'],"['genentech', 'roche', 'chugai pharmaceutical']","['kras g12c-mutant', 'previously untreated advanced', 'metastatic']",,High,
1172,A randomized phase 3 study of ivonescimab plus chemotherapy versus pembrolizumab plus chemotherapy for the first-line treatment of metastatic non‚Äìsmall cell lung cancer: HARMONi-3.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['first line metastatic non small cell lung cancer'],['pd1/vegf bispecific antibody'],['ivonescimab'],[],['pembrolizumab'],['summit therapeutics'],"['first-line', 'metastatic']",,High,
1041,First-line (1L) datopotamab deruxtecan (Dato-DXd) + rilvegostomig in advanced or metastatic non-small cell lung cancer (a/mNSCLC): Results from TROPION-Lung04 (cohort 5).,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],"['advanced non-small cell lung cancer', 'metastatic non-small cell lung cancer']","['pd1 inhibitor', 'trop2 antibody drug conjugate']","['datopotamab deruxtecan', 'rilvegostomig']",[],[],"['daiichi sankyo', 'astrazeneca']","['advanced', 'metastatic']",,Low,1
1042,Exploratory ctDNA analyses for the EVOKE-1 study in metastatic non-small cell lung cancer (mNSCLC).,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['metastatic non-small cell lung cancer'],[],[],[],[],['gilead sciences'],['metastatic'],,Low,1
1044,Potential biomarker of PD-L1 expression phenotypes in tumor and immune cells for combined PD-1 and CTLA-4 blockade therapies in advanced NSCLC.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['advanced non-small cell lung cancer'],"['pd1 inhibitor', 'ctla4 inhibitor']",[],[],[],[],['advanced'],,Low,1
1045,"Effects of immediate elevation of inflammatory cytokines after platinum, pemetrexed, and pembrolizumab on antitumor efficacy in advanced non-squamous, non-small cell lung cancer.",Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-squamous non-small cell lung cancer'],['advanced non-squamous non-small cell lung cancer'],"['antimetabolite', 'pd1 inhibitor']","['pembrolizumab', 'pemetrexed']",[],[],[],['advanced'],,Low,1
1046,Characterization of histology-dependent immunobiological differences in metastatic NSCLC: Implications for treatment with PD-1 and LAG-3 inhibitors.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['metastatic non-small cell lung cancer'],"['pd1 inhibitor', 'lag3 inhibitor']",[],[],[],"['bristol-myers squibb', 'ono pharmaceutical']",['metastatic'],,Low,1
1047,Unraveling relatlimab (RELA)-specific biology: Biomarker analyses in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) treated with 1L nivolumab (NIVO) + RELA high-dose (HD) and platinum-doublet chemotherapy (PDCT).,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['metastatic non-small cell lung cancer'],"['pd1 inhibitor', 'alkylating agent', 'top2 inhibitor', 'ctla4 targeted therapy']","['nivolumab', 'relatlimab']",[],[],['bristol-myers squibb'],['metastatic'],,Low,1
1048,Genomic and circulating tumor DNA landscape in young-onset non-small cell lung cancer.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['young onset non small cell lung cancer'],[],[],[],[],['guardant health'],['young'],,Low,1
1049,Sacituzumab tirumotecan (sac-TMT) in combination with tagitanlimab (anti-PD-L1) in first-line (1L) advanced non-small-cell lung cancer (NSCLC): Non-squamous cohort from the phase II OptiTROP-Lung01 study.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-squamous non-small cell lung cancer'],['first line advanced non-squamous non-small cell lung cancer'],"['trop2 targeted therapy', 'pdl1 inhibitor']","['tagitanlimab', 'sacituzumab tirumotecan']",[],[],['sichuan kelun-biotech biopharmaceutical'],['first-line advanced'],,Low,1
1050,"Clinical, genomic, and pathological features and therapeutic outcomes of non-small cell lung cancer with MTAP-loss.",Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['mtap loss non-small cell lung cancer'],[],[],[],[],[],['mtap-deficient'],,Low,1
1051,Tumor-derived ILT5 and suppression of T cell immunity in non-small cell lung cancer.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['non-small cell lung cancer'],[],[],[],[],[],[],,Low,1
1052,Host immune classifier to predict survival with chemoimmunotherapy in PD-L1 ‚â•50% metastatic NSCLC.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['pd-l1-mutant metastatic non-small cell lung cancer'],[],[],[],[],['biodesix'],['metastatic'],,Low,1
1337,Multicenter study of the impact of trial eligibility criteria on enrollment to KRAS G12C inhibitor trials in patients with non-small cell lung cancer.,Quality Care/Health Services Research,Poster Session,['non-small cell lung cancer'],['non-small cell lung cancer'],['kras g12c inhibitor'],[],[],[],[],[],,High,
1055,Artificial intelligence-powered spatial analysis of tumor microenvironment in non-small cell lung cancer patients who acquired resistance after EGFR tyrosine kinase inhibitors.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['non-small cell lung cancer'],['egfr tyrosine kinase inhibitor'],[],[],[],[],[],,Low,1
1057,Clinical outcomes and characterization of HER2 alterations in non-small cell lung cancer (NSCLC).,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['her2 altered non-small cell lung cancer'],[],[],[],[],['caris life sciences'],[],,Low,1
1490,First-line adagrasib (ADA) with pembrolizumab (PEMBRO) in patients (pts) with advanced/metastatic KRASG12C-mutated non-small cell lung cancer (NSCLC) from the phase 2 portion of the KRYSTAL-7 study.,Lung Cancer - Non-Small Cell Metastatic,Oral Abstract Session,['non-small cell lung cancer'],['first line advanced/metastatic krasg12c-mutated non-small cell lung cancer'],"['pd1 inhibitor', 'kras g12c inhibitor']","['pembrolizumab', 'adagrasib']",[],[],"['mirati therapeutics', 'bristol-myers squibb']","['metastatic', 'first-line advanced']",,High,
1061,Prediction of site-specific immune-related adverse events of PD-L1 blockade in advanced non-small cell lung cancer through baseline organ-metastatic landscape: Pooled post-hoc analyses of two randomized controlled trials.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['advanced non-small cell lung cancer'],['pdl1 inhibitor'],[],[],[],[],['advanced'],,Low,1
1062,"A phase II trial to evaluate the safety and efficacy of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, as a monotherapy in patients with advanced NSCLC.",Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['advanced non-small cell lung cancer'],['pd1/vegf bispecific antibody'],['ssgj-707'],[],[],['shenyang sunshine pharmaceuticals'],['advanced'],,Low,1
1063,Clinical features associated with an exceptional response to immunotherapy in patients with metastatic non-small cell lung cancer (NSCLC).,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['metastatic non-small cell lung cancer'],[],[],[],[],[],['metastatic'],,Low,1
1064,Breaking barriers for patients with stage IV non-small cell lung cancer with brain metastases: Insight into the impact of immunotherapy on survival and survival disparities.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,"['secondary brain cancer', 'non-small cell lung cancer']","['stage iv non-small cell lung cancer', 'brain metastasis']",[],[],[],[],[],['metastatic'],,Low,1
1065,Association between pretreatment emotional distress and survival outcomes in patients with advanced non‚Äìsmall-cell lung cancer: An individual patient data meta-analysis of 4632 patients in 7 trials.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['advanced non-small cell lung cancer'],[],[],[],[],['astrazeneca'],['advanced'],,Low,1
1067,"Camrelizumab combined with 2 cycles of chemotherapy as first-line treatment for advanced non-small cell lung cancer (NSCLC): A two-arm, single-center, phase 2 study.",Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['first-line advanced non-small cell lung cancer'],['pd1 targeted therapy'],['camrelizumab'],[],[],[],['first-line advanced'],,Low,1
1068,Evaluation of the combination of regorafenib + avelumab in patients with non-small cell lung cancer without oncogenic addiction: The phase II REGOMUNE study.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['non-small cell lung cancer'],"['multi kinase inhibitor', 'pdl1 targeted therapy']","['regorafenib', 'avelumab']",[],[],"['bayer', 'merck']",[],,Low,1
1069,Identification of immunotherapy early treatment failure in non-small cell lung cancer (NSCLC) using a novel cell-free DNA (cfDNA) tissue-agnostic genome-wide methylome enrichment assay.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['non-small cell lung cancer'],[],[],[],[],['adela'],[],,Low,1
1070,A phase I trial of intratumoral adenovirus-interleukin-12 (IT-ADV/IL-12) and atezolizumab in metastatic non-small cell lung cancer (NSCLC) progressed on first-line immunotherapy.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['metastatic non-small cell lung cancer'],"['adenovirus interleukin 12 therapy', 'pdl1 inhibitor']",['atezolizumab'],[],[],[],['metastatic'],,Low,1
1071,Circulating CD28-KLRG1+CD8+ T cells as prognostic indicators in advanced NSCLC chemoimmunotherapy.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['advanced non-small cell lung cancer'],[],[],[],[],[],['advanced'],,Low,1
1072,T-cell effector cytokine signature as predictor of survival and toxicity in metastatic NSCLC patients treated with immunotherapy.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['metastatic non-small cell lung cancer'],[],[],[],[],[],['metastatic'],,Low,1
1073,Comparative efficacy of osimertinib with and without radiation therapy in EGFR-mutated non-small cell lung cancer with brain metastases.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,"['secondary brain cancer', 'non-small cell lung cancer']","['egfr-mutated non-small cell lung cancer', 'brain metastasis']",['egfr inhibitor'],['osimertinib'],[],[],[],['egfr mutated'],,Low,1
1077,Phase 2 study of pembrolizumab (pembro) plus plinabulin (plin) and docetaxel (doc) for patients (pts) with metastatic NSCLC after progression on first-line immune checkpoint inhibitor alone or combination therapy: Initial efficacy and safety results on immune re-sensitization.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['metastatic non-small cell lung cancer'],"['microtubule destabilising agent', 'top2 inhibitor', 'pd1 inhibitor']","['plinabulin', 'pembrolizumab', 'docetaxel']",[],[],"['merck sharp & dohme', 'beyondspring pharmaceuticals']",['metastatic'],,Low,1
1078,A phase 2 study of HLX07 plus serplulimab with or without chemotherapy versus serplulimab plus chemotherapy as first-line therapy in advanced squamous non-small cell lung cancer.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['squamous non-small cell lung cancer'],['first line advanced squamous non-small cell lung cancer'],"['pd1 targeted therapy', 'egfr targeted antibody']","['serplulimab', 'hlx07']",[],['serplulimab'],['shanghai henlius biotech'],['first-line advanced'],,Low,1
1079,Differential predictive impact of PD-L1 expression on immunotherapy outcomes and immunophenotype in squamous versus non-squamous NSCLC.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,"['squamous non-small cell lung cancer', 'non-squamous non-small cell lung cancer']","['pd-l1 expressing non-squamous non-small cell lung cancer', 'pd-l1 expressing squamous non-small cell lung cancer']",[],[],[],[],[],['pd-l1 expressing'],,Low,1
1080,Clinical outcomes and predictors of response to PD-(L)1 blockade in patients with oncogene-driver negative NSCLC who have never smoked.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['oncogene-driver negative non-small cell lung cancer'],[],[],[],[],[],['driven gene-negative'],,Low,1
1081,Efficacy and safety of metronomic oral vinorelbine combined with PD-1 inhibitors as first-line therapy in advanced non-small-cell lung cancer in elderly patients.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['first-line elderly advanced non-small cell lung cancer'],"['pd1 inhibitor', 'vinca alkaloid']",['vinorelbine'],[],[],[],"['advanced', 'first-line', 'elderly']",,Low,1
1083,Race-associated clinicogenomic correlates of outcomes to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer (NSCLC).,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['non-small cell lung cancer'],[],[],[],[],[],[],,Low,1
1084,Predictive implications of immune-related adverse events after exposure to VEGF inhibitors on outcomes in patients with advanced NSCLC treated with prior immune check point inhibitor.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['advanced non-small cell lung cancer'],['vegf inhibitor'],[],[],[],[],['advanced'],,Low,1
1085,Digital pathology‚Äìbased AI spatial biomarker to predict outcomes for immune checkpoint inhibitors in advanced non-small cell lung cancer.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['advanced non-small cell lung cancer'],[],[],[],[],[],['advanced'],,Low,1
1086,SMET12 and toripalimab combined chemotherapy in patients with advanced non-small cell lung cancer who are treatment-naive or have developed resistance to standard therapy.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['treatment naive/resistant advanced non-small cell lung cancer'],"['pd1 targeted therapy', 'cd3/egfr bispecific antibody']","['toripalimab', 'smet12']",[],[],[],['advanced'],,Low,1
1087,Exploratory study on the impact of intestinal low-dose radiation on the efficacy and prognosis of immunotherapy in metastatic non-small cell lung cancer.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['metastatic non-small cell lung cancer'],[],[],[],[],[],['metastatic'],,Low,1
1088,Artificial intelligence-powered spatial analysis of tumor infiltrating lymphocytes and tertiary lymphoid structures in non-small cell lung cancer patients treated with immune-checkpoint inhibitors¬±chemotherapy.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['non-small cell lung cancer'],[],[],[],[],[],[],,Low,1
1089,"First-line envafolimab in combination with recombinant human endostatin and chemotherapy for advanced squamous non-small cell lung cancer: Updated results from a prospective, single-arm, multicenter phase II study.",Lung Cancer - Non - Small Cell Metastatic,Poster Session,['squamous non-small cell lung cancer'],['advanced squamous non-small cell lung cancer'],['pd1 inhibitor'],['envafolimab'],[],[],[],['advanced'],,Low,1
1090,First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors for patients with BRAFV600E-mutated metastatic non-small cell lung cancer: The FRONT-BRAF study.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['first line braf v600e-mutant metastatic non-small cell lung cancer'],[],[],[],[],[],"['braf v600e-mutant', 'first-line', 'metastatic']",,Low,1
1091,A meta-analysis of safety and efficacy of datopotamab deruxtecan and sacituzumab govitecan for second line treatment of metastatic non-small cell lung cancer (NSCLC).,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['second line metastatic non-small cell lung cancer'],"['trop2 antibody drug conjugate', 'top inhibitor']","['datopotamab deruxtecan', 'sacituzumab govitecan']",[],[],[],"['second-line', 'metastatic']",,Low,1
1094,"Multimodal AI using host, tumor, and ghost biomarker for predicting immunotherapy efficacy in NSCLC.",Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['non-small cell lung cancer'],[],[],[],[],[],[],,Low,1
1095,Longitudinal plasma proteomic analysis: A monitoring strategy for NSCLC patients treated with immunotherapy.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['non-small cell lung cancer'],[],[],[],[],['oncohost'],[],,Low,1
1096,Phase 2 study of atezolizumab with carboplatin plus pemetrexed followed by maintenance atezolizumab with pemetrexed for elderly patients with advanced non-squamous non-small cell lung cancer: CJLSG1902.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-squamous non-small cell lung cancer'],['elderly advanced non-squamous non-small cell lung cancer'],"['antimetabolite', 'pdl1 targeted therapy', 'alkylating agent']","['pemetrexed', 'atezolizumab', 'carboplatin']","['pemetrexed', 'atezolizumab']",[],[],"['advanced', 'elderly']",,Low,1
1097,Radiomic phenotypes of tumor angiogenesis compared with PD-L1 in pre-treatment prediction of outcomes across immunotherapy regimens in NSCLC: An external validation study.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['non-small cell lung cancer'],[],[],[],[],[],[],,Low,1
1098,Validation of HistoTME-predicted immune subtypes and immunotherapy outcomes using human interpretable features (HIFs) from H&E images in non-small cell lung cancer.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['non-small cell lung cancer'],[],[],[],[],[],[],,Low,1
1099,Survival and safety of two year-fixed duration vs continuous immune checkpoint inhibitor therapy in advanced or metastatic NSCLC: A systematic review.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['advanced/metastatic non-small cell lung cancer'],[],[],[],[],[],"['advanced', 'metastatic']",,Low,1
1100,Phase 2 study of telomere-targeting agent THIO sequenced with cemiplimab in third-line immune checkpoint inhibitor‚Äìresistant advanced NSCLC: Evaluation of overall survival (OS).,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['third-line advanced non-small cell lung cancer'],"['pd1 targeted therapy', 'telomerase inhibitor']","['thio', 'cemiplimab']",[],[],['maia biotechnology'],"['advanced', 'third-line']",,Low,1
1102,"Survival after osimertinib dose-reduction, discontinuation in 1L EGFR-mutated metastatic non-small cell lung cancer (mNSCLC).",Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['first line egfr-mutant metastatic non-small cell lung cancer'],['egfr inhibitor'],['osimertinib'],[],[],[],"['egfr mutated', 'first-line', 'metastatic']",,Low,1
1103,Clinical relevance of starting alectinib at a reduced dose in patients with ALK-positive non-small cell lung cancer.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['alk-positive non-small cell lung cancer'],['alk inhibitor'],['alectinib'],[],[],[],['alk-positive'],,Low,1
1104,Depth of response and progression-free survival in patients with advanced ALK-positive non‚Äìsmall-cell lung cancer treated with lorlatinib.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['advanced alk-positive non small cell lung cancer'],['alk/ros1 inhibitor'],['lorlatinib'],[],[],['pfizer'],"['advanced', 'alk-positive']",,Low,1
1105,Impact of lorlatinib dose modifications on adverse event outcomes in the phase 3 CROWN study.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['metastatic non-small cell lung cancer'],['alk/ros1 inhibitor'],['lorlatinib'],[],[],['pfizer'],['metastatic'],,Low,1
1106,"Dynamic changes in target protein expression following treatment in NSCLC: Simultaneous evaluation of MET, TROP2, HER2, B7-H4, and MDM2 expression in paired biopsies.",Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],"['her2 expressed non-small cell lung cancer', 'met expressed non-small cell lung cancer', 'mdm2 expressed non-small cell lung cancer', 'b7-h4 expressed non-small cell lung cancer', 'trop2 expressed non-small cell lung cancer']",[],[],[],[],[],[],,Low,1
1642,Should we treat TP53-mutated high-risk myeloid neoplasms in older patients?,"Hematologic Malignancies - Leukemia, Myelodysplastic Syndromes, and Allotransplant",Poster Session,['myeloid tumor'],['tp53-mutant high risk myeloid neoplasm'],[],[],[],[],[],"['tp53-mutated', 'high-risk']",,High,1
1108,Area deprivation index and EGFR-mutated non-small-cell lung cancer.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['egfr-mutant non-small cell lung cancer'],[],[],[],[],[],['egfr mutated'],,Low,1
1109,Final results of afatinib plus chemotherapy with genomic profiling in osimertinib-refractory EGFR-mutant NSCLC: NEJ025B.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['refractory egfr-mutant non-small cell lung cancer'],['egfr inhibitor'],"['osimertinib', 'afatinib']",[],[],[],"['egfr mutated', 'refractory']",,Low,1
1111,Longer follow-up for survival and safety from the EVOKE-01 trial of sacituzumab govitecan (SG) vs docetaxel in patients (pts) with metastatic non-small cell lung cancer (mNSCLC).,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['metastatic non-small cell lung cancer'],"['trop2 antibody drug conjugate', 'taxane']",['sacituzumab govitecan'],[],['docetaxel'],['gilead sciences'],['metastatic'],,Low,1
1112,A retrospective study of anlotinib plus third-generation EGFR-TKIs in advanced non-small cell lung cancer with gradual or oligo progression after EGFR-TKIs treatment (ALTER-L058).,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['advanced non-small cell lung cancer'],"['multi kinase inhibitor', 'egfr inhibitor']",['anlotinib'],[],[],['chiatianqing pharmaceutical'],['advanced'],,Low,1
1115,Real-world treatment patterns and time-to-treatment discontinuation among advanced ALK-positive non-small cell lung cancer patients.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['advanced alk-positive non-small cell lung cancer'],[],[],[],[],[],"['advanced', 'alk-positive']",,Low,1
1116,Osimertinib plus repotrectinib phase I trial in TKI-resistant non-small cell lung cancer (NSCLC) with EGFR mutations.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['egfr-mutant non-small cell lung cancer'],"['ros1 inhibitor', 'egfr inhibitor']","['osimertinib', 'repotrectinib']",[],[],['turning point therapeutics'],['egfr mutated'],,Low,1
1648,Impact of TP53 mutations and variant allelic frequency on survival in adults with newly diagnosed acute lymphoblastic leukemia.,"Hematologic Malignancies - Leukemia, Myelodysplastic Syndromes, and Allotransplant",Poster Session,['acute lymphocytic leukemia'],['adult newly diagnosed acute lymphocytic leukemia'],[],[],[],[],[],"['adult', 'newly diagnosed']",,High,1
1120,Real-world comparative outcomes of alectinib and brigatinib in ALK-positive non‚Äìsmall cell lung cancer: A retrospective cohort analysis using HIRA data.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['alk-positive non small cell lung cancer'],['alk inhibitor'],['alectinib'],[],['brigatinib'],[],['alk-positive'],,Low,1
1121,High-dose furmonertinib combined with bevacizumab and pemetrexed in non-small cell lung cancer patients with EGFR mutations and leptomeningeal metastasis: A prospective real-world study.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,"['non-small cell lung cancer', 'neoplastic meningitis']","['leptomeningeal metastasis', 'egfr-mutant non-small cell lung cancer']","['vegf targeted therapy', 'antifolate', 'egfr inhibitor']","['furmonertinib', 'bevacizumab', 'pemetrexed']",[],[],[],['egfr mutated'],,Low,1
1123,"Interim results of PDL1V (PF-08046054), a vedotin-based ADC targeting PD-L1, in patients with NSCLC in a phase 1 trial.",Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['non-small cell lung cancer'],['pdl1 antibody drug conjugate'],['pf-08046054'],[],[],"['seagen', 'pfizer']",[],,Low,1
1124,Exploring decisional needs of patients considering first line treatment of advanced EGFR+ lung cancer: An interpretive descriptive study.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['first-line advanced egfr-positive non-small cell lung cancer'],[],[],[],[],[],['first-line advanced'],,Low,1
1125,"MYTX-011, a cMET-targeting antibody-drug conjugate (ADC), in patients with previously treated, advanced NSCLC: Updated dose escalation results in the phase 1 KisMET-01 study.",Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['previously treated advanced non-small cell lung cancer'],['cmet antibody drug conjugate'],['mytx-011'],[],[],['mythic therapeutics'],"['advanced', 'previously treated']",,Low,1
1126,GBC-11004: An AI-driven novel kinase target with potential to overcome osimertinib resistance in NSCLC.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['non-small cell lung cancer'],['egfr inhibitor'],['gbc-11004'],[],[],[],[],,Low,1
1127,Sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated locally advanced or metastatic (LA/M) non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: Preliminary results from a phase 2 study.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['previously treated locally advanced/metastatic non-small cell lung cancer'],['trop2 antibody drug conjugate'],['sacituzumab tirumotecan'],[],[],['sichuan kelun-biotech biopharmaceutical'],"['previously treated', 'metastatic', 'locally advanced']",,Low,1
1128,"Phase I/II study of DZD6008, a 4th-generation EGFR TKI with full BBB penetration, in EGFR-mutant NSCLC.",Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['egfr mutant non-small cell lung cancer'],['egfr inhibitor'],['dzd6008'],[],[],['dizal pharmaceutical'],['egfr mutated'],,Low,1
1129,Patient and caregiver treatment preferences for ALK+ non-small cell lung cancer in the United States.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['alk-positive non-small cell lung cancer'],[],[],[],[],['takeda'],['alk-positive'],,Low,1
1130,"LUMINOSITY, a phase 2 study of telisotuzumab vedotin in patients with c-Met protein‚Äìoverexpressing non-squamous EGFR-wildtype advanced NSCLC: Efficacy outcomes by prior therapy.",Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['c-met protein overexpressing non-squamous egfr-wild type advanced non-small cell lung cancer'],['cmet antibody drug conjugate'],['telisotuzumab vedotin'],[],[],['abbvie'],['advanced'],,Low,1
1131,EATON: A phase I trial of nazartinib (EGF816) and trametinib in EGFR-mutant (EGFRmut) non-small cell lung cancer (NSCLC).,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['egfr mutant non-small cell lung cancer'],"['mek inhibitor', 'egfr inhibitor']","['nazartinib', 'trametinib']",[],[],[],['egfr mutated'],,Low,1
1132,Patient-reported outcomes (PRO) evaluating physical functioning and symptoms in patients with pretreated HER2-mutant advanced non-small cell lung cancer (NSCLC): Results from the Beamion LUNG-1 trial.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['previously treated her2-mutant advanced non-small cell lung cancer'],[],[],[],[],['boehringer ingelheim'],"['advanced', 'previously treated']",,Low,1
1133,Advancing evidence-based NSCLC testing and treatment across academic and community-based settings.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['non-small cell lung cancer'],[],[],[],[],[],[],,Low,1
1134,Novel potent and selective fourth-generation inhibitors targeting EGFR for NSCLC therapy.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['egfr-mutant non-small cell lung cancer'],['egfr inhibitor'],[],[],[],[],['egfr mutated'],,Low,1
1135,Final overall survival analysis for a phase 3 randomized trial comparing afatinib to chemotherapy in treatment-na√Øve non-small cell lung cancer with a sensitizing uncommon epidermal growth factor receptor mutation (ACHILLES/TORG1834).,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['treatment na√Øve egfr-mutant non-small cell lung cancer'],['egfr inhibitor'],['afatinib'],[],[],[],['egfr mutated'],,Low,1
1137,Rare ALK: Clinical characteristics and efficacy of targeted therapy in NSCLC with ALK fusions other than EML4::ALK.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],"['eml4::alk fusion non-small cell lung cancer', 'alk fusion non-small cell lung cancer']",[],[],[],[],[],[],,Low,1
1138,Clinico-genomic characteristics of clinical trial participation and its impact on clinical outcome in metastatic NSCLC: A nationwide database analysis in Japan.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['metastatic non-small cell lung cancer'],[],[],[],[],[],['metastatic'],,Low,1
1139,"Osimertinib plus anlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer with concurrent gene alterations: A single-arm, prospective, multicenter phase II study.",Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['untreated egfr-mutated advanced non-small cell lung cancer'],"['multi kinase inhibitor', 'egfr inhibitor']","['osimertinib', 'anlotinib']",[],[],[],"['egfr mutated', 'advanced', 'untreated']",,Low,1
1140,Association of circulating tumor DNA (ctDNA) variant allelic frequency (VAF) with outcomes on matched targeted therapies (TT) in advanced non-small cell lung cancer (aNSCLC).,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['advanced non-small cell lung cancer'],[],[],[],[],['foundation medicine'],['advanced'],,Low,1
1989,Distinguishing tumor vs. clonal hematopoiesis (CH)‚Äìderived TP53 and BRCA1/2 alterations in ovarian cancer liquid biopsies with a predictive algorithm to inform clinical decision-making.,Gynecologic Cancer,Poster Session,['ovarian cancer'],"['tp53-altered ovarian cancer', 'brca1/2 altered ovarian cancer']",[],[],[],[],['foundation medicine'],['tp53 altered'],,High,1
1142,Clinical outcomes of tepotinib and immune checkpoint inhibitor therapy for MET exon 14 skipping NSCLC: A multicentric retrospective analysis.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['met exon 14 skipping non-small cell lung cancer'],"['immune checkpoint inhibitor', 'met inhibitor']",['tepotinib'],[],[],[],['met exon 14 skipping'],,Low,1
1143,Vebreltinib plus PLB1004 in EGFR-mutated NSCLC with acquired MET amplification or overexpression after failure on EGFR-TKI treatment: A phase Ib/II study.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['acquired met amplified/overexpressed egfr-mutated non-small cell lung cancer'],"['met inhibitor', 'egfr inhibitor']","['vebreltinib', 'plb-1004']",[],[],['avistone biotechnology'],"['met-amplified', 'egfr mutated']",,Low,1
1144,Hypothesis generative head-to-head study comparing efficacy of afatinib and osimertinib based on immunological biomarkers in Japanese NSCLC patients with EGFR mutations: Heat on Beat randomized phase II study.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['egfr-mutant non-small cell lung cancer'],['egfr inhibitor'],"['osimertinib', 'afatinib']",[],"['osimertinib', 'afatinib']",['nippon boehringer ingelheim'],['egfr mutated'],,Low,1
1145,Therapeutic responses in 555 advanced NSCLC patients enrolled in phase I studies at MD Anderson Cancer Center.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['advanced non-small cell lung cancer'],[],[],[],[],[],['advanced'],,Low,1
1146,Artificial intelligence-powered real-time model for predicting survival in advanced EGFR-mutant NSCLC.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['advanced egfr-mutant non-small cell lung cancer'],[],[],[],[],[],"['egfr mutated', 'advanced']",,Low,1
1147,Efficacy and omics-based insights of TROP2 ADC in non‚Äìsmall cell lung cancer with or without actionable genomic alterations (AGAs).,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],"['non-small cell lung cancer', 'actionable genomic altered non-small cell lung cancer']",['trop2 antibody drug conjugate'],[],[],[],[],[],,Low,1
1149,Amivantamab plus chemotherapy vs chemotherapy in EGFR-mutant advanced NSCLC after disease progression on osimertinib: Outcomes by osimertinib resistance mechanisms in MARIPOSA-2.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['egfr-mutant advanced non-small cell lung cancer'],"['egfr targeted therapy', 'alkylating agent']",['amivantamab'],[],['osimertinib'],['johnson & johnson'],"['egfr mutated', 'advanced']",,Low,1
1150,"Vabametkib in MET exon 14 skipping non-small-cell lung cancer: Efficacy and safety from the open-label, phase 2, cohort-1 trial.",Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['met exon 14 skipping non-small cell lung cancer'],['met inhibitor'],['vabametkib'],[],[],['abion'],['met exon 14 skipping'],,Low,1
1151,Dermatologic prophylaxis and impact on patient-reported outcomes in first-line EGFR-mutant advanced NSCLC treated with amivantamab plus lazertinib: Results from the phase 2 COCOON trial.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['first-line egfr-mutant advanced non-small cell lung cancer'],"['egfr/met bispecific antibody', 'egfr inhibitor']","['amivantamab', 'lazertinib']",[],[],['johnson & johnson'],"['egfr mutated', 'advanced', 'first-line']",,Low,1
1152,"Use of targeted therapy, healthcare costs, and survival with large panel testing, narrow testing, or no molecular testing in patients with metastatic non-small cell lung cancer (mNSCLC).",Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['metastatic non-small cell lung cancer'],[],[],[],[],['guardant health'],['metastatic'],,Low,1
1153,Comparable efficacy and safety of taletrectinib for advanced ROS1+ non‚Äìsmall cell lung cancer across pivotal studies and between races and world regions.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['advanced ros1-positive non-small cell lung cancer'],['ros1 inhibitor'],['taletrectinib'],[],[],['nuvation bio'],"['ros1-positive', 'advanced']",,Low,1
1154,Efficacy and safety of pralsetinib in patients with advanced RET-fusion-positive NSCLC: Final data from the phase 1/2 ARROW study.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['advanced ret fusion-positive non-small cell lung cancer'],['ret inhibitor'],['pralsetinib'],[],[],"['roche', 'rigel pharmaceuticals']",['advanced'],,Low,1
1156,Rechallenge with first-generation RET inhibitors in RET-rearranged NSCLC pre-treated with selpercatinib or pralsetinib: Results from the RET MAP registry.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['ret-rearranged pretreated non-small cell lung cancer'],['ret inhibitor'],"['pralsetinib', 'selpercatinib']",[],[],[],"['previously treated', 'ret-rearranged']",,Low,1
1157,TROPION-Lung14: A phase 3 study of osimertinib ¬± datopotamab deruxtecan (Dato-DXd) as first-line (1L) treatment for patients with EGFR-mutated locally advanced or metastatic (LA/M) non-small cell lung cancer (NSCLC).,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['first line egfr-mutated locally advanced/metastatic non-small cell lung cancer'],['egfr inhibitor'],['osimertinib'],['datopotamab deruxtecan'],[],"['daiichi sankyo', 'astrazeneca']","['egfr mutated', 'first-line', 'locally advanced', 'metastatic']",,Low,1
1158,SOHO-02: Phase III trial of BAY 2927088 in patients with locally advanced or metastatic NSCLC with HER2-activating mutations.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],"['her2-activating mutant locally advanced non-small cell lung cancer', 'her2-activating mutant metastatic non-small cell lung cancer']",['her2 inhibitor'],['bay-2927088'],[],[],['bayer'],"['metastatic', 'locally advanced']",,Low,1
1995,E7386 study 102: Global dose-expansion cohort of E7386 + lenvatinib (LEN) in patients (pts) with advanced endometrial cancer (aEC) that progressed on platinum-based chemotherapy (chemo) and an anti-PD-(L)1 immunotherapy (IO).,Gynecologic Cancer,Poster Session,['endometrial cancer'],['advanced endometrial cancer'],"['vegfr inhibitor', 'cbp/beta catenin inhibitor']","['e7386', 'lenvatinib']",[],[],['eisai'],['advanced'],,High,
1160,"Phase 1/2 clinical trial of JIN-A02, a 4th generation EGFR-TKI in EGFR-mutated advanced/metastatic non-small cell lung cancer.",Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],"['egfr-mutated advanced non-small cell lung cancer', 'egfr-mutated metastatic non-small cell lung cancer']",['egfr inhibitor'],['jin-a02'],[],[],['j ints bio'],"['egfr mutated', 'advanced', 'metastatic']",,Low,1
1161,Phase 3 trial of the therapeutic cancer vaccine OSE2101 versus docetaxel in patients with metastatic non-small cell lung cancer and secondary resistance to immunotherapy.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['metastatic non-small cell lung cancer'],['cancer vaccine'],['ose-2101'],[],['docetaxel'],"['genome diagnostics', 'ose immunotherapeutics']",['metastatic'],,Low,1
1162,KEYMAKER-U01 substudy 01A: Phase 1/2 study of pembrolizumab plus ifinatamab deruxtecan (I-DXd) or patritumab deruxtecan (HER3-DXd) with or without chemotherapy in untreated stage IV non‚Äìsmall-cell lung cancer.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['untreated stage iv non-small cell lung cancer'],"['her3 antibody drug conjugate', 'pd1 targeted therapy', 'antibody drug conjugate']","['pembrolizumab', 'patritumab deruxtecan', 'ifinatamab deruxtecan']",[],[],"['daiichi sankyo', 'merck']","['untreated', 'metastatic']",,Low,1
1163,"ARTEMIDE-Lung03: A phase 3, randomized, double-blind, multicenter, global study of rilvegostomig or pembrolizumab in combination with platinum-based chemotherapy as first-line treatment for patients with metastatic non-squamous non-small-cell lung cancer whose tumors express PD-L1.",Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-squamous non-small cell lung cancer'],['first line metastatic non-squamous non-small cell lung cancer'],"['pd1 targeted therapy', 'pd1/tigit bispecific antibody']","['pembrolizumab', 'rilvegostomig']",[],[],['astrazeneca'],"['first-line', 'metastatic']",,Low,1
1164,Phase 1b/2 study evaluating telisotuzumab adizutecan (ABBV-400; Temab-A) in combination with budigalimab in patients (pts) with advanced non-squamous (NSQ) non-small cell lung cancer (NSCLC) with no prior treatment for advanced disease and no actionable genomic alterations.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-squamous non-small cell lung cancer'],['advanced non squamous non small cell lung cancer'],"['pd1 inhibitor', 'cd3 targeted therapy']","['budigalimab', 'telisotuzumab adizutecan']",[],[],['abbvie'],['advanced'],,Low,1
2025,"Randomized study evaluating optimal dose, efficacy and safety of E7386 + lenvatinib versus treatment of physicians‚Äô choice in advanced/recurrent endometrial carcinoma previously treated with anti‚ÄìPD-(L)1 immunotherapy.",Gynecologic Cancer,Poster Session,['endometrial carcinoma'],"['recurrent endometrial carcinoma', 'advanced endometrial carcinoma']","['multi kinase inhibitor', 'pd1/pdl1 targeted therapy', 'wnt/beta catenin inhibitor']","['e7386', 'lenvatinib']",[],[],['eisai'],"['advanced', 'recurrent']",,High,
1166,"TeliMET NSCLC-04: A phase 2, open-label, randomized, global study of 2 telisotuzumab vedotin regimens in patients with previously treated c-Met protein‚Äìoverexpressing, locally advanced/metastatic non-squamous EGFR wildtype non-small cell lung cancer.",Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['previously treated c-met protein overeater locally advanced/metastatic non squamous egfr wild type non small cell lung cancer'],['cmet antibody drug conjugate'],['telisotuzumab vedotin'],[],[],['abbvie'],"['previously treated', 'metastatic', 'locally advanced']",,Low,1
1167,"Phase 2, multicenter study of frontline maintenance therapy with lifileucel plus pembrolizumab in advanced non-small cell lung cancer.",Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['advanced non-small cell lung cancer'],"['pd1 targeted therapy', 't cell therapy']","['pembrolizumab', 'lifileucel']",[],[],['iovance biotherapeutics'],['advanced'],,Low,1
1168,NAPISTAR 1-01: An international phase I/II trial of the novel ADC TUB-040 in platinum-resistant ovarian cancer (PROC) and relapsed/refractory adenocarcinoma non-small cell lung cancer (NSCLC).,Lung Cancer - Non - Small Cell Metastatic,Poster Session,"['adenocarcinoma', 'non-small cell lung cancer', 'ovarian cancer']","['platinum resistant ovarian cancer', 'relapsed/refractory adenocarcinoma non small cell lung cancer']",['antibody drug conjugate'],['tub-040'],[],[],['tubulis'],"['relapsed/refractory', 'platinum resistant']",,Low,1
1169,"A multicenter, open-label, single-arm phase I/II study to assess the efficacy and safety of WSD0922-FU in patients with EGFR C797Sm+ advanced non-small cell lung cancer (NSCLC) in China (NCT06631989).",Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['egfr c797sm-positive advanced non-small cell lung cancer'],['egfr inhibitor'],['wsd0922-fu'],[],[],['wayshine biopharm'],['advanced'],,Low,1
1170,"Phase 2 cohort-2 trial in progress: Vabametkib plus lazertinib for patients with EGFR-mutant NSCLC who developed resistance to 1st-line, 3rd-gen-EGFR TKIs via C-Met dysregulation.",Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['first-line third-generation egfr-mutant non-small cell lung cancer'],"['egfr inhibitor', 'cmet inhibitor']","['vabametkib', 'lazertinib']",[],[],['abion'],"['egfr mutated', 'first-line']",,Low,1
1171,"A phase 1/2 open-label, multicenter, first-in-human study of the safety, tolerability, pharmacokinetics, and antitumor activity of BH-30643 in adult subjects with locally advanced or metastatic NSCLC harboring EGFR and/or HER2 mutations (SOLARA).",Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],"['egfr/her2-mutant locally advanced non-small cell lung cancer', 'egfr/her2-mutant metastatic non-small cell lung cancer']",['macrocyclic kinase inhibitor'],['bh-30643'],[],[],['blossomhill therapeutics'],"['metastatic', 'locally advanced']",,Low,1
2312,S1900E: A phase II study examining impact of co-mutations on sotorasib for previously treated stage IV/recurrent KRAS G12C mutated (MUT) non-squamous (Non-sq) non-small cell lung cancer (NSCLC) (ECOG-ACRIN led Lung-MAP Sub-study).,Lung Cancer - Non-Small Cell Metastatic,Rapid Oral Abstract Session,['non-squamous non-small cell lung cancer'],['previously treated stage iv/recurrent kras g12c-mutant non-squamous non-small cell lung cancer'],['kras g12c inhibitor'],['sotorasib'],[],[],[],"['previously treated', 'kras g12c-mutant', 'recurrent', 'metastatic']",,High,
1173,"NVL-330, a selective HER2 tyrosine kinase inhibitor, in patients with advanced or metastatic HER2-altered non-small cell lung cancer: The phase 1 HEROEX-1 study.",Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['advanced/metastatic her2 altered non small cell lung cancer'],['her2 tyrosine kinase inhibitor'],['nvl-330'],[],[],['nuvalent'],"['advanced', 'metastatic']",,Low,1
1174,"Neladalkib (NVL-655), a highly selective anaplastic lymphoma kinase (ALK) inhibitor, compared to alectinib in first-line treatment of patients with ALK-positive advanced non-small cell lung cancer: The phase 3 ALKAZAR study.",Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['first-line alk-positive advanced non-small cell lung cancer'],['alk inhibitor'],['neladalkib'],[],['alectinib'],['nuvalent'],"['advanced', 'first-line', 'alk-positive']",,Low,1
1176,"TACTI-004: A double-blinded, randomized phase 3 trial in patients with advanced/metastatic non-small cell lung cancer receiving eftilagimod alfa (MHC class II agonist) in combination with pembrolizumab (P) and chemotherapy (C) versus placebo + P + C.",Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['advanced/metastatic non-small cell lung cancer'],"['pd1 targeted therapy', 'mhc class ii agonist']","['eftilagimod alfa', 'pembrolizumab']",[],[],"['merck', 'immutep']","['advanced', 'metastatic']",,Low,1
1177,"A biomarker-directed, multi-center phase II/III study of ctDNA molecular response adaptive immuno-chemotherapy in patients with non-small cell lung cancer (BR.36).",Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['non-small cell lung cancer'],[],[],[],[],['labcorp'],[],,Low,1
1225,Demographic and genomic landscape of early mortality in patients with stage IV non‚Äìsmall-cell lung cancer.,Quality Care/Health Services Research,Poster Session,['non-small cell lung cancer'],['stage iv non-small cell lung cancer'],[],[],[],[],[],['metastatic'],,Low,1
1247,Longitudinal changes in credit status for newly diagnosed metastatic colorectal cancer patients (SWOG S1417).,Quality Care/Health Services Research,Poster Session,['colorectal cancer'],['newly diagnosed metastatic colorectal cancer'],[],[],[],[],[],"['newly diagnosed', 'metastatic']",,Low,1
1251,"Insurance coverage of germline genetic testing for ovarian, pancreatic, and early-onset colorectal, endometrial, and breast cancers, stratified by self-reported race and ethnicity.",Quality Care/Health Services Research,Poster Session,"['ovarian cancer', 'colorectal cancer', 'pancreatic cancer', 'breast cancer', 'endometrial cancer']","['ovarian cancer', 'early onset colorectal cancer', 'pancreatic cancer', 'breast cancer', 'endometrial cancer']",[],[],[],[],['labcorp'],['early onset'],,Low,1
1271,Utilization and timeliness of next-generation sequencing testing for patients with resected or metastatic non-small cell lung cancer: A real-world analysis.,Quality Care/Health Services Research,Poster Session,['non-small cell lung cancer'],['resectable/metastatic non small cell lung cancer'],[],[],[],[],[],"['resectable', 'metastatic']",,Low,1
1273,Patient preference for first-line treatments of ALK-positive metastatic non-small cell lung cancer: A discrete choice experiment.,Quality Care/Health Services Research,Poster Session,['non-small cell lung cancer'],['first-line alk-positive metastatic non-small cell lung cancer'],[],[],[],[],[],"['alk-positive', 'first-line', 'metastatic']",,Low,1
1294,Circulating tumor DNA (ctDNA) analysis guiding adjuvant therapy in patients (pts) with colorectal cancer (CRC): Impact on fear of cancer recurrence (FCR).,Quality Care/Health Services Research,Poster Session,['colorectal cancer'],['recurrent colorectal cancer'],[],[],[],[],[],['recurrent'],,Low,1
1299,Electronic patient-reported outcomes (ePRO)-based alerts deployed in clinical practice to inform treatment burden and care management in pancreatic cancer.,Quality Care/Health Services Research,Poster Session,['pancreatic cancer'],['pancreatic cancer'],[],[],[],[],[],[],,Low,1
1305,"Improving genetic counseling uptake for breast, pancreatic, and prostate cancers at a safety net hospital.",Quality Care/Health Services Research,Poster Session,"['prostate cancer', 'pancreatic cancer', 'breast cancer']","['prostate cancer', 'pancreatic cancer', 'breast cancer']",[],[],[],[],[],[],,Low,1
1320,Regional trends in disability adjusted life years (DALYs) and mortality of pancreatic cancer among older adults (70+): A global burden of disease study (1990‚Äì2021).,Quality Care/Health Services Research,Poster Session,['pancreatic cancer'],['elderly pancreatic cancer'],[],[],[],[],[],['elderly'],,Low,1
1321,Characterizing health related quality of life among individuals living with non-small cell lung in the United States: Findings from the Cancer Experience Registry.,Quality Care/Health Services Research,Poster Session,['non-small cell lung cancer'],['non small cell lung cancer'],[],[],[],[],['gilead sciences'],[],,Low,1
1322,Use of targeted therapy in patients with advanced non-small cell lung cancer in response to broad genomic profiling.,Quality Care/Health Services Research,Poster Session,['non-small cell lung cancer'],['advanced non small cell lung cancer'],[],[],[],[],[],['advanced'],,Low,1
1327,Evaluation of large language model (LLM)-based clinical abstraction of electronic health records (EHRs) for non-small cell lung cancer (NSCLC) patients.,Quality Care/Health Services Research,Poster Session,['non-small cell lung cancer'],['non small cell lung cancer'],[],[],[],[],['tempus'],[],,Low,1
1328,Real-world analysis of factors influencing turnaround time (TAT) for tissue comprehensive genomic profiling (CGP) in non-small cell lung cancer (NSCLC).,Quality Care/Health Services Research,Poster Session,['non-small cell lung cancer'],['non small cell lung cancer'],[],[],[],[],['foundation medicine'],[],,Low,1
2313,Safety and efficacy of olomorasib + immunotherapy in first-line treatment of patients with KRAS G12C-mutant advanced NSCLC: Update from the LOXO-RAS-20001 trial.,Lung Cancer - Non-Small Cell Metastatic,Rapid Oral Abstract Session,['non-small cell lung cancer'],['first-line kras g12c-mutant advanced non-small cell lung cancer'],['kras inhibitor'],['olomorasib'],[],[],"['eli lilly and company', 'merck']","['kras g12c-mutant', 'advanced', 'first-line']",,High,
1375,Panel Question and Answer,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Oral Abstract Session,"['hepatobiliary cancer', 'gastrointestinal cancer', 'pancreatic cancer', 'gastro-esophageal cancer']","['hepatobiliary cancer', 'gastrointestinal cancer', 'pancreatic cancer', 'gastroesophageal cancer']",[],[],[],[],[],[],,Low,1
1376,Results of a randomized phase III trial of pre-operative chemotherapy with mFOLFIRINOX or PAXG regimen for stage I-III pancreatic ductal adenocarcinoma.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Oral Abstract Session,['pancreatic ductal adenocarcinoma'],['stage i-iii pancreatic ductal adenocarcinoma'],"['thymidylate synthetase inhibitor', 'nucleoside metabolic inhibitor', 'dna synthesis inhibitor', 'top1 inhibitor']","['mfolfirinox', 'paxg']",[],[],[],['stage i'],,Low,1
1377,PANOVA-3: Phase 3 study of tumor treating fields (TTFields) with gemcitabine and nab-paclitaxel for locally advanced pancreatic ductal adenocarcinoma (LA-PAC).,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Oral Abstract Session,['pancreatic ductal adenocarcinoma'],['locally advanced pancreatic ductal adenocarcinoma'],"['nucleoside metabolic inhibitor', 'microtubule inhibitor']","['gemcitabine', 'nab-paclitaxel']",[],[],['novocure'],['locally advanced'],,Low,1
1378,Preliminary results from the randomized phase 2 study (1801 part 3B) of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) versus GnP alone in patients (pts) with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Oral Abstract Session,['pancreatic ductal adenocarcinoma'],['previously untreated metastatic pancreatic ductal adenocarcinoma'],"['antimetabolite', 'microtubule stabilizing agent', 'flap inhibitor']","['gemcitabine', 'elraglusib']",[],[],['actuate therapeutics'],"['previously untreated', 'metastatic']",,Low,1
1379,Persistence and Progress in Pancreatic Cancer,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Oral Abstract Session,['pancreatic cancer'],['pancreatic cancer'],[],[],[],[],[],[],,Low,1
1380,Panel Question and Answer,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Oral Abstract Session,"['hepatobiliary cancer', 'gastrointestinal cancer', 'pancreatic cancer', 'gastro-esophageal cancer']","['hepatobiliary cancer', 'gastrointestinal cancer', 'pancreatic cancer', 'gastroesophageal cancer']",[],[],[],[],[],[],,Low,1
1383,Panel Question and Answer,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Oral Abstract Session,"['hepatobiliary cancer', 'gastrointestinal cancer', 'pancreatic cancer', 'gastro-esophageal cancer']","['hepatobiliary cancer', 'gastrointestinal cancer', 'pancreatic cancer', 'gastroesophageal cancer']",[],[],[],[],[],[],,Low,1
1384,Surgical Advances and Perioperative Care for Locally Advanced Non‚ÄìSmall Cell Lung Cancer,"Advancing Non‚ÄìSmall Cell Lung Cancer Care: Strategic Integration of Neoadjuvant, Surgical, and Adjuvant Therapies",Education Session,['non-small cell lung cancer'],['locally advanced non-small cell lung cancer'],[],[],[],[],[],['locally advanced'],,Low,1
1385,Optimizing Neoadjuvant Therapy in Locally Advanced Non‚ÄìSmall Cell Lung Cancer: Current and Emerging Strategies,"Advancing Non‚ÄìSmall Cell Lung Cancer Care: Strategic Integration of Neoadjuvant, Surgical, and Adjuvant Therapies",Education Session,['non-small cell lung cancer'],['locally advanced non-small cell lung cancer'],[],[],[],[],[],['locally advanced'],,Low,1
1386,Optimizing Adjuvant Therapy for Locally Advanced Non‚ÄìSmall Cell Lung Cancer: Current and Emerging Strategies,"Advancing Non‚ÄìSmall Cell Lung Cancer Care: Strategic Integration of Neoadjuvant, Surgical, and Adjuvant Therapies",Education Session,['non-small cell lung cancer'],['locally advanced non-small cell lung cancer'],[],[],[],[],[],['locally advanced'],,Low,1
1387,Panel Question and Answer,"Advancing Non‚ÄìSmall Cell Lung Cancer Care: Strategic Integration of Neoadjuvant, Surgical, and Adjuvant Therapies",Education Session,['non-small cell lung cancer'],['advanced non-small cell lung cancer'],[],[],[],[],[],['advanced'],,Low,1
1463,Panel Question and Answer,Liver-Directed Therapies in Colorectal Cancer: Old Hats and New Tricks,Education Session,['colorectal cancer'],['colorectal cancer'],[],[],[],[],[],[],,Low,1
1471,Gastrointestinal Cancer‚ÄîColorectal and Anal,Highlights of the Day I,Highlights of the Day Session,"['anal cancer', 'colorectal cancer']","['colorectal cancer', 'anal cancer']",[],[],[],[],[],[],,Low,1
1472,"Gastrointestinal Cancer‚ÄîGastroesophageal, Pancreatic, and Hepatobiliary",Highlights of the Day I,Highlights of the Day Session,"['gastro-esophageal cancer', 'pancreatic cancer', 'hepatobiliary cancer']","['gastroesophageal cancer', 'pancreatic cancer', 'hepatobiliary cancer']",[],[],[],[],[],[],,Low,1
2314,Sosimerasib monotherapy in patients with previously treated KRAS G12C‚Äìmutated non-small cell lung cancer: Primary results of a phase 2 study.,Lung Cancer - Non-Small Cell Metastatic,Rapid Oral Abstract Session,['non-small cell lung cancer'],['previously treated kras g12c-mutated non-small cell lung cancer'],['kras g12c inhibitor'],['sosimerasib'],[],[],['shanghai jeyou pharmaceutical'],"['kras g12c-mutant', 'previously treated']",,High,
1491,TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy for advanced non-small cell lung cancer (aNSCLC).,Lung Cancer - Non-Small Cell Metastatic,Oral Abstract Session,['non-small cell lung cancer'],['first-line advanced non-small cell lung cancer'],"['pd1 targeted therapy', 'trop2 antibody drug conjugate']","['pembrolizumab', 'datopotamab deruxtecan']",[],[],"['daiichi sankyo', 'merck']",['first-line advanced'],,Low,1
1492,"CAMPASS: Benmelstobart in combination with anlotinib vs pembrolizumab in the first-line treatment of advanced non-small cell lung cancer (aNSCLC)-A randomized, single-blind, multicenter phase 3 study.",Lung Cancer - Non-Small Cell Metastatic,Oral Abstract Session,['non-small cell lung cancer'],['first-line advanced non-small cell lung cancer'],"['pd1 inhibitor', 'vegfr inhibitor', 'angiogenesis inhibitor']","['benmelstobart', 'anlotinib']",[],['pembrolizumab'],['chia tai tianqing pharmaceutical group'],['first-line advanced'],,Low,1
1493,Right out of the Gate: New Directions in Front-Line Therapy in Metastatic Non‚ÄìSmall Cell Lung Cancer,Lung Cancer - Non-Small Cell Metastatic,Oral Abstract Session,['non-small cell lung cancer'],['front line metastatic non small cell lung cancer'],[],[],[],[],[],['metastatic'],,Low,1
1494,Panel Question and Answer,Lung Cancer - Non-Small Cell Metastatic,Oral Abstract Session,['non-small cell lung cancer'],['metastatic non-small cell lung cancer'],[],[],[],[],[],['metastatic'],,Low,1
1495,Efficacy of zipalertinib in NSCLC patients with EGFR exon 20 insertion mutations who received prior platinum-based chemotherapy with or without amivantamab.,Lung Cancer - Non-Small Cell Metastatic,Oral Abstract Session,['non-small cell lung cancer'],['egfr exon20 insertion mutated non small cell lung cancer'],['egfr targeted therapy'],['zipalertinib'],['amivantamab'],[],['cullinan therapeutics'],[],,Low,1
1496,SOHO-01: Safety and efficacy of BAY 2927088 in patients with advanced HER2-mutant non-small cell lung cancer (NSCLC) who were pretreated but na√Øve to HER2-targeted therapy or had not received any treatment for advanced disease.,Lung Cancer - Non-Small Cell Metastatic,Oral Abstract Session,['non-small cell lung cancer'],['advanced her2-mutated non-small cell lung cancer'],['her2 inhibitor'],['bay-2927088'],[],[],['bayer'],"['advanced', 'her2-mutated']",,Low,1
1497,"Targeting HER2 and EGFR Exon 20: Same Zip Code, Different Address",Lung Cancer - Non-Small Cell Metastatic,Oral Abstract Session,['non-small cell lung cancer'],['metastatic non-small cell lung cancer'],[],[],[],[],[],['metastatic'],,Low,1
1498,Panel Question and Answer,Lung Cancer - Non-Small Cell Metastatic,Oral Abstract Session,['non-small cell lung cancer'],['metastatic non-small cell lung cancer'],[],[],[],[],[],['metastatic'],,Low,1
1499,Savolitinib (Savo) combined with osimertinib (osi) versus chemotherapy (chemo) in EGFR-mutant (EGFRm) and MET-amplification (METamp) advanced NSCLC after disease progression (PD) on EGFR tyrosine kinase inhibitor (TKI): Results from a randomized phase 3 SACHI study.,Lung Cancer - Non-Small Cell Metastatic,Oral Abstract Session,['non-small cell lung cancer'],['advanced non-small cell lung cancer'],"['met inhibitor', 'egfr inhibitor']","['osimertinib', 'savolitinib']",[],[],['hutchmed'],['advanced'],,Low,1
1500,Patritumab deruxtecan (HER3-DXd) in resistant EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) after a third-generation EGFR TKI: The phase 3 HERTHENA-Lung02 study.,Lung Cancer - Non-Small Cell Metastatic,Oral Abstract Session,['non-small cell lung cancer'],['resistant egfr-mutated advanced non-small cell lung cancer'],['her3 antibody drug conjugate'],['patritumab deruxtecan'],[],[],"['daiichi sankyo', 'merck']","['egfr mutated', 'advanced']",,Low,1
1501,Sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced EGFR-mutated non-small cell lung cancer (NSCLC): Results from the randomized OptiTROP-Lung03 study.,Lung Cancer - Non-Small Cell Metastatic,Oral Abstract Session,['non-small cell lung cancer'],['previously treated advanced egfr-mutated non-small cell lung cancer'],['trop2 antibody drug conjugate'],['sacituzumab tirumotecan'],[],[],['sichuan kelun-biotech biopharmaceutical'],"['egfr mutated', 'advanced', 'previously treated']",,Low,1
1502,Breaking Resistance in EGFR-Mutant Non‚ÄìSmall Cell Lung Cancer: What's the Next Move?,Lung Cancer - Non-Small Cell Metastatic,Oral Abstract Session,['non-small cell lung cancer'],['egfr-mutated non-small cell lung cancer'],[],[],[],[],[],['egfr mutated'],,Low,1
1503,Panel Question and Answer,Lung Cancer - Non-Small Cell Metastatic,Oral Abstract Session,['non-small cell lung cancer'],['metastatic non-small cell lung cancer'],[],[],[],[],[],['metastatic'],,Low,1
2475,TP53 genomic alterations including targetable TP53 Y220C mutation in clinically advanced breast cancer.,Breast Cancer - Metastatic,Poster Session,['breast cancer'],"['tp53 altered advanced breast cancer', 'tp53 y220c mutated advanced breast cancer']",[],[],[],[],['foundation medicine'],"['tp53 altered', 'advanced']",,High,1
2531,A phase 1b study of Plk1 inhibitor onvansertib in combination with paclitaxel in metastatic triple-negative breast cancer (mTNBC) patients.,Breast Cancer - Metastatic,Poster Session,['triple negative breast cancer'],['metastatic triple negative breast cancer'],"['microtubule inhibitor', 'plk1 inhibitor']","['onvansertib', 'paclitaxel']",[],[],['cardiff oncology'],['metastatic'],,High,1
2911,A phase II study of ACR-368 and low dose gemcitabine combination therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.,Head and Neck Cancer,Poster Session,['head and neck squamous cell carcinoma'],['recurrent/metastatic head and neck squamous cell carcinoma'],"['antimetabolite', 'chk1/2 inhibitor']","['acr-368', 'gemcitabine']",[],[],['acrivon therapeutics'],"['recurrent', 'metastatic']",,High,
1779,Efficacy and safety of IBI363 monotherapy or in combination with bevacizumab in patients with advanced colorectal cancer.,Turning ‚ÄúCold‚Äù Tumors ‚ÄúHot‚Äù,Clinical Science Symposium,['colorectal cancer'],['advanced colorectal cancer'],['pdl1 inhibitor'],['ibi363'],['bevacizumab'],[],['innovent biologics'],['advanced'],,Low,1
1788,Fear of cancer recurrence in long-term colorectal cancer survivors: A randomized controlled trial of a therapist-guided eHealth intervention.,Symptom Science and Palliative Care,Oral Abstract Session,['colorectal cancer'],['recurrent colorectal cancer'],[],[],[],[],[],['recurrent'],,Low,1
1793,"Romiplostim for chemotherapy‚Äëinduced thrombocytopenia (CIT) in colorectal, gastroesophageal, and pancreatic cancers: A global, phase 3, randomized, placebo-controlled trial (RCT).",Symptom Science and Palliative Care,Oral Abstract Session,"['colorectal cancer', 'pancreatic cancer', 'gastro-esophageal cancer', 'thrombocytopenia']","['colorectal cancer', 'pancreatic cancer', 'gastroesophageal cancer', 'thrombocytopenia']",['thrombopoietin receptor agonist'],['romiplostim'],[],[],['amgen'],[],,Low,1
1817,Cost and resource utilisation for liquid biopsy vs tissue biopsy genotyping in advanced NSCLC: A micro-costing model.,Care Delivery/Models of Care,Poster Session,['non-small cell lung cancer'],['advanced non-small cell lung cancer'],[],[],[],[],[],['advanced'],,Low,1
1824,Improving access to cancer screening through national telehealth-based lung and colorectal cancer screening programs.,Care Delivery/Models of Care,Poster Session,"['colorectal cancer', 'lung cancer']","['colorectal cancer', 'lung cancer']",[],[],[],[],[],[],,Low,1
1833,Association of deep learning CT response assessment and interpretable components with overall survival in advanced NSCLC: Validation in a trial of sasanlimab and a real-world dataset.,Care Delivery/Models of Care,Poster Session,['non-small cell lung cancer'],['advanced non-small cell lung cancer'],['pd1 inhibitor'],['sasanlimab'],[],[],['pfizer'],['advanced'],,Low,1
1847,Biologically interpretable pathomics-driven transformer model with self-supervised training for outcome prediction of immunotherapy in non-small cell lung cancer.,Care Delivery/Models of Care,Poster Session,['non-small cell lung cancer'],['non-small cell lung cancer'],[],[],[],[],[],[],,Low,1
1850,Exploring social determinants of health and immunotherapy utilization in patients with stage III non-small cell lung cancer following definitive chemoradiation.,Care Delivery/Models of Care,Poster Session,['non-small cell lung cancer'],['stage iii non-small cell lung cancer'],[],[],[],[],[],['stage iii'],,Low,1
1867,The impact of race on the association between structural racism and the quality of non-small cell lung cancer (NSCLC).,Care Delivery/Models of Care,Poster Session,['non-small cell lung cancer'],['non-small cell lung cancer'],[],[],[],[],[],[],,Low,1
1913,"Assessing circadian rhythms and chemotherapy safety in remote patients with pancreatic ductal adenocarcinoma (PDAC) using a multidimensional digital platform (MultiDom, NCT04263948).",Care Delivery/Models of Care,Poster Session,['pancreatic ductal adenocarcinoma'],['pancreatic ductal adenocarcinoma'],[],[],[],[],[],[],,Low,1
1926,Impacting quality of life and pancreatic cancer survivorship through a telehealth intervention.,Care Delivery/Models of Care,Poster Session,['pancreatic cancer'],['pancreatic cancer'],[],[],[],[],[],[],,Low,1
3416,A phase Ib study of a pooled synthetic long peptide mutant KRAS vaccine combined with balstilimab/botensilimab in metastatic pancreatic cancer and metastatic MMR-proficient colorectal cancer in the maintenance setting.,Developmental Therapeutics - Immunotherapy,Poster Session,"['colorectal cancer', 'pancreatic cancer']","['metastatic pancreatic cancer', 'metastatic mmr proficient colorectal cancer']","['pd1 targeted therapy', 'kras targeted therapy', 'ctla4 targeted therapy']","['botensilimab', 'balstilimab', 'kras vaccine']",[],[],['agenus'],['metastatic'],,High,
3417,A phase I study of a pooled synthetic long peptide mutant KRAS vaccine in patients with pancreatic cystic neoplasms at risk for developing pancreatic cancer.,Developmental Therapeutics - Immunotherapy,Poster Session,"['cancer', 'pancreatic cancer']","['pancreatic cancer', 'pancreatic cystic neoplasm']",['kras targeted therapy'],['kras vaccine'],[],[],[],[],,High,
3487,"The first-in-human phase 1/2 study of TSN1611, a highly selective KRAS G12D inhibitor, in patients with advanced solid tumors.",Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology,Poster Session,['solid tumor'],['advanced solid tumor'],['kras g12d inhibitor'],['tsn-1611'],[],[],['tyligand bioscience'],['advanced'],,High,
3524,"Safety and efficacy of a small-molecule c-Myc degrader WBC100 in solid tumors: A first-in-human, phase I trial.",Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology,Poster Session,['solid tumor'],['solid tumor'],['cmyc degrader'],['wbc100'],[],[],['hangzhou weben pharma'],[],,High,
3568,"A phase 1/2 study of FOG-001, a first-in-class direct Œ≤-catenin: TCF inhibitor, in patients with colorectal cancer (CRC) and other locally advanced or metastatic solid tumors.",Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology,Poster Session,"['colorectal cancer', 'solid tumor']","['colorectal cancer', 'metastatic solid tumor', 'locally advanced solid tumor']",['beta catenin/tcf inhibitor'],['fog-001'],[],[],['parabilis medicines'],"['metastatic', 'locally advanced']",,High,
3577,Trial in progress: Phase 1 study of the selective protein degrader ASP4396 in patients with locally advanced or metastatic solid tumors with KRAS G12D mutations.,Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology,Poster Session,['solid tumor'],['kras g12d-mutant locally advanced/metastatic solid tumor'],['kras targeted protac'],['asp 4396'],[],[],['astellas pharma'],"['kras g12d-mutant', 'metastatic', 'locally advanced']",,High,
3712,"Ivonescimab (PD-1/VEGF bispecific antibody) combined with HAIC for first-line treatment of unresectable hepatocellular carcinoma (uHCC): A prospective, single-arm phase II study.","Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['hepatocellular carcinoma of liver'],['first-line unresectable hepatocellular carcinoma'],['pd1/vegf bispecific antibody'],['ivonescimab'],[],[],[],"['first-line', 'unresectable']",,High,
2098,Panel Question and Answer,Gastrointestinal Cancer - Colorectal and Anal,Rapid Oral Abstract Session,"['anal cancer', 'colorectal cancer', 'gastrointestinal cancer']","['colorectal cancer', 'anal cancer', 'gastrointestinal cancer']",[],[],[],[],[],[],,Low,1
3829,Plasma TP53 as an indicator of poor survival in neoadjuvant-treated triple negative breast cancer: A prospective study and meta-analysis.,Breast Cancer - Local/Regional/Adjuvant,Publication Only,['triple negative breast cancer'],['triple negative breast cancer'],[],[],[],[],[],[],,High,1
2101,"Phase 2 dose expansion study of DSP107, a first-in-class bi-specific 4-1BB T-cell engager, with and without atezolizumab in metastatic MSS colorectal cancer patients.",Gastrointestinal Cancer - Colorectal and Anal,Rapid Oral Abstract Session,['colorectal cancer'],['metastatic microsatellite stable colorectal cancer'],['41bb targeted t cell engager'],['dsp-107'],['atezolizumab'],[],['kahr medical'],"['microsatellite stable', 'metastatic']",,Low,1
2102,Panel Question and Answer,Gastrointestinal Cancer - Colorectal and Anal,Rapid Oral Abstract Session,"['anal cancer', 'colorectal cancer', 'gastrointestinal cancer']","['colorectal cancer', 'anal cancer', 'gastrointestinal cancer']",[],[],[],[],[],[],,Low,1
2105,Proposed changes to the pathologic staging for colon cancer (CC): AJCC Colon Cancer Expert Panel (AJCCCCEP).,Gastrointestinal Cancer - Colorectal and Anal,Rapid Oral Abstract Session,"['anal cancer', 'colorectal cancer', 'gastrointestinal cancer']","['colorectal cancer', 'anal cancer', 'gastrointestinal cancer']",[],[],[],[],[],[],,Low,1
2106,Panel Question and Answer,Gastrointestinal Cancer - Colorectal and Anal,Rapid Oral Abstract Session,"['anal cancer', 'colorectal cancer', 'gastrointestinal cancer']","['colorectal cancer', 'anal cancer', 'gastrointestinal cancer']",[],[],[],[],[],[],,Low,1
2147,"p53 Mutations, the Holy Grail of Cancer Targets: What Have We Learned and What Are Innovative Targeted Strategies in Pancreatic Cancer and Other Solid Malignancies?",Capturing Unicorns: No Target Is Out of the Realm of Possibility,Education Session,"['cancer', 'pancreatic cancer']","['p53-mutated pancreatic cancer', 'p53-mutated solid malignancy']",[],[],[],[],[],[],,Low,1
4027,"A shortcut from ovarian cancer development to metastasis: MYC/FASN/SEMA7A, a promising therapeutic axis.",Gynecologic Cancer,Publication Only,['ovarian cancer'],['ovarian cancer'],[],[],[],[],[],[],,High,
2161,"Association of post-surgical MRD status with neoadjuvant ctDNA dynamics, genomic mutations, and clinical outcomes in patients with resectable NSCLC (R-NSCLC) from the phase 3 AEGEAN trial.",Lung Cancer - Non-Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Rapid Oral Abstract Session,['non-small cell lung cancer'],['resectable non-small cell lung cancer'],[],[],[],[],['astrazeneca'],['resectable'],,Low,1
2162,Perioperative nivolumab (NIVO) vs placebo (PBO) in patients (pts) with resectable NSCLC: updated survival and biomarker analyses from CheckMate 77T.,Lung Cancer - Non-Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Rapid Oral Abstract Session,['non-small cell lung cancer'],['resectable non-small cell lung cancer'],['pd1 inhibitor'],['nivolumab'],[],[],['bristol-myers squibb'],['resectable'],,Low,1
2163,ctDNA-based MRD detection in unresectable NSCLC undergoing curatively intended chemoradiotherapy and durvalumab.,Lung Cancer - Non-Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Rapid Oral Abstract Session,['non-small cell lung cancer'],['unresectable non-small cell lung cancer'],['pdl1 inhibitor'],['durvalumab'],[],[],['astrazeneca'],['unresectable'],,Low,1
2164,Panel Question and Answer,Lung Cancer - Non-Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Rapid Oral Abstract Session,"['non-small cell lung cancer', 'small-cell lung cancer', 'thoracic cancers']","['non-small cell lung cancer', 'thoracic cancer', 'small cell lung cancer']",[],[],[],[],[],[],,Low,1
2165,The preliminary results of a randomized phase II trial evaluating induction toripalimab plus chemotherapy followed by concurrent chemoradiotherapy and consolidation toripalimab in bulky unresectable stage III non-small-cell lung cancer (InTRist).,Lung Cancer - Non-Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Rapid Oral Abstract Session,['non-small cell lung cancer'],['unresectable stage iii non-small cell lung cancer'],['pd1 targeted therapy'],['toripalimab'],[],[],['shanghai junshi bioscience'],"['stage iii', 'unresectable']",,Low,1
2168,Panel Question and Answer,Lung Cancer - Non-Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Rapid Oral Abstract Session,"['non-small cell lung cancer', 'small-cell lung cancer', 'thoracic cancers']","['non-small cell lung cancer', 'thoracic cancer', 'small cell lung cancer']",[],[],[],[],[],[],,Low,1
2169,Alectinib as neoadjuvant treatment in potentially resectable stage III ALK-positive NSCLC: Final analysis of ALNEO phase II trial (GOIRC-01-2020-ML42316).,Lung Cancer - Non-Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Rapid Oral Abstract Session,['non-small cell lung cancer'],['resectable stage iii alk-positive non-small cell lung cancer'],['alk inhibitor'],['alectinib'],[],[],[],"['stage iii', 'resectable', 'alk-positive']",,Low,1
2172,Panel Question and Answer,Lung Cancer - Non-Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Rapid Oral Abstract Session,"['non-small cell lung cancer', 'small-cell lung cancer', 'thoracic cancers']","['non-small cell lung cancer', 'thoracic cancer', 'small cell lung cancer']",[],[],[],[],[],[],,Low,1
2180,Can Lifestyle Save Lives in Colorectal Cancer?,Adjunctive Therapies in Colon Cancer: As Good as a Drug?,Clinical Science Symposium,['colorectal cancer'],['colorectal cancer'],[],[],[],[],[],[],,Low,1
2181,Association between empirical dietary inflammatory pattern (EDIP) and survival in patients with stage III colon cancer: Findings from CALGB/SWOG 80702 (Alliance).,Adjunctive Therapies in Colon Cancer: As Good as a Drug?,Clinical Science Symposium,['colorectal cancer'],['stage iii colorectal cancer'],[],[],[],[],[],['stage iii'],,Low,1
2183,Diet and Exercise After Colorectal Cancer Treatment: Challenges and Opportunities,Adjunctive Therapies in Colon Cancer: As Good as a Drug?,Clinical Science Symposium,['colorectal cancer'],['colorectal cancer'],[],[],[],[],[],[],,Low,1
2184,"Aspirin as secondary prevention for colorectal cancer liver metastases (ASAC): A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial.",Adjunctive Therapies in Colon Cancer: As Good as a Drug?,Clinical Science Symposium,['colorectal cancer'],"['colorectal cancer', 'liver metastasis']",['cyclooxygenase inhibitor'],['aspirin'],[],[],[],['metastatic'],,Low,1
2185,Controversies in Chemoprevention for Colorectal Cancer,Adjunctive Therapies in Colon Cancer: As Good as a Drug?,Clinical Science Symposium,['colorectal cancer'],['colorectal cancer'],[],[],[],[],[],[],,Low,1
4051,Advancing therapeutic approaches for targeting KRAS in cancer treatment.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,"['gastro-esophageal cancer', 'pancreatic cancer', 'hepatobiliary cancer']","['gastroesophageal cancer', 'pancreatic cancer', 'hepatobiliary cancer']",['kras targeted therapy'],[],[],[],[],[],,High,
2293,Novel Precision Strategies in Pancreatic Cancer,Innovative Biomarkers and Vaccines in Pancreatic¬†Cancer,Clinical Science Symposium,['pancreatic cancer'],['pancreatic cancer'],[],[],[],[],[],[],,Low,1
2294,Maintenance with OSE2101 plus FOLFIRI vs FOLFIRI alone after FOLFIRINOX (FFX) induction in patients (Pts) with advanced pancreatic ductal adenocarcinoma (aPDAC): Primary endpoint results of a randomized TEDOPAM GERCOR D17-01 PRODIGE 63 trial.,Innovative Biomarkers and Vaccines in Pancreatic¬†Cancer,Clinical Science Symposium,['pancreatic ductal adenocarcinoma'],['advanced pancreatic ductal adenocarcinoma'],"['cancer vaccine', 'nucleoside metabolic inhibitor', 'folic acid analog', 'top1 inhibitor']","['folfiri', 'ose-2101']",[],['folfiri'],['ose immunotherapeutics'],['advanced'],,Low,1
2295,"Efficacy and safety of cafelkibart (LM-108), an anti-CCR8 monoclonal antibody, in combination with anti-PD-1 therapy in patients with pancreatic cancer: Results from phase 1/2 studies.",Innovative Biomarkers and Vaccines in Pancreatic¬†Cancer,Clinical Science Symposium,['pancreatic cancer'],['pancreatic cancer'],"['pd1 targeted therapy', 'ccr8 targeted antibody']",['cafelkibart'],[],[],['lanova medicines'],[],,Low,1
2296,T-Cell Tug of War in Pancreatic Cancer,Innovative Biomarkers and Vaccines in Pancreatic¬†Cancer,Clinical Science Symposium,['pancreatic cancer'],['pancreatic cancer'],['t cell therapy'],['t cell'],[],[],[],[],,Low,1
2297,NeoPancONE: GATA6 expression as a predictor of benefit to peri-operative modified FOLFIRINOX in resectable pancreatic adenocarcinoma (r-PDAC): A multicentre phase II study.,Innovative Biomarkers and Vaccines in Pancreatic¬†Cancer,Clinical Science Symposium,['pancreatic ductal adenocarcinoma'],['resectable pancreatic ductal adenocarcinoma'],"['thymidylate synthetase inhibitor', 'nucleoside metabolic inhibitor', 'dna synthesis inhibitor', 'top1 inhibitor']",['mfolfirinox'],[],[],[],['resectable'],,Low,1
2298,Is Pancreas Subtyping Ready for Prime Time?,Innovative Biomarkers and Vaccines in Pancreatic¬†Cancer,Clinical Science Symposium,['pancreatic cancer'],['pancreatic cancer'],[],[],[],[],[],[],,Low,1
2299,Panel Question and Answer,Innovative Biomarkers and Vaccines in Pancreatic¬†Cancer,Clinical Science Symposium,['pancreatic cancer'],['pancreatic cancer'],[],[],[],[],[],[],,Low,1
2303,Lung Cancer‚ÄîNon-Small Cell Metastatic,Highlights of the Day II,Highlights of the Day Session,['non-small cell lung cancer'],['metastatic non-small cell lung cancer'],[],[],[],[],[],['metastatic'],,Low,1
2304,"Telisotuzumab adizutecan (ABBV-400; Temab-A), a c-Met protein‚Äìtargeting antibody-drug conjugate (ADC), in patients (pts) with advanced EGFR-mutated (MT) non-squamous (NSQ) non-small cell lung cancer (NSCLC): Results from a phase 1 study.",Lung Cancer - Non-Small Cell Metastatic,Rapid Oral Abstract Session,['non-squamous non-small cell lung cancer'],['advanced egfr-mutant non-squamous non-small cell lung cancer'],['cmet antibody drug conjugate'],['telisotuzumab adizutecan'],[],[],['abbvie'],"['egfr mutated', 'advanced']",,Low,1
2305,Efficacy and CNS results from a randomized subset of the phase 2 SAVANNAH study comparing savolitinib (savo) + osimertinib (osi) combination with savo + placebo (PBO).,Lung Cancer - Non-Small Cell Metastatic,Rapid Oral Abstract Session,['non-small cell lung cancer'],['metastatic non small cell lung cancer'],"['met inhibitor', 'egfr inhibitor']","['osimertinib', 'savolitinib']",[],['savolitinib'],"['astrazeneca', 'hutchmed']",['metastatic'],,Low,1
2306,Phase 3 study of benmelstobart in combination with chemotherapy followed by sequential combination with anlotinib for the first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer (sq-NSCLC).,Lung Cancer - Non-Small Cell Metastatic,Rapid Oral Abstract Session,['squamous non-small cell lung cancer'],['first line locally advanced/metastatic squamous non-small cell lung cancer'],"['vegf inhibitor', 'pdl1 inhibitor']","['benmelstobart', 'anlotinib']",[],[],['chia tai tianqing pharmaceutical group'],"['first-line', 'metastatic', 'locally advanced']",,Low,1
2307,Panel Question and Answer,Lung Cancer - Non-Small Cell Metastatic,Rapid Oral Abstract Session,['non-small cell lung cancer'],['metastatic non-small cell lung cancer'],[],[],[],[],[],['metastatic'],,Low,1
2308,Plasma-guided adaptive first-line chemoimmunotherapy for non-small cell lung cancer (NSCLC).,Lung Cancer - Non-Small Cell Metastatic,Rapid Oral Abstract Session,['non-small cell lung cancer'],['first-line non-small cell lung cancer'],[],[],[],[],['inivata'],['first-line'],,Low,1
2309,Randomized trial of relevance of time-of-day of immunochemotherapy for progression-free and overall survival in patients with non-small cell lung cancer.,Lung Cancer - Non-Small Cell Metastatic,Rapid Oral Abstract Session,['non-small cell lung cancer'],['non-small cell lung cancer'],[],[],[],[],[],[],,Low,1
2310,"Hypoxia-responsive CEA CAR-T cells therapy for relapsed or refractory non-small cell lung cancer: A single-arm, open-label, phase I trial.",Lung Cancer - Non-Small Cell Metastatic,Rapid Oral Abstract Session,['non-small cell lung cancer'],['relapsed/refractory non-small cell lung cancer'],['cea targeted car t therapy'],['cea-responsive car t-cell'],[],[],['chongqing precision biotech'],['relapsed/refractory'],,Low,1
2311,Panel Question and Answer,Lung Cancer - Non-Small Cell Metastatic,Rapid Oral Abstract Session,['non-small cell lung cancer'],['metastatic non-small cell lung cancer'],[],[],[],[],[],['metastatic'],,Low,1
4054,Impact of TP53 somatic mutations on prognosis in endometrial cancer: A systematic review and meta-analysis.,Gynecologic Cancer,Publication Only,['endometrial cancer'],['endometrial cancer'],[],[],[],[],[],[],,High,1
4187,Advancing therapeutic target discovery with multi-omics: Effect of unbiased phosphoproteomic and metabolic profiling in WT and KRAS mutant colorectal cancer cells on molecular interplay between protein regulation and metabolic rewiring.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],"['wt colorectal cancer', 'kras mutant colorectal cancer']",[],[],[],[],[],['kras mutant'],,High,
4749,Cadonilimab in combination with ivonescimab and chemotherapy as first-line (1L) therapy in patients with advanced gastric (G) or gastroesophageal junction adenocarcinoma (GEJA).,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,"['gastroesophageal junction adenocarcinoma', 'gastric adenocarcinoma']","['first-line advanced gastric adenocarcinoma', 'first-line advanced gastroesophageal junction adenocarcinoma']",['antibody dependent cell cytotoxicity'],"['ivonescimab', 'cadonilimab']",[],[],[],['first-line advanced'],,High,1
2315,Panel Question and Answer,Lung Cancer - Non-Small Cell Metastatic,Rapid Oral Abstract Session,['non-small cell lung cancer'],['metastatic non-small cell lung cancer'],[],[],[],[],[],['metastatic'],,Low,1
2452,Advances in Biomarker-Based Management of Metastatic Colorectal Cancer,State-of-the-Art Updates in Colorectal Cancer,Education Session,['colorectal cancer'],['metastatic colorectal cancer'],[],[],[],[],[],['metastatic'],,Low,1
2454,State of Knowledge on Young-Onset Colorectal Cancer,State-of-the-Art Updates in Colorectal Cancer,Education Session,['colorectal cancer'],['young onset colorectal cancer'],[],[],[],[],[],['young'],,Low,1
2455,Panel Question and Answer,State-of-the-Art Updates in Colorectal Cancer,Education Session,['colorectal cancer'],['colorectal cancer'],[],[],[],[],[],[],,Low,1
4838,Avutometinib/defactinib and gemcitabine/nab-paclitaxel combination in first-line metastatic pancreatic ductal adenocarcinoma: Updated safety and efficacy of a phase 1b/2 study (RAMP 205).,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic ductal adenocarcinoma'],['first line metastatic pancreatic ductal adenocarcinoma'],"['mek inhibitor', 'microtubule inhibitor', 'pyrimidine analog', 'fak inhibitor']","['avutometinib', 'gemcitabine', 'nab-paclitaxel', 'defactinib']",[],[],['verastem'],"['first-line', 'metastatic']",,High,1
4985,Unlocking the potential of zolbetuximab in CLDN18.2-positive gastric cancer: A comprehensive systematic review of clinical efficacy and safety.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['gastric cancer'],['cldn18.2-positive gastric cancer'],['cldn18.2 targeted therapy'],['zolbetuximab'],[],[],[],[],,High,1
5158,Evaluating pegylated SN38 (PLX38A) and rucaparib in TP53 wild-type endometrial cancer.,Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology,Publication Only,['endometrial cancer'],['tp53 wild type endometrial cancer'],"['parp inhibitor', 'top inhibitor']","['rucaparib', 'pegylated sn38']",[],[],[],[],,High,1
2962,Sensitivity of age and family history (FH) criteria for determining pancreatic cancer (PC) surveillance (PCS) eligibility among individuals with hereditary PC risk.,"Prevention, Risk Reduction, and Genetics",Oral Abstract Session,['pancreatic cancer'],['hereditary pancreatic cancer'],[],[],[],[],[],[],,Low,1
2987,Panel Question and Answer,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Rapid Oral Abstract Session,"['gastro-esophageal cancer', 'pancreatic cancer', 'hepatobiliary cancer']","['gastroesophageal cancer', 'pancreatic cancer', 'hepatobiliary cancer']",[],[],[],[],[],[],,Low,1
2990,Panel Question and Answer,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Rapid Oral Abstract Session,"['gastro-esophageal cancer', 'pancreatic cancer', 'hepatobiliary cancer']","['gastroesophageal cancer', 'pancreatic cancer', 'hepatobiliary cancer']",[],[],[],[],[],[],,Low,1
2991,"Clinical activity of EBC-129, a first-in class, anti N256-glycosylated CEACAM5 and CEACAM6 antibody-drug conjugate (ADC), in patients with pancreatic ductal adenocarcinoma (PDAC) in a phase 1 study.","Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Rapid Oral Abstract Session,['pancreatic ductal adenocarcinoma'],['pancreatic ductal adenocarcinoma'],['ceacam5/ceacam6 antibody drug conjugate'],['ebc-129'],[],[],[],[],,Low,1
2994,Panel Question and Answer,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Rapid Oral Abstract Session,"['gastro-esophageal cancer', 'pancreatic cancer', 'hepatobiliary cancer']","['gastroesophageal cancer', 'pancreatic cancer', 'hepatobiliary cancer']",[],[],[],[],[],[],,Low,1
3026,Novel Strategies to Stimulate the Immune System to Treat Pancreatic Cancer,Treatment Innovations in Pancreatic Cancer: Balancing Hope and Expectations,Education Session,['pancreatic cancer'],['pancreatic cancer'],[],[],[],[],[],[],,Low,1
3027,Innovations and Challenges in Targeting Treatment for Pancreatic Cancer,Treatment Innovations in Pancreatic Cancer: Balancing Hope and Expectations,Education Session,['pancreatic cancer'],['pancreatic cancer'],[],[],[],[],[],[],,Low,1
3028,"Enhancing the Generation, Interpretation, and Communication of Evidence About Pancreatic Cancer",Treatment Innovations in Pancreatic Cancer: Balancing Hope and Expectations,Education Session,['pancreatic cancer'],['pancreatic cancer'],[],[],[],[],[],[],,Low,1
3029,Panel Question and Answer,Treatment Innovations in Pancreatic Cancer: Balancing Hope and Expectations,Education Session,['pancreatic cancer'],['pancreatic cancer'],[],[],[],[],[],[],,Low,1
3140,Single-cell RNA sequencing atlas of intestinal injury induced by different clinical treatments in colorectal cancer patients.,Symptom Science and Palliative Care,Poster Session,['colorectal cancer'],"['colorectal cancer', 'intestinal injury']",[],[],[],[],[],[],,Low,1
3143,Incidence of venous thromboembolism (VTE) events in patients with EGFR-mutant non-small cell lung cancer (NSCLC) treated with amivantamab: A systematic review and combined meta-analysis of phase 3 randomized controlled trials.,Symptom Science and Palliative Care,Poster Session,"['non-small cell lung cancer', 'venous thromboembolism']","['egfr-mutated non-small cell lung cancer', 'venous thromboembolism']",['egfr/met bispecific antibody'],['amivantamab'],[],[],[],['egfr mutated'],,Low,1
3146,Impact of pembrolizumab on geriatric syndromes in older patients with NSCLC: A propensity-matched retrospective cohort study.,Symptom Science and Palliative Care,Poster Session,['non-small cell lung cancer'],"['non-small cell lung cancer', 'elderly geriatric syndrome']",['pd1 inhibitor'],['pembrolizumab'],[],[],[],['elderly'],,Low,1
3180,Outpatient palliative care consultation and end-of-life outcomes among a retrospective cohort of patients treated with immunotherapy for non-small cell lung cancer.,Symptom Science and Palliative Care,Poster Session,['non-small cell lung cancer'],['non-small cell lung cancer'],[],[],[],[],[],[],,Low,1
3190,The impact of early versus late palliative care referral (PCR) on healthcare utilization in pancreatic cancer patients: A single-center retrospective study.,Symptom Science and Palliative Care,Poster Session,['pancreatic cancer'],['pancreatic cancer'],[],[],[],[],[],[],,Low,1
3196,Economic outcomes of palliative care in colorectal cancer hospitalizations: A propensity-matched retrospective cohort study on resource utilization.,Symptom Science and Palliative Care,Poster Session,['colorectal cancer'],['colorectal cancer'],[],[],[],[],[],[],,Low,1
3239,Supervised home-based exercise in patients with advanced non-small cell lung cancer (NSCLC) on maintenance immune checkpoint inhibitors (ICI).,Symptom Science and Palliative Care,Poster Session,['non-small cell lung cancer'],['advanced non small cell lung cancer'],['immune checkpoint inhibitor'],[],[],[],[],['advanced'],,Low,1
3246,Overall survival with neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) in patients with resectable NSCLC in CheckMate 816.,Lung Cancer - Non-Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Oral Abstract Session,['non-small cell lung cancer'],['resectable non-small cell lung cancer'],['pd1 inhibitor'],['nivolumab'],[],[],"['bristol-myers squibb', 'ono pharmaceutical']",['resectable'],,Low,1
3247,Neoadjuvant (neoadj) osimertinib (osi) ¬± chemotherapy (CT) vs CT alone in resectable (R) epidermal growth factor receptor-mutated (EGFRm) NSCLC: NeoADAURA.,Lung Cancer - Non-Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Oral Abstract Session,['non-small cell lung cancer'],['resectable egfr-mutant non-small cell lung cancer'],['egfr inhibitor'],['osimertinib'],[],[],['astrazeneca'],"['egfr mutated', 'resectable']",,Low,1
3250,Panel Question and Answer,Lung Cancer - Non-Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Oral Abstract Session,"['non-small cell lung cancer', 'thoracic cancers']","['non-small cell lung cancer', 'thoracic cancer']",[],[],[],[],[],[],,Low,1
3251,"SWOG/NRG S1914: Randomized phase III trial of induction/consolidation atezolizumab + SBRT versus SBRT alone in high risk, early-stage NSCLC.",Lung Cancer - Non-Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Oral Abstract Session,['non-small cell lung cancer'],['high risk early stage non-small cell lung cancer'],['pdl1 inhibitor'],['atezolizumab'],[],[],[],"['early-stage', 'high-risk']",,Low,1
3252,"R-ALPS: A randomized, double-blind, placebo-controlled, multicenter phase III clinical trial of TQB2450 with or without anlotinib as maintenance treatment in patients with locally advanced and unresectable (stage III) NSCLC without progression following concurrent or sequential chemoradiotherapy.",Lung Cancer - Non-Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Oral Abstract Session,['non-small cell lung cancer'],['locally advanced unresectable stage iii non-small cell lung cancer'],['pdl1 inhibitor'],['tqb2450'],['anlotinib'],[],['chia tai tianqing pharmaceutical'],"['stage iii', 'unresectable', 'locally advanced']",,Low,1
3255,Panel Question and Answer,Lung Cancer - Non-Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Oral Abstract Session,"['non-small cell lung cancer', 'thoracic cancers']","['non-small cell lung cancer', 'thoracic cancer']",[],[],[],[],[],[],,Low,1
3260,Panel Question and Answer,Lung Cancer - Non-Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Oral Abstract Session,"['non-small cell lung cancer', 'thoracic cancers']","['non-small cell lung cancer', 'thoracic cancer']",[],[],[],[],[],[],,Low,1
3265,"A phase 1 study of the OX40 agonist BGB-A445, with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced NSCLC, HNSCC, or NPC.",Developmental Therapeutics - Immunotherapy,Poster Session,"['nasopharyngeal carcinoma', 'non-small cell lung cancer', 'head and neck squamous cell carcinoma']","['advanced head and neck squamous cell carcinoma', 'advanced non-small cell lung cancer', 'advanced nasopharyngeal carcinoma']",['ox40 agonist'],['bgb-a445'],['tislelizumab'],[],['beone medicines'],['advanced'],,Low,1
3270,Comprehensive analysis of NSAIDs use and oncological outcomes in non-small cell lung cancer patients treated with immune checkpoint inhibitors.,Developmental Therapeutics - Immunotherapy,Poster Session,['non-small cell lung cancer'],['non-small cell lung cancer'],"['immune checkpoint inhibitor', 'nonsteroidal anti inflammatory drug']",[],[],[],[],[],,Low,1
3280,Association of lymphopenia rescue and CA19-9 levels with overall survival following IL-15 superagonist N-803 and PD-L1 t-haNK chemo-immunotherapy for 3rd line or greater metastatic pancreatic cancer.,Developmental Therapeutics - Immunotherapy,Poster Session,['pancreatic cancer'],['third line/greater metastatic pancreatic cancer'],"['pdl1 targeted therapy', 'il 15 targeted superagonist']",['n-803'],[],[],['immunity bio'],"['metastatic', 'third-line']",,Low,1
3283,Personalized tumor-informed circulating tumor DNA as predictor of progression risk after long-term responses to immunotherapy in advanced non-small-cell lung cancer.,Developmental Therapeutics - Immunotherapy,Poster Session,['non-small cell lung cancer'],['advanced non small cell lung cancer'],[],[],[],[],[],['advanced'],,Low,1
3287,Precision medicine research on chemo-immunotherapy combination treatment for locally advanced or metastatic non-small cell lung cancer based on deep plasma proteomics.,Developmental Therapeutics - Immunotherapy,Poster Session,['non-small cell lung cancer'],['locally advanced/metastatic non-small cell lung cancer'],[],[],[],[],[],"['metastatic', 'locally advanced']",,Low,1
3288,T-cell exhaustion and pre-existing T-cell immunity in circulation as predictive biomarkers for immunotherapy in NSCLC patients.,Developmental Therapeutics - Immunotherapy,Poster Session,['non-small cell lung cancer'],['non-small cell lung cancer'],[],[],[],[],[],[],,Low,1
3293,Predictive imaging of the immunotherapy and radioimmunotherapy response by immunoPET via a new target (CD103) and innovative protein formats in preclinical NSCLC.,Developmental Therapeutics - Immunotherapy,Poster Session,['non-small cell lung cancer'],['non-small cell lung cancer'],['cd103 targeted therapy'],[],[],[],[],[],,Low,1
3296,Role of pelareorep in activating anti-tumor immunity in PDAC.,Developmental Therapeutics - Immunotherapy,Poster Session,['pancreatic ductal adenocarcinoma'],['pancreatic ductal adenocarcinoma'],['oncolytic virus therapy'],['pelareorep'],[],[],['oncolytics biotech'],[],,Low,1
3297,ctDNA features of acquired resistance to immunotherapy in advanced NSCLC.,Developmental Therapeutics - Immunotherapy,Poster Session,['non-small cell lung cancer'],['advanced non-small cell lung cancer'],[],[],[],[],['amgen'],['advanced'],,Low,1
3299,Investigating the association of blood-to-tissue tumor mutation burden (TMB) ratio with overall survival and intratumor heterogeneity (ITH) in advanced NSCLC.,Developmental Therapeutics - Immunotherapy,Poster Session,['non-small cell lung cancer'],['advanced non-small cell lung cancer'],[],[],[],[],[],['advanced'],,Low,1
3301,Dietary compounds and patterns associated with immune checkpoint inhibitor (ICI) outcomes in advanced non-small cell lung cancer (NSCLC).,Developmental Therapeutics - Immunotherapy,Poster Session,['non-small cell lung cancer'],['advanced non small cell lung cancer'],[],[],[],[],[],['advanced'],,Low,1
3305,Influence of salmonella-IL2 in combination with FOLFIRINOX on overall and progression-free survival in stage IV metastatic pancreatic cancer.,Developmental Therapeutics - Immunotherapy,Poster Session,['pancreatic cancer'],['stage iv metastatic pancreatic cancer'],"['thymidylate synthetase inhibitor', 'nucleoside metabolic inhibitor', 'top1 inhibitor', 'dna synthesis inhibitor', 'il2 replacement']","['salmonella-il2', 'folfirinox']",[],[],['salspera'],['metastatic'],,Low,1
3307,SLAMF8 as a potential therapeutic target for modulating tumor-associated macrophages in colorectal cancer.,Developmental Therapeutics - Immunotherapy,Poster Session,['colorectal cancer'],['colorectal cancer'],[],[],[],[],[],[],,Low,1
3336,Phase I/II study of the EP4 antagonist vorbipiprant combined with anti-PD-1 immunotherapy: Safety and efficacy results in metastatic gastrointestinal non-colorectal cancers.,Developmental Therapeutics - Immunotherapy,Poster Session,['colorectal cancer'],['metastatic gastrointestinal non-colorectal cancer'],"['ep4 antagonist', 'pd1 targeted therapy']",['vorbipiprant'],[],[],"['agenus', 'rottapharm biotech']",['metastatic'],,Low,1
3337,Bispecific innate cell engager (ICE) AFM24 in combination with atezolizumab in patients with advanced/metastatic EGFR-expressing non-small cell lung cancer (NSCLC) without driver mutations: Initial results from a phase 2a study.,Developmental Therapeutics - Immunotherapy,Poster Session,['non-small cell lung cancer'],['advanced/metastatic egfr expressing non small cell lung cancer'],"['cd16a/egfr targeted bispecific innate cell engager', 'pdl1 inhibitor']","['afm-24', 'atezolizumab']",[],[],['affimed'],"['advanced', 'metastatic']",,Low,1
3338,Combination of bispecific innate cell engager (ICE) AFM24 with atezolizumab in patients with advanced/metastatic non-small cell lung cancer (NSCLC) with EGFR kinase domain mutations (EGFRmut): Initial results from a phase 2a study.,Developmental Therapeutics - Immunotherapy,Poster Session,['non-small cell lung cancer'],['advanced/metastatic non small cell lung cancer'],"['cd16a/egfr targeted bispecific innate cell engager', 'pdl1 inhibitor']","['afm-24', 'atezolizumab']",[],[],['affimed'],"['advanced', 'metastatic']",,Low,1
3341,Stereotactic radiotherapy plus immunotherapy and influence on prognosis in driver-gene‚Äìnegative non-small cell lung cancer patients with brain oligo-metastases.,Developmental Therapeutics - Immunotherapy,Poster Session,['non-small cell lung cancer'],"['non-small cell lung cancer', 'brain oligo-metastasis']",[],[],[],[],[],['metastatic'],,Low,1
3348,Delineation of immunotherapeutic predictive versus prognostic transcriptional programs to identify SLC22A5-centric carnitine metabolism-driven resistance to anti-PD-L1 treatment in advanced non‚Äìsmall-cell lung cancer.,Developmental Therapeutics - Immunotherapy,Poster Session,['non-small cell lung cancer'],['advanced non small cell lung cancer'],['pdl1 inhibitor'],[],[],[],[],['advanced'],,Low,1
3349,Biomarkers associated with outcomes from OPTIMIZE-1: CD40 agonist mitazalimab with mFOLFIRINOX in patients with untreated metastatic pancreatic cancer.,Developmental Therapeutics - Immunotherapy,Poster Session,['pancreatic cancer'],['untreated metastatic pancreatic cancer'],"['folate analog', 'top inhibitor', 'alkylating agent', 'cd40 agonist', 'antimetabolite']","['mfolfirinox', 'mitazalimab']",[],[],['alligator bioscience'],"['untreated', 'metastatic']",,Low,1
3352,Levels of immune responses in tertiary lymphoid structures of non-small cell lung cancer (NSCLC) and association with survival.,Developmental Therapeutics - Immunotherapy,Poster Session,['non-small cell lung cancer'],['non-small cell lung cancer'],[],[],[],[],[],[],,Low,1
3358,Tertiary lymphoid structures and their association with immune checkpoint inhibitor response and survival outcomes in patients with non-small cell lung cancer.,Developmental Therapeutics - Immunotherapy,Poster Session,['non-small cell lung cancer'],['non-small cell lung cancer'],[],[],[],[],['bostongene'],[],,Low,1
3359,CCR8 positive Tregs and their correlation with immunotherapy response in advanced non-small cell lung cancer (NSCLC).,Developmental Therapeutics - Immunotherapy,Poster Session,['non-small cell lung cancer'],['advanced non-small cell lung cancer'],['t cell therapy'],['ccr8 positive regulatory t cell'],[],[],['bayer'],['advanced'],,Low,1
3376,"Gut dysbiosis as a potential guide for immunotherapy (dis)continuation after 2 years in non-small cell lung cancer: A mono-institutional, multi-omic assessment.",Developmental Therapeutics - Immunotherapy,Poster Session,['non-small cell lung cancer'],['non small cell lung cancer'],[],[],[],[],[],[],,Low,1
5390,Utilizing TP53 mutation status and initial disease burden at presentation to risk-stratify patients with advanced EGFR-mutated NSCLC treated with osimertinib.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['advanced egfr-mutant non-small cell lung cancer'],['egfr inhibitor'],['osimertinib'],[],[],[],"['egfr mutated', 'advanced']",,High,1
3414,"A phase 1b study of combined treatment with dupilumab (anti-IL-4Ra) and cemiplimab (anti-PD-1) in patients with early-stage, resectable NSCLC.",Developmental Therapeutics - Immunotherapy,Poster Session,['non-small cell lung cancer'],['early stage resectable non-small cell lung cancer'],"['pd1 targeted therapy', 'il4ra targeted therapy']","['dupilumab', 'cemiplimab']",[],[],[],"['early-stage', 'resectable']",,Low,1
5730,Kras-mutant oncolytic virus vaccine therapy for metastatic colorectal cancer: A preclinical study.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['metastatic colorectal cancer'],['kras mutant oncolytic virus vaccine'],[],[],[],['sph biotherapeutics'],['metastatic'],,High,
5733,Impact of anti-VEGF therapy duration on KRAS/NRAS WT mCRC survival after anti-EGFR therapy.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['kras/nras wild type colorectal cancer'],"['egfr targeted therapy', 'vegf targeted therapy']",[],[],[],[],[],,High,Should have been Medium
3434,Association of genomic alterations in circulating tumor DNA (ctDNA) with clinical response to telisotuzumab vedotin (Teliso-V) in 2L+ EGFR wildtype (EGFRwt) non-squamous non-small cell lung cancer (NSCLC) patients (pts) with c-Met overexpression (OE).,Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology,Poster Session,['non-squamous non-small cell lung cancer'],['c-met overexpressing second-line egfr wild type non-squamous non-small cell lung cancer'],['cmet antibody drug conjugate'],['telisotuzumab vedotin'],[],[],['abbvie'],"['second-line', 'met-overexpressed']",,Low,1
3443,"Precemtabart tocentecan (M9140), an anti-CEACAM5 ADC with exatecan payload, in patients with metastatic colorectal cancer (mCRC): Results from the dose optimization of the phase 1 PROCEADE CRC-01 study.",Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology,Poster Session,['colorectal cancer'],['metastatic colorectal cancer'],['ceacam5 antibody drug conjugate'],['precemtabart tocentecan'],[],[],"['emd serono', 'merck']",['metastatic'],,Low,1
3449,Prognostic significance of preoperational circulating tumor DNA detection in early-stage NSCLC using a tissue-free blood test.,Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology,Poster Session,['non-small cell lung cancer'],['early stage non-small cell lung cancer'],[],[],[],[],['burning rock biotech'],['early-stage'],,Low,1
3466,Clinical outcomes of a prospective multicenter study evaluating a combined circulating tumor DNA (ctDNA) and RNA (ctRNA) liquid biopsy assay in metastatic non-small cell lung cancer (NSCLC).,Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology,Poster Session,['non-small cell lung cancer'],['metastatic non-small cell lung cancer'],[],[],[],[],['lucence health'],['metastatic'],,Low,1
3468,Tumor-educated platelets as a source of potential biomarkers for colorectal cancer.,Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology,Poster Session,['colorectal cancer'],['colorectal cancer'],[],[],[],[],[],[],,Low,1
3471,Non-invasive PD-L1 prediction in NSCLC patients using 3D self-supervised deep learning and radiomics.,Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology,Poster Session,['non-small cell lung cancer'],['non-invasive non-small cell lung cancer'],['pdl1 inhibitor'],[],[],[],[],['non-invasive'],,Low,1
3474,Analysing the impact of size of NGS panel in defining first line therapeutic strategies in NSCLC.,Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology,Poster Session,['non-small cell lung cancer'],['first-line non-small cell lung cancer'],[],[],[],[],[],['first-line'],,Low,1
3475,Evaluation of 68Ga-FAPI PET/CT and 18F-FDG PET/CT for the primary staging of non-small cell lung cancer (NSCLC).,Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology,Poster Session,['non-small cell lung cancer'],['non-small cell lung cancer'],"['glucose metabolism imaging agent', 'positron emission tomography enhancer']","['68ga-fapi', '18f-fdg']",[],[],[],[],,Low,1
3478,"HRD status prediction in patients with advanced breast, prostate, ovarian and pancreatic cancers in a liquid biopsy assay.",Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology,Poster Session,"['ovarian cancer', 'prostate cancer', 'pancreatic cancer', 'breast cancer']","['advanced pancreatic cancer', 'advanced ovarian cancer', 'advanced breast cancer', 'advanced prostate cancer']",[],[],[],[],['guardant health'],['advanced'],,Low,1
3479,Efficacy and safety of distinct regimens for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: A systematic review and network meta-analysis.,Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology,Poster Session,['non-small cell lung cancer'],['advanced egfr-mutated non-small cell lung cancer'],[],[],[],[],[],"['egfr mutated', 'advanced']",,Low,1
5769,Outcomes with KRAS G12C inhibitors in metastatic colorectal cancer: A systematic review and meta-analysis.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['kras g12c-mutant metastatic colorectal cancer'],['kras g12c inhibitor'],[],[],[],[],"['kras g12c-mutant', 'metastatic']",,High,1
3492,The effect of HIFU treatment on liver metastasis of colorectal cancer in mice and its impact on immunity.,Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology,Poster Session,['colorectal cancer'],"['colorectal cancer', 'liver metastasis']",[],[],[],[],[],['metastatic'],,Low,1
5793,"Impact of mutant STK11, KEAP1, and KRAS on firstline chemoimmunotherapy survival outcomes in metastatic non-small cell lung cancer (NSCLC): A meta-analysis of randomized and comparative studies.",Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['first line metastatic non-small cell lung cancer'],[],[],[],[],[],"['first-line', 'metastatic']",,High,1
5799,Testing and treatment patterns in KRAS mutant mNSCLC: Results from the MYLUNG Consortium.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['kras mutant non-small cell lung cancer'],[],[],[],[],[],['kras mutant'],,High,1
3525,In vitro efficacy of CDK9 inhibitor tambiciclib (SLS009) in ASXL1 mutated colorectal cancer cell lines.,Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology,Poster Session,['colorectal cancer'],['asxl1-mutated colorectal cancer'],['cdk9 inhibitor'],['tambiciclib'],[],[],['sellas life sciences group'],[],,Low,1
3532,Long non-coding RNA (lncRNA) SNHG11 as a prognostic and predictive biomarker in metastatic colorectal cancer (mCRC): Insights from CALGB (Alliance)/SWOG 80405.,Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology,Poster Session,['colorectal cancer'],['metastatic colorectal cancer'],[],[],[],[],['bristol-myers squibb'],['metastatic'],,Low,1
3537,Regorafenib response prediction in metastatic colorectal cancer by a novel genomic and transcriptomic model.,Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology,Poster Session,['colorectal cancer'],['metastatic colorectal cancer'],['multi kinase inhibitor'],['regorafenib'],[],[],['caris life sciences'],['metastatic'],,Low,1
3540,Comparative analysis of T-cell subsets and vessel features in matched primary colorectal tumors and corresponding resected liver metastases.,Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology,Poster Session,"['colorectal cancer', 'secondary liver cancer']","['primary colorectal tumor', 'resectable liver metastases']",[],[],[],[],[],['resectable'],,Low,1
3546,Small nucleolar RNAs (snoRNAs) expression and effects on patient (pt) outcomes in metastatic colorectal cancer (mCRC): Data from CALGB (Alliance)/SWOG 80405.,Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology,Poster Session,['colorectal cancer'],['metastatic colorectal cancer'],[],[],[],[],['bristol-myers squibb'],['metastatic'],,Low,1
5832,Outcomes with KRAS G12C inhibitors in metastatic non-small cell cancer: A systematic review and meta-analysis.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['kras g12c-mutant metastatic non-small cell lung cancer'],['kras g12c inhibitor'],[],[],[],[],"['kras g12c-mutant', 'metastatic']",,High,1
3572,Trial in progress: First-in-human study of PFL-721/STX-721 in participants with locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 20 insertion mutations.,Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology,Poster Session,['non-small cell lung cancer'],['locally advanced/metastatic non-small cell lung cancer'],['egfr inhibitor'],['pfl-721'],[],[],['scorpion therapeutics'],"['metastatic', 'locally advanced']",,Low,1
5833,Clinical outcomes and safety profile of adagrasib in KRAS G12C-mutated solid tumors: A single-arm meta-analysis.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['solid tumor'],['kras g12c-mutated solid tumor'],['kras inhibitor'],['adagrasib'],[],[],[],['kras g12c-mutant'],,High,1
3586,Perfume trial: Phase II trial of binimetinib in patients with BRAF fusion-positive low-grade glioma or pancreatic cancer.,Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology,Poster Session,"['pancreatic cancer', 'low-grade gliomas']","['braf fusion-positive low grade pancreatic cancer', 'braf fusion-positive low grade glioma']",['mek inhibitor'],['binimetinib'],[],[],['ono pharmaceutical'],"['braf-fusion positive', 'low-grade']",,Low,1
3601,Overall survival according to time-of-day of combined immuno-chemotherapy for advanced non-small cell lung cancer: A bicentric bicontinental study.,Real-World Immunotherapy: Bridging the Gap Between Trials and Treatment,Clinical Science Symposium,['non-small cell lung cancer'],['advanced non small cell lung cancer'],[],[],[],[],[],['advanced'],,Low,1
3621,Special Populations: Optimizing Perioperative Management Strategies in Patients With EGFR Mutations,"Genomic Insights in Perioperative Decision-Making in Non‚ÄìSmall Cell Lung Cancer: Navigating EGFR, ALK, and Emerging Biomarkers",Education Session,['non-small cell lung cancer'],['egfr-mutant non-small cell lung cancer'],[],[],[],[],[],['egfr mutated'],,Low,1
3622,Special Populations: Optimizing Perioperative Management Strategies in Patients With ALK Mutations,"Genomic Insights in Perioperative Decision-Making in Non‚ÄìSmall Cell Lung Cancer: Navigating EGFR, ALK, and Emerging Biomarkers",Education Session,['non-small cell lung cancer'],['alk-mutant non-small cell lung cancer'],[],[],[],[],[],['alk-mutated'],,Low,1
3623,Expanding Horizons: Exploring Emerging Biomarkers in the Perioperative Management of Non‚ÄìSmall Cell Lung Cancer,"Genomic Insights in Perioperative Decision-Making in Non‚ÄìSmall Cell Lung Cancer: Navigating EGFR, ALK, and Emerging Biomarkers",Education Session,['non-small cell lung cancer'],['non-small cell lung cancer'],[],[],[],[],[],[],,Low,1
3624,Panel Question and Answer,"Genomic Insights in Perioperative Decision-Making in Non‚ÄìSmall Cell Lung Cancer: Navigating EGFR, ALK, and Emerging Biomarkers",Education Session,['non-small cell lung cancer'],['non-small cell lung cancer'],[],[],[],[],[],[],,Low,1
3632,Lung Cancer‚ÄîNon-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers,Highlights of the Day III,Highlights of the Day Session,"['non-small cell lung cancer', 'small-cell lung cancer', 'thoracic cancers']","['local-regional non-small cell lung cancer', 'thoracic cancer', 'small cell lung cancer']",[],[],[],[],[],[],,Low,1
3634,First-in-class PD-1/IL-2 bispecific antibody IBI363 in patients (Pts) with advanced immunotherapy-treated non-small cell lung cancer (NSCLC).,"Two Targets, One Goal: The Potential for Bispecific Antibodies in Thoracic Malignancies",Clinical Science Symposium,['non-small cell lung cancer'],['advanced non-small cell lung cancer'],['il2/pd1 targeted bispecific antibody'],['ibi-363'],[],[],['innovent biologics'],['advanced'],,Low,1
3706,The Next Era for EGFR+ mNSCLC First-Line Treatment,The Next Era for EGFR+ mNSCLC First-Line Treatment,Industry Expert Theater,['non-small cell lung cancer'],['egfr+ metastatic non-small cell lung cancer'],[],[],[],[],['johnson & johnson'],['metastatic'],,Low,1
3707,An Innovative Perspective on Advanced NSCLC Treatment,An Innovative Perspective on Advanced NSCLC Treatment,Industry Expert Theater,['non-small cell lung cancer'],['advanced non-small cell lung cancer'],[],[],[],[],['abbvie'],['advanced'],,Low,1
5876,The prognostic role of TP53 mutations in MUTYH-associated colorectal cancers (MUTYH-CRCs).,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,"['anal cancer', 'colorectal cancer']","['mutyh-associated colorectal cancer', 'anal cancer']",[],[],[],[],[],[],,High,1
3718,Overall survival (OS) with NALIRIFOX (NFX) compared to FOLFIRINOX (FFX) in patients not previously treated for metastatic pancreatic ductal adenocarcinoma (mPDAC): An external control arm study.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic ductal adenocarcinoma'],['previously untreated metastatic pancreatic ductal adenocarcinoma'],"['nucleoside metabolic inhibitor', 'folic acid analog', 'dna synthesis inhibitor', 'top1 inhibitor']",['nalirifox'],[],['folfirinox'],['ipsen'],"['previously untreated', 'metastatic']",,Low,1
3720,"Nanoparticle polymeric micellar paclitaxel combined with gemcitabine in first-line treatment of patients with metastatic pancreatic cancer: A single-arm, phase II clinical study.","Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic cancer'],['first line metastatic pancreatic cancer'],"['antimetabolite', 'microtubule stabilizing agent']","['gemcitabine', 'paclitaxel']",[],[],[],"['first-line', 'metastatic']",,Low,1
3725,Integrated supportive and nutrition care program for older adults with advanced pancreatic cancer: A feasibility study.,Symptom Science and Palliative Care,Publication Only,['pancreatic cancer'],['elderly advanced pancreatic cancer'],[],[],[],[],[],"['advanced', 'elderly']",,Low,1
3738,Chemotherapy progression decision score to improve subsequent treatment regimen selection after initial assessment for pancreatic ductal adenocarcinoma.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic ductal adenocarcinoma'],['pancreatic ductal adenocarcinoma'],[],[],[],[],[],[],,Low,1
3743,Clinical study on splenic radiation dose constraints.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,"['gastro-esophageal cancer', 'pancreatic cancer', 'hepatobiliary cancer']","['gastroesophageal cancer', 'pancreatic cancer', 'hepatobiliary cancer']",[],[],[],[],[],[],,Low,1
3744,Association between oral contraceptive use and pancreatic cancer risk: An updated systematic review and meta-analysis.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic cancer'],['pancreatic cancer'],[],[],[],[],[],[],,Low,1
3745,Impact of frailty on outcomes in elderly pancreatic cancer patients undergoing chemotherapy: A National Inpatient Sample analysis.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic cancer'],['elderly pancreatic cancer'],[],[],[],[],[],['elderly'],,Low,1
3794,PD-1 inhibitors versus PD-L1 inhibitors in PD-L1‚Äìnegative advanced non-small cell lung cancer: A meta-analysis of survival outcomes.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['pd-l1 negative advanced non-small cell lung cancer'],"['pd1 inhibitor', 'pdl1 inhibitor']",[],[],[],[],['advanced'],,Low,1
3799,A meta-analysis analyzing the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in previously treated patients with non-small cell lung cancer (NSCLC).,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['previously treated non-small cell lung cancer'],['trop2 antibody drug conjugate'],['datopotamab deruxtecan'],[],[],[],['previously treated'],,Low,1
3819,"Development of a prognostic score for stage IV NSCLC using advance machine learning algorithms: An international comparative study across South Korea, US, and France.",Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['stage iv non-small cell lung cancer'],[],[],[],[],['sanofi'],['metastatic'],,Low,1
5886,The prognostic impact of TP53 mutation on survival outcomes in ALK fusion‚Äìpositive lung cancer.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['alk fusion-positive non-small cell lung cancer'],[],[],[],[],[],['alk fusion-positive'],,High,1
3835,Incidence and characteristics of mismatch repair (MMR) protein deficient colorectal cancer (CRC) in a community hospital based cancer center in rural central Nebraska.,"Prevention, Risk Reduction, and Genetics",Publication Only,"['colorectal cancer', 'deficiency']",['mismatch repair protein deficient colorectal cancer'],[],[],[],[],[],[],,Low,1
3901,Genetic counseling (GC) in the era of next generation sequencing (NGS) to diagnose microsatellite instability (MSI) and deficient mismatch repair (dMMR) expression in colorectal cancer (CRC).,"Prevention, Risk Reduction, and Genetics",Publication Only,"['colorectal cancer', 'deficiency']",['microsatellite instability and deficient match repair colorectal cancer'],[],[],[],[],[],['microsatellite instability'],,Low,1
3943,Exploration of the benefits and resistance mechanisms of immunotherapy based on PD-L1 expression and ctDNA profiles.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,"['gastro-esophageal cancer', 'pancreatic cancer', 'hepatobiliary cancer']","['gastroesophageal cancer', 'pancreatic cancer', 'hepatobiliary cancer']",[],[],[],[],[],[],,Low,1
3953,"Dipeptidyl peptidase 9 (DPP9) depletion from hepatocytes in mice to retard tumour growth, increase intrahepatic caspase-1 activation, and alter metabolic markers.","Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,"['gastro-esophageal cancer', 'pancreatic cancer', 'hepatobiliary cancer']","['gastroesophageal cancer', 'pancreatic cancer', 'hepatobiliary cancer']",[],[],[],[],[],[],,Low,1
3960,Association of inflammation with depression in pancreatic ductal adenocarcinoma.,Symptom Science and Palliative Care,Publication Only,"['inflammation', 'pancreatic ductal adenocarcinoma']","['inflammation', 'pancreatic ductal adenocarcinoma']",[],[],[],[],[],[],,Low,1
3978,"A phase II study of NALIRIFOX (liposomal irinotecan, 5-fluorouracil, leucovorin and oxaliplatin) in patients with locally advanced pancreatic cancer (LAPC).","Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic cancer'],['locally advanced pancreatic cancer'],"['nucleoside metabolic inhibitor', 'folic acid analog', 'dna synthesis inhibitor', 'top1 inhibitor']",['nalirifox'],[],[],[],['locally advanced'],,Low,1
3986,Innovative data visualization tool for tracking system failures in colorectal cancer screening.,Care Delivery/Models of Care,Publication Only,['colorectal cancer'],['colorectal cancer'],[],[],[],[],[],[],,Low,1
3990,The prevalence and outcomes of ascites in patients hospitalized with pancreatic cancer: Insights from the Nationwide Inpatient Sample.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,"['ascites', 'pancreatic cancer']","['ascites', 'pancreatic cancer']",[],[],[],[],[],[],,Low,1
3999,Real world evidence for patients with advanced and metastatic pancreatic cancer treated with sacituzumab govitecan: A retrospective trial in China.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic cancer'],['advanced and metastatic pancreatic cancer'],['trop2 antibody drug conjugate'],['sacituzumab govitecan'],[],[],[],"['advanced', 'metastatic']",,Low,1
4008,"The application of a novel split-type robotic system, Carina Platform, for esophageal surgery.","Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,"['gastro-esophageal cancer', 'pancreatic cancer', 'hepatobiliary cancer']","['gastroesophageal cancer', 'pancreatic cancer', 'hepatobiliary cancer']",[],[],[],[],[],[],,Low,1
4016,ctDNA informed management of metastatic pancreatic cancer.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic cancer'],['metastatic pancreatic cancer'],[],[],[],[],[],['metastatic'],,Low,1
4019,Global and regional burden of high BMI-related pancreatic cancer from 1990 to 2021: An analysis of GBD study 2021.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic cancer'],['pancreatic cancer'],[],[],[],[],[],[],,Low,1
4024,Personalized recurrence risk stratification in surgically resected non-small cell lung cancer: Multicenter deep learning model development and validation.,Care Delivery/Models of Care,Publication Only,['non-small cell lung cancer'],['recurrent resectable non-small cell lung cancer'],[],[],[],[],[],"['resectable', 'recurrent']",,Low,1
5911,TP53 mutation as a prognostic factor in metastatic non-small cell lung cancer (NSCLC): A retrospective review.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['tp53-mutant metastatic non-small cell lung cancer'],[],[],[],[],[],"['tp53-mutated', 'metastatic']",,High,1
4044,Impact of tobacco use and sociodemographic factors on mortality in pancreatic cancer in the United States: A time trend analysis.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic cancer'],['pancreatic cancer'],[],[],[],[],[],[],,Low,1
5992,Potent antitumor activity of the KRASG12D inhibitor MRTX1133 in pancreatic cancer: Augmenting the nanoparticle-paclitaxel chemotherapy response.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic cancer'],['pancreatic cancer'],"['kras g12d inhibitor', 'microtubule inhibitor']","['mrtx1133', 'paclitaxel']",[],[],[],[],,High,1
6277,Exploring variables associated with prolonged survival in AML with TP53 aberration.,"Hematologic Malignancies - Leukemia, Myelodysplastic Syndromes, and Allotransplant",Publication Only,['acute myeloid leukemia'],['tp53 aberration acute myeloid leukemia'],[],[],[],[],[],[],,High,1
4058,Effect of genetically engineered Salmonella typhimurium secreting conantokin G on PD-L1 antibody therapy and tumor regression in colorectal cancer.,Developmental Therapeutics - Immunotherapy,Publication Only,['colorectal cancer'],['colorectal cancer'],"['nmda receptor antagonist', 'pdl1 inhibitor']",['conantokin g'],[],[],[],[],,Low,1
6463,Impact of TP53 mutation status on cancer-specific survival after first-line treatment in lymphoplasmacytic lymphoma.,Hematologic Malignancies - Plasma Cell Dyscrasia,Publication Only,['waldenstrom macroglobulinemia'],['tp53 mutant lymphoplasmacytic lymphoma'],[],[],[],[],[],[],,High,1
4103,Measuring pancreatic cancer spatial conformation to predict recurrence risk after total neoadjuvant therapy.,Developmental Therapeutics - Immunotherapy,Publication Only,['pancreatic cancer'],['pancreatic cancer'],[],[],[],[],[],[],,Low,1
4106,Real-world survival outcomes and adverse events with adjuvant osimertinib in resected EGFR mutation-positive non-small cell lung cancer.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Publication Only,['non-small cell lung cancer'],['resected egfr mutation-positive non-small cell lung cancer'],['egfr inhibitor'],['osimertinib'],[],[],[],"['egfr mutated', 'resected']",,Low,1
4113,"A phase 2 study of the OX40 agonist BGB-A445, in combination with docetaxel or BGB-15025, an HPK1 inhibitor, in patients with NSCLC pretreated by anti-PD-(L)1 antibodies.",Developmental Therapeutics - Immunotherapy,Publication Only,['non-small cell lung cancer'],['previously treated non-small cell lung cancer'],"['hpk1 inhibitor', 'microtubule inhibitor', 'ox40 agonist']","['bgb-a445', 'docetaxel', 'bgb-15025']",[],[],"['beigene', 'beone medicines']",['previously treated'],,Low,1
4114,"Neoadjuvant and adjuvant iruplinalkib in resectable ALK or ROS1 fusion-positive, non-small cell lung cancer (NSCLC): The preliminary results of the single-arm, exploratory Neo-INFINITY study.",Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Publication Only,['non-small cell lung cancer'],"['resectable ros1 fusion-positive non-small cell lung cancer', 'resectable alk fusion-positive non-small cell lung cancer']",['alk/ros1 inhibitor'],['iruplinalkib'],[],[],['qilu pharmaceutical'],"['alk fusion-positive', 'ros1-fusion positive', 'resectable']",,Low,1
4116,"A living systematic literature review (L-SLR) for non‚Äìsmall-cell lung (NSCLC), prostate (PC), and breast cancer (BC), built with an agentic text annotation system powered by large language models (LLM) to assist treatment decision making.",Care Delivery/Models of Care,Publication Only,"['prostate cancer', 'non-small cell lung cancer', 'breast cancer']","['prostate cancer', 'non-small cell lung cancer', 'breast cancer']",[],[],[],[],[],[],,Low,1
4120,The mediating role of inflammation in the association between platinum-based chemotherapy and cardiovascular adverse events in older non-small cell lung cancer patients.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Publication Only,['non-small cell lung cancer'],['elderly non small cell lung cancer'],['platinum therapy'],[],[],[],[],['elderly'],,Low,1
4123,Evaluation of the efficacy and safety of anlotinib in postoperative non-pCR non-small cell lung cancer.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Publication Only,['non-small cell lung cancer'],['non-small cell lung cancer'],['multi kinase inhibitor'],['anlotinib'],[],[],[],[],,Low,1
4131,Perioperative immunotherapy for stage II-III NSCLC patients: A retrospective real-world analysis.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Publication Only,['non-small cell lung cancer'],['stage ii-iii non-small cell lung cancer'],[],[],[],[],[],['stage ii'],,Low,1
4153,Efficacy and safety analysis of adjuvant atezolizumab in non-small cell lung cancer patients in China: A single center retrospective analysis.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Publication Only,['non-small cell lung cancer'],['non small cell lung cancer'],['pdl1 inhibitor'],['atezolizumab'],[],[],[],[],,Low,1
4156,Comparative efficacy and safety of nivolumab vs. docetaxel as second-line treatment in advanced non-small cell lung cancer: A systematic review and meta-analysis.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Publication Only,['non-small cell lung cancer'],['second line advanced non-small cell lung cancer'],['pd1 inhibitor'],['nivolumab'],[],['docetaxel'],[],"['second-line', 'advanced']",,Low,1
6534,Effect of co-occurring TP53 and intracellular proliferation pathway mutations on disease recurrence and survival benefits in head and neck cancers.,Head and Neck Cancer,Publication Only,['head and neck cancer'],['recurrent head and neck cancer'],[],[],[],[],['onecell dx'],['recurrent'],,High,1
4184,ADRB2-driven immunosuppression as a novel prognostic indicator and therapeutic avenue following neoadjuvant treatment in colorectal cancer.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['colorectal cancer'],[],[],[],[],['haplox biotechnology'],[],,Low,1
4185,Exposure to magnetic resonance imaging (MRI) procedures in relation to increased risk of early-onset colorectal cancer.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['early onset colorectal cancer'],[],[],[],[],[],['early onset'],,Low,1
6655,TP53 multihit mutations in 142 patients with MPN or AML: Comparative analysis of survival and risk factors.,"Hematologic Malignancies - Leukemia, Myelodysplastic Syndromes, and Allotransplant",Publication Only,"['myeloproliferative neoplasm', 'acute myeloid leukemia']","['myeloproliferative neoplasm', 'acute myeloid leukemia']",[],[],[],[],[],[],,High,1
4189,"Conducting stoma-free intersphincteric resection for ultra-low rectal cancers by selective delayed coloanal anastomosis, a single center experience.",Gastrointestinal Cancer - Colorectal and Anal,Publication Only,"['anal cancer', 'colorectal cancer']","['colorectal cancer', 'anal cancer']",[],[],[],[],[],[],,Low,1
4193,"DAILY: A prospective single arm study evaluating the impact of vitamin D, aspirin, exercise, and diet in colorectal cancer patients with ctDNA-defined minimal residual disease.",Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['colorectal cancer'],"['nonsteroidal anti inflammatory drug', 'vitamin supplement']","['vitamin d', 'aspirin']",[],[],[],[],,Low,1
4195,Likelihood of colorectal cancer screening by poor health status: A cross-sectional analysis of the Behavioral Risk Factor Surveillance System 2022.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['colorectal cancer'],[],[],[],[],[],[],,Low,1
4196,Peripheral myeloid-derived suppressor cell as a biomarker for diagnosing and predicting the treatment efficacy of colorectal cancer.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['colorectal cancer'],[],[],[],[],[],[],,Low,1
4200,Exploring the cytotoxic effects of bioactive compounds from Alcea rosea against stem cell-driven colon carcinogenesis.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,"['anal cancer', 'colorectal cancer']","['colorectal cancer', 'anal cancer']",[],[],[],[],[],[],,Low,1
4202,Real-world observational study of fruquintinib in combination with irinotecan and capecitabine as second-line treatment in patients with advanced colorectal cancer.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['second line advanced colorectal cancer'],"['nucleoside metabolic inhibitor', 'vegf inhibitor', 'top1 inhibitor']","['capecitabine', 'fruquintinib', 'irinotecan']",[],[],[],"['second-line', 'advanced']",,Low,1
4210,A cohort study of the effect of traditional Chinese medicine combined with Western medicine standard treatment on survival of patients with liver metastasis of colorectal cancer.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],"['liver metastasis', 'metastatic colorectal cancer']",[],[],[],[],[],['metastatic'],,Low,1
4212,Real-world outcomes in a Latin American setting with first-line osimertinib in EGFR-mutated NSCLC.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['egfr-mutated non-small cell lung cancer'],['egfr inhibitor'],['osimertinib'],[],[],[],['egfr mutated'],,Low,1
4215,"Exploring the prognostic and predictive value of IL-1Œ≤, TROP2, and B7-H3 in EGFR-mutated (EGFRm) NSCLC: Insights for personalized treatment strategies.",Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['egfr-mutant non-small cell lung cancer'],[],[],[],[],['caris life sciences'],['egfr mutated'],,Low,1
4219,Methylation-specific epigenetic and ctDNA biomarkers in prognosis of advanced NSCLC.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['advanced non-small cell lung cancer'],[],[],[],[],[],['advanced'],,Low,1
6741,Efficacy and safety of KRAS p.G12C inhibitors in advanced NSCLC: A systematic review and meta-analysis.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['advanced non-small cell lung cancer'],['kras g12c inhibitor'],[],[],[],[],['advanced'],,High,1
4252,Impact of tumor burden on outcomes after immune versus conventional therapies.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['metastatic non-small cell lung cancer'],[],[],[],[],[],['metastatic'],,Low,1
4253,Prognostic prediction of combined pre- and post-operative ctDNA detection in non-small cell lung cancer.,Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology,Publication Only,['non-small cell lung cancer'],['non-small cell lung cancer'],[],[],[],[],['jiangsu simcere diagnostics'],[],,Low,1
4260,"Investigating the oncolytic bacteria product SGN1 and its impact on PD-L1 expression, CD8+ T cell infiltration, and synergy with anti-PD-L1 combo in preclinical models of pancreatic adenocarcinoma, hepatocellular cancer, and melanoma.",Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology,Publication Only,"['melanoma', 'pancreatic adenocarcinoma', 'liver cancer']","['melanoma', 'hepatocellular cancer', 'pancreatic adenocarcinoma']","['bacteria replacement', 'pdl1 inhibitor']",['sgn1'],[],[],['guangzhou sinogen pharmaceutical'],[],,Low,1
4262,Chitinase 3-like-1 (CHI3L1): A potential prognostic biomarker for immunotherapy (IO) in non-small cell lung cancer (NSCLC).,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['non-small cell lung cancer'],[],[],[],[],['caris life sciences'],[],,Low,1
4263,The impacts on prognosis of the relationship between decline in renal function associated with pemetrexed and the ratio of pemetrexed administration.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['metastatic non-small cell lung cancer'],['antifolate'],['pemetrexed'],[],[],[],['metastatic'],,Low,1
4266,Clinical impact of single nucleotide polymorphisms (SNPs) in PDCD1 in patients with non-small cell lung cancer (NSCLC) receiving anti-PD1 immunotherapy.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['non-small cell lung cancer'],['pdl1 inhibitor'],[],[],[],[],[],,Low,1
4268,Unraveling the oncogenic potential of p53 amyloids in colorectal cancer.,Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology,Publication Only,['colorectal cancer'],['colorectal cancer'],[],[],[],[],[],[],,Low,1
4269,Myocarditis in patients with non-small cell lung cancer treated with immune checkpoint inhibitors: A multicenter study.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,"['myocarditis', 'non-small cell lung cancer']","['myocarditis', 'non-small cell lung cancer']",[],[],[],[],[],[],,Low,1
4270,Clinical outcomes in patients with mismatch repair-deficient colorectal cancer: A retrospective real-world evaluation in a single tertiary cancer centre.,Quality Care/Health Services Research,Publication Only,['colorectal cancer'],['mismatch repair deficiency colorectal cancer'],[],[],[],[],[],['dmmr'],,Low,1
4273,"Liquid biopsy at an NCI comprehensive cancer center: Patterns of utilization, performance, and outcomes.",Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['metastatic non-small cell lung cancer'],[],[],[],[],[],['metastatic'],,Low,1
4274,"Chylopericardium and chylous effusions during treatment with selective RET inhibitors, selpercatinib and pralsetinib, in non-small cell lung cancer (NSCLC).",Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['non-small cell lung cancer'],['ret inhibitor'],"['pralsetinib', 'selpercatinib']",[],[],[],[],,Low,1
4276,Investigation of pharmacodynamic and prognostic potential of FAP-activity assessed through FAP-mediated cleavage of type III collagen in patients with PDAC undergoing chemotherapy.,Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology,Publication Only,['pancreatic ductal adenocarcinoma'],['pancreatic ductal adenocarcinoma'],[],[],[],[],['nordic bioscience'],[],,Low,1
4279,Clinical prognostic factors associated with progression-free survival in pts with metastatic EGFR-mutant non-small cell lung cancer treated with gefitinib first-line therapy.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['metastatic egfr-mutant non-small cell lung cancer'],['egfr inhibitor'],['gefitinib'],[],[],[],"['egfr mutated', 'metastatic']",,Low,1
4281,Prognostic role of pre-treatment eosinophilia in NSCLC patients undergoing immune checkpoint inhibitor therapy: A meta-analysis.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,"['eosinophilia', 'non-small cell lung cancer']","['non-small cell lung cancer', 'eosinophilia ']",[],[],[],[],[],[],,Low,1
4286,Gender-specific trends in disability-adjusted life years (DALYs) and mortality rates of pancreatic cancer in adults aged 70 and older: A Global Burden of Disease analysis (1990-2021).,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic cancer'],['adult pancreatic cancer'],[],[],[],[],[],['adult'],,Low,1
4294,Sociodemographic disparities in survival outcomes among adolescent and young adult patients with pancreatic cancer: Insights from a SEER database analysis.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic cancer'],['adolescent/young adult pancreatic cancer'],[],[],[],[],[],"['young adult', 'adolescent']",,Low,1
4299,The impact of opioid use prior to pancreatic cancer diagnosis on overall survival: Insights from SEER-Medicare data.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic cancer'],['pancreatic cancer'],['opioid'],[],[],[],[],[],,Low,1
4301,Real-world data on the treatment of patients with ROS1-positive non-small cell lung cancer.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['ros1-positive non-small cell lung cancer'],[],[],[],[],[],['ros1-positive'],,Low,1
4304,Assessing the efficacy of ALK inhibitors in ALK-positive non-small cell lung cancer: A real-world data analysis.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['alk-positive non-small cell lung cancer'],['alk inhibitor'],[],[],[],[],['alk-positive'],,Low,1
4322,An extracellular vesicle-based assay for early detection of pancreatic ductal adenocarcinoma.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic ductal adenocarcinoma'],['pancreatic ductal adenocarcinoma'],[],[],[],[],[],[],,Low,1
4330,Textbook outcomes after esophagectomy: A five-year of experience at a specialized centre in a developing country.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,"['gastro-esophageal cancer', 'pancreatic cancer', 'hepatobiliary cancer']","['gastroesophageal cancer', 'pancreatic cancer', 'hepatobiliary cancer']",[],[],[],[],[],[],,Low,1
4332,Genomic testing in newly diagnosed patients with metastatic non small cell lung cancer (NSCLC): A report from a single centre within the Kaleido registry.,Care Delivery/Models of Care,Publication Only,['non-small cell lung cancer'],['newly diagnosed metastatic non small cell lung cancer'],[],[],[],[],[],"['newly diagnosed', 'metastatic']",,Low,1
4333,Gender-specific trends in incidence and prevalence of pancreatic cancer: A Global Burden of Disease analysis in adults aged 70 and older (1990‚Äì2021).,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic cancer'],['adult pancreatic cancer'],[],[],[],[],[],['adult'],,Low,1
4338,Impact of diagnostic workup location on time to treatment for patients with non-small cell lung cancer seen in the emergency department.,Care Delivery/Models of Care,Publication Only,['non-small cell lung cancer'],['non small cell lung cancer'],[],[],[],[],[],[],,Low,1
4339,Global trends in disability-adjusted life years (DALYs) and mortality rates of pancreatic cancer in adults aged 70 and older: A Global Burden of Disease analysis (1990‚Äì2021).,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic cancer'],['adult pancreatic cancer'],[],[],[],[],[],['adult'],,Low,1
4355,A real-world study of the NALIRIFOX regimen in perioperative treatment of borderline resectable and locally advanced pancreatic cancer in China.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic cancer'],['borderline resectable locally advanced pancreatic cancer'],"['nucleoside metabolic inhibitor', 'folic acid analog', 'dna synthesis inhibitor', 'top1 inhibitor']",['nalirifox'],[],[],[],"['borderline resectable', 'locally advanced']",,Low,1
4376,AI-enhanced literature review: Comparing advanced pancreatic and gastric cancer trial outcomes by performance status.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,"['pancreatic cancer', 'gastric cancer']","['advanced pancreatic cancer', 'advanced gastric cancer']",[],[],[],[],['medicus pharma'],['advanced'],,Low,1
4388,Temporal trends and disparities in pancreatic cancer mortality: A nationwide analysis from 1968-2020.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic cancer'],['pancreatic cancer'],[],[],[],[],[],[],,Low,1
4390,"Relationship between access to shelter arrangement and adherence to breast, cervical, and colorectal cancer screening in the Providence's unhoused population.",Care Delivery/Models of Care,Publication Only,"['colorectal cancer', 'cervical cancer', 'breast cancer']","['colorectal cancer', 'cervical cancer', 'breast cancer']",[],[],[],[],['genentech'],[],,Low,1
4394,PancreaX: Artificial intelligence‚Äìdriven diagnosis of pancreatic cancer.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic cancer'],['pancreatic cancer'],[],[],[],[],['spatialx diagnostics'],[],,Low,1
4400,AI-driven integration of microbiome and exosome profiles for precision diagnostics and therapeutics in colorectal cancer.,Care Delivery/Models of Care,Publication Only,['colorectal cancer'],['colorectal cancer'],[],[],[],[],[],[],,Low,1
4401,Correlation of elevated CA19-9 and cancer associated macrophages in blood with outcomes in pancreatic cancer patients over 5 years.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic cancer'],['pancreatic cancer'],[],[],[],[],['creatv microtech'],[],,Low,1
4402,Deep learning to predict treatment response of immune checkpoint inhibitors from pretreatment chest X-rays in non‚Äìsmall-cell lung cancer.,Care Delivery/Models of Care,Publication Only,['non-small cell lung cancer'],['non-small cell lung cancer'],[],[],[],[],[],[],,Low,1
4410,A multi-omic liquid biopsy for the earlier detection of pancreatic cancer.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic cancer'],['pancreatic cancer'],[],[],[],[],['dxcover'],[],,Low,1
4424,"Metastatic pancreatic cancer: Molecular characterization, therapeutic implications, and survival outcomes from community oncology practice in western India.","Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic cancer'],['metastatic pancreatic cancer'],[],[],[],[],[],['metastatic'],,Low,1
4436,Trends and disparities in end-of-life care among patients with pancreatic cancer.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic cancer'],['pancreatic cancer'],[],[],[],[],[],[],,Low,1
4437,"Efficacy and safety of nimotuzumab plus AG regimen as conversion therapy for locally advanced pancreatic cancer: A prospective, single-arm study.","Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic cancer'],['locally advanced pancreatic cancer'],['egfr targeted therapy'],['nimotuzumab'],[],[],['biotech pharmaceuticals'],['locally advanced'],,Low,1
4450,Efficacy of nanoliposomal irinotecan in metastatic pancreatic ductal adenocarcinoma: A meta-analysis of NAPOLI randomized clinical trials.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic ductal adenocarcinoma'],['metastatic pancreatic ductal adenocarcinoma'],['top1 inhibitor'],['nanoliposomal irinotecan'],[],[],"['merrimack pharmaceuticals', 'ipsen']",['metastatic'],,Low,1
4467,Real-world adoption of adjuvant molecularly targeted therapy and immunotherapy for resected stage Ib-III non-small cell lung cancer within the Veterans Health Administration.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Publication Only,['non-small cell lung cancer'],['resectable stage ib-iii non-small cell lung cancer'],[],[],[],[],[],"['resectable', 'stage ib']",,Low,1
4481,Real-world outcomes and patterns of recurrence in a cohort treated with PACIFIC protocol: A single-center retrospective study.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Publication Only,"['non-small cell lung cancer', 'small-cell lung cancer', 'thoracic cancers']","['non-small cell lung cancer', 'thoracic cancer', 'small cell lung cancer']",[],[],[],[],[],[],,Low,1
4506,Novel robotic navigation system for CT-guided lung ablation: First efficacy and safety evaluation.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Publication Only,"['non-small cell lung cancer', 'small-cell lung cancer', 'thoracic cancers']","['non-small cell lung cancer', 'thoracic cancer', 'small cell lung cancer']",[],[],[],[],[],[],,Low,1
4508,Racial disparities in molecularly targeted trials of tyrosine kinase inhibitors (TKI) for the perioperative management of oncogene-driven non-small cell lung cancer (NSCLC): A systematic review.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Publication Only,['non-small cell lung cancer'],['non-small cell lung cancer'],['tyrosine kinase inhibitor'],[],[],[],[],[],,Low,1
4520,Comparative survival outcomes among histological subtypes of non-small cell lung cancer in the United States.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Publication Only,['non-small cell lung cancer'],['non-small cell lung cancer'],[],[],[],[],[],[],,Low,1
4524,Digital profiling of tumor-derived extracellular vesicle-RNA: A sensitive approach for early detection of EGFR mutations in osimertinib-resistant non-small cell lung cancer.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Publication Only,['non-small cell lung cancer'],['non small cell lung cancer'],[],[],[],[],['exodiscovery'],[],,Low,1
4531,Age-stratified analysis of socioeconomic disparities in non-small cell lung cancer outcomes: A National Cancer Database study.,Care Delivery/Models of Care,Publication Only,['non-small cell lung cancer'],['non small cell lung cancer'],[],[],[],[],[],[],,Low,1
4534,Strategic planning to transform pancreatic cancer care: A comprehensive interdisciplinary roadmap.,Care Delivery/Models of Care,Publication Only,['pancreatic cancer'],['pancreatic cancer'],[],[],[],[],[],[],,Low,1
4542,Efficacy and safety of stereotactic body radiotherapy vs. conventional radiotherapy for early-stage non-small cell lung cancer: A systematic review.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Publication Only,['non-small cell lung cancer'],['early stage non small cell lung cancer'],[],[],[],[],[],['early-stage'],,Low,1
4549,Association of SMOX gene expression with immune checkpoint therapy response in patients with non-small cell lung cancer.,Developmental Therapeutics - Immunotherapy,Publication Only,['non-small cell lung cancer'],['non-small cell lung cancer'],[],[],[],[],[],[],,Low,1
4592,Effect of chemotherapy treatment on immunotherapy efficacy in colorectal cancer (CRC) patients with high microsatellite instability (MSI-H) and/or tumor mutational burden (TMB-H).,Developmental Therapeutics - Immunotherapy,Publication Only,['colorectal cancer'],"['high tumor mutational burden colorectal cancer', 'high microsatellite instability colorectal cancer']",[],[],[],[],[],['microsatellite instability'],,Low,1
4599,Balancing tumor control and toxicity: SBRT strategies for ultra-central NSCLC.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Publication Only,['non-small cell lung cancer'],['non-small cell lung cancer'],[],[],[],[],[],[],,Low,1
4602,Use of Al-based models integrating serum proteomics and clinicopathologic features to predict survival outcomes in NSCLC patients undergoing immunotherapy.,Developmental Therapeutics - Immunotherapy,Publication Only,['non-small cell lung cancer'],['non-small cell lung cancer'],[],[],[],[],[],[],,Low,1
4632,Novel protein biomarkers for early detection of pancreatic ductal adenocarcinoma using longitudinal serum protein measurements and machine learning.,Developmental Therapeutics - Immunotherapy,Publication Only,['pancreatic ductal adenocarcinoma'],['pancreatic ductal adenocarcinoma'],[],[],[],[],[],[],,Low,1
4645,"Irinotecan liposome in Chinese patients with advanced pancreatic cancer: A prospective, multicenter, observational real-world study.","Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic cancer'],['advanced pancreatic cancer'],['top1 inhibitor'],['irinotecan liposome'],[],[],[],['advanced'],,Low,1
4652,Effect of enrollment in a clinical trial on treatment outcomes of patients with pancreas cancer.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic cancer'],['pancreatic cancer'],[],[],[],[],[],[],,Low,1
4673,Real-world outcomes for dMMR/MSI-H colorectal cancer: Navigating rapidly evolving oncologic practices in a community hospital.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['dmmr/msi-h colorectal cancer'],[],[],[],[],[],"['dmmr', 'msi-h']",,Low,1
4675,Incidence and survival trends in early-onset colorectal cancer.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['early onset colorectal cancer'],[],[],[],[],[],['early onset'],,Low,1
4677,Combination of nivolumab plus ipilimumab in microsatellite instability-high metastatic colorectal cancer: A systematic review and meta-analysis.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['microsatellite instability-high metastatic colorectal cancer'],"['pd1 inhibitor', 'ctla4 inhibitor']","['nivolumab', 'ipilimumab']",[],[],[],"['msi-h', 'metastatic']",,Low,1
4680,Ipilimumab and nivolumab after disease progression on single agent immunotherapy in mismatch repair deficient metastatic colorectal cancer.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['mismatch repair deficient metastatic colorectal cancer'],"['pd1 inhibitor', 'ctla4 inhibitor']","['nivolumab', 'ipilimumab']",[],[],[],"['dmmr', 'metastatic']",,Low,1
4682,Cardiovascular toxicity of fruquintinib in patients with colorectal and other cancers: A systematic review and meta-analysis.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,"['colorectal cancer', 'cancer']","['cancer', 'colorectal cancer']",['vegfr inhibitor'],['fruquintinib'],[],[],[],[],,Low,1
4685,The CREAFORMO-004 study: A phase II study of HR070803 plus 5-fluorouracil/leucovorin and bevacizumab as second-line treatment in patients with metastatic colorectal cancer.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['second line metastatic colorectal cancer'],"['folic acid analog', 'top1 inhibitor', 'vegf inhibitor', 'antimetabolite']","['bevacizumab', '5-fluorouracil/leucovorin', 'hr-070803']",[],[],[],"['second-line', 'metastatic']",,Low,1
4686,A single institution review of early onset colorectal cancer: 10 year retrospective clinical study.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['early onset colorectal cancer'],[],[],[],[],[],['early onset'],,Low,1
4692,Effect of cyclin E overexpression on anti-tumor immune responses via activation of the cGAS/STING pathway following radiotherapy.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,"['anal cancer', 'colorectal cancer']","['colorectal cancer', 'anal cancer']",[],[],[],[],[],[],,Low,1
4693,Comparison of the efficacy and safety of regorafenib monotherapy and regorafenib combination therapy in the third-line treatment of metastatic colorectal cancer: A real-world study.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['third line metastatic colorectal cancer'],['multi kinase inhibitor'],['regorafenib'],[],[],[],"['metastatic', 'third-line']",,Low,1
4694,A multi-cohort real-world study of treatment for metastatic colorectal cancer (mCRC): Overall efficacy analysis and subgroup analysis of previous bevacizumab use or not.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['metastatic colorectal cancer'],['vegf inhibitor'],['bevacizumab'],[],[],[],['metastatic'],,Low,1
4698,Real-world study of anti‚ÄìPD-1 combined with regorafenib and raltitrexed as third-line therapy in colorectal cancer.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['third line colorectal cancer'],"['pd1 inhibitor', 'thymidylate synthase inhibitor', 'alkylating agent']","['regorafenib', 'raltitrexed']",[],[],[],['third-line'],,Low,1
4700,Disparities in colorectal cancer incidence and mortality in Appalachian Kentucky.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['colorectal cancer'],[],[],[],[],[],[],,Low,1
4711,Navigating third-line therapies: A comprehensive review of regorafenib versus fruquintinib with placebo comparator for metastatic colorectal cancer‚ÄîA systematic review and meta-analysis.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['third line metastatic colorectal cancer'],['multi kinase inhibitor'],['regorafenib'],[],['fruquintinib'],[],"['metastatic', 'third-line']",,Low,1
4712,Safety of fruquintinib in young and late-elderly Chinese patients with colorectal cancer in real-world clinical practice: Age subgroup analysis of a fruquintinib phase IV study.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],"['young colorectal cancer', 'elderly colorectal cancer']",['vegfr inhibitor'],['fruquintinib'],[],[],['hutchmed'],"['young', 'elderly']",,Low,1
4717,Safety of fruquintinib monotherapy and combination therapy in Chinese patients with colorectal cancer in real-world clinical practice: A subgroup analysis from phase IV study.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['colorectal cancer'],['vegfr inhibitor'],['fruquintinib'],[],[],['hutchmed'],[],,Low,1
4718,Evaluating the immune landscape in early onset colorectal cancer patients.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['early onset colorectal cancer'],[],[],[],[],[],['early onset'],,Low,1
4720,"Efficacy of anti-VEGF & anti-EGFRs in microsatellite instable (MSI-H) metastatic colorectal cancer, Turkish Oncology Group (TOG) study.",Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['microsatellite instability-high metastatic colorectal cancer'],"['egfr inhibitor', 'vegf inhibitor']",[],[],[],[],"['msi-h', 'metastatic']",,Low,1
4736,Combined preoperative segmental hepatic arteries embolization with hepatic artery resection in radical pancreatic resections for locally advanced pancreatic cancer.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic cancer'],['locally advanced pancreatic cancer'],[],[],[],[],[],['locally advanced'],,Low,1
4741,Risk of pulmonary toxicities in patients with EGFR-mutant non-small cell lung cancer (NSCLC) treated with amivantamab: A systematic review and meta-analysis of phase 3 randomized controlled trials.,Symptom Science and Palliative Care,Publication Only,['non-small cell lung cancer'],['egfr-mutant non-small cell lung cancer'],['egfr/met bispecific antibody'],['amivantamab'],[],[],[],['egfr mutated'],,Low,1
6777,Use of AlphaFold 2 to predict stabilizing mutations for the R337H variant in the tetramerization domain of TP53.,Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology,Publication Only,['cancer'],['cancer'],[],[],[],[],[],[],,High,1
4754,Neoadjuvant treatments for resectable (RPC) and borderline resectable pancreatic adenocarcinoma (BRPC): A pairwise and network meta-analysis (NMA).,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic adenocarcinoma'],['resectable/borderline resectable pancreatic adenocarcinoma'],[],[],[],[],[],"['resectable', 'borderline resectable']",,Low,1
4768,Improving germline genetic testing in pancreatic cancer: A quality improvement project.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic cancer'],['pancreatic cancer'],[],[],[],[],[],[],,Low,1
4773,A single-center experience of chemotherapy combined with radiofrequency ablation and immunotherapy in patients with locally advanced/metastatic pancreatic ductal adenocarcinoma.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic ductal adenocarcinoma'],['locally advanced/metastatic pancreatic ductal adenocarcinoma'],[],[],[],[],[],"['metastatic', 'locally advanced']",,Low,1
4782,The Pancreas Tissue Bank (PCRFTB): Global facilitation of pancreatic research.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,"['gastro-esophageal cancer', 'pancreatic cancer', 'hepatobiliary cancer']","['gastroesophageal cancer', 'pancreatic cancer', 'hepatobiliary cancer']",[],[],[],[],[],[],,Low,1
4813,Effect of external beam radiotherapy on hepatic parenchymal resection rate.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,"['gastro-esophageal cancer', 'pancreatic cancer', 'hepatobiliary cancer']","['gastroesophageal cancer', 'pancreatic cancer', 'hepatobiliary cancer']",[],[],[],[],[],[],,Low,1
4836,Association between frailty and healthcare resource utilization in older adults with pancreatic cancer: A retrospective cohort study.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic cancer'],['older adult pancreatic cancer'],[],[],[],[],[],['elderly'],,Low,1
6806,Association of co-occurring KRAS and gain of function TP53 mutations with aggressive metastasis through comprehensive genomic profiling of pancreatic ductal adenocarcinoma.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic ductal adenocarcinoma'],"['pancreatic ductal adenocarcinoma', 'kras/tp53-mutant aggressive metastasis']",[],[],[],[],['onecell dx'],"['aggressive', 'metastatic', 'tp53-mutated']",,High,1
4851,Effect of clonal competition model of PDAC liver metastasis on a pan-carcinoma gene signature of metastatic potential.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic ductal adenocarcinoma'],['metastatic pancreatic ductal adenocarcinoma liver metastasis'],[],[],[],[],[],['metastatic'],,Low,1
4876,"Effects of Akt inhibitors on radiation sensitivity, oxidative stress, EMT reversal, and immune microenvironment reprogramming in pancreatic cancer.","Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic cancer'],['pancreatic cancer'],['akt inhibitor'],[],[],[],[],[],,Low,1
4895,Efficacy of multimodal thermal therapy combined with immune checkpoint inhibitors and chemotherapy in unresectable pancreatic cancer with liver metastases.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic cancer'],"['unresectable liver metastasis', 'unresectable pancreatic cancer']",[],[],[],[],[],"['metastatic', 'unresectable']",,Low,1
4897,Efficacy and safety of FOLFIRINOX versus gemcitabine-based regimens for treatment of metastatic pancreatic cancer: A systematic review and meta-analysis.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic cancer'],['metastatic pancreatic cancer'],"['thymidylate synthetase inhibitor', 'nucleoside metabolic inhibitor', 'dna synthesis inhibitor', 'top1 inhibitor']",['folfirinox'],[],['gemcitabine'],[],['metastatic'],,Low,1
4909,Survival outcomes in pancreatic cancer: A single-center retrospective study in a large healthcare system.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic cancer'],['pancreatic cancer'],[],[],[],[],[],[],,Low,1
4915,Intravenous vitamin C as an adjunct to standard therapy in pancreatic ductal adenocarcinoma: A systematic review of clinical trials.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic ductal adenocarcinoma'],['pancreatic ductal adenocarcinoma'],['vitamin supplement'],['vitamin c'],[],[],[],[],,Low,1
4920,Textbook outcomes in liver surgery: A decade of experience at a cancer-dedicated centre.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,"['gastro-esophageal cancer', 'pancreatic cancer', 'hepatobiliary cancer']","['gastroesophageal cancer', 'pancreatic cancer', 'hepatobiliary cancer']",[],[],[],[],[],[],,Low,1
4923,Investigating survival in patients undergoing surgery for pancreatic ductal adenocarcinoma using liquid biopsy: Preliminary results of PAN-CGE-BLISS pilot study.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic ductal adenocarcinoma'],['pancreatic ductal adenocarcinoma'],[],[],[],[],[],[],,Low,1
4980,Experience of 25 patients treated with echoendoscopically implanted 32P microparticles associated with chemotherapy in locally advanced pancreatic adenocarcinoma.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic adenocarcinoma'],['locally advanced pancreatic adenocarcinoma'],[],[],[],[],[],['locally advanced'],,Low,1
4983,Racial and socioeconomic disparities in molecular testing and targeted therapy utilization among patients with advanced non-small cell lung cancer: A National Cancer Database analysis.,Care Delivery/Models of Care,Publication Only,['non-small cell lung cancer'],['advanced non small cell lung cancer'],[],[],[],[],[],['advanced'],,Low,1
6809,Outcomes of KRAS G12C inhibitors in metastatic pancreatic cancer: A systematic review and meta-analysis.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic cancer'],['metastatic pancreatic cancer'],['kras g12c inhibitor'],[],[],[],[],['metastatic'],,High,1
4992,Plasma metabolomic signatures for predicting pancreatic ductal adenocarcinoma survival: The clinical application of targeted mass spectrometry lipidomics.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic ductal adenocarcinoma'],['pancreatic ductal adenocarcinoma'],[],[],[],[],['metabolomycs'],[],,Low,1
5002,Tumor-derived extracellular vesicles: A potential novel liquid biomarker for pancreatic ductal adenocarcinoma.,Developmental Therapeutics - Immunotherapy,Publication Only,['pancreatic ductal adenocarcinoma'],['pancreatic ductal adenocarcinoma'],[],[],[],[],[],[],,Low,1
5039,Image harmonization for PD-(L)1 immune checkpoint inhibitor response prediction using radiomic features and deep learning in advanced NSCLC.,Care Delivery/Models of Care,Publication Only,['non-small cell lung cancer'],['advanced non-small cell lung cancer'],['pdl1 immune checkpoint inhibitor'],[],[],[],['onc.ai'],['advanced'],,Low,1
5048,Artificial intelligence in target discovery: CURE AI prediction of TIGIT and PD-L1 as immunotherapy targets in NSCLC.,Care Delivery/Models of Care,Publication Only,['non-small cell lung cancer'],['non-small cell lung cancer'],"['tigit targeted therapy', 'pdl1 targeted therapy']",[],[],[],[],[],,Low,1
5049,Vitamin D serum level as a predictor of response to immunotherapy for non-small cell lung cancer.,Developmental Therapeutics - Immunotherapy,Publication Only,['non-small cell lung cancer'],['non-small cell lung cancer'],[],[],[],[],[],[],,Low,1
5068,Sequential curative surgery and outcome in a multicenter randomized phase III trial comparing conversion chemotherapy followed by chemoradiotherapy vs continuous chemotherapy in patients with unresectable pancreatic cancer (CONKO-007 trial).,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic cancer'],['unresectable pancreatic cancer'],[],[],[],[],[],['unresectable'],,Low,1
5075,Health-related social needs and mortality risk among United States Veterans with non-small cell lung cancer.,Care Delivery/Models of Care,Publication Only,['non-small cell lung cancer'],['non-small cell lung cancer'],[],[],[],[],[],[],,Low,1
5093,National trends in prevalence of pancreatic cancer in adults aged 70 and older: A global burden of disease analysis (1990‚Äì2021).,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic cancer'],['adult pancreatic cancer'],[],[],[],[],[],['adult'],,Low,1
5097,Regional trends in incidence and prevalence of pancreatic cancer among older adults (70+): A 30-year global burden of disease analysis (1990‚Äì2021).,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic cancer'],['elderly pancreatic cancer'],[],[],[],[],[],['elderly'],,Low,1
5098,Clinico-radiographic predictors of overall survival in stage II-III pancreatic cancer.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic cancer'],['stage ii/stage iii pancreatic cancer'],[],[],[],[],[],"['stage ii', 'stage iii']",,Low,1
5101,Impact of clinical and socioeconomic factors on survival outcomes in non-small cell lung cancer: A retrospective analysis.,Care Delivery/Models of Care,Publication Only,['non-small cell lung cancer'],['non small cell lung cancer'],[],[],[],[],[],[],,Low,1
5103,Exploring the mutational and molecular profile of pancreatic cancer: A comprehensive genomics approach.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic cancer'],['pancreatic cancer'],[],[],[],[],['4basecare'],[],,Low,1
5105,Effect of cDC2 licensing by CCL5+ Th1 cells following BCL9/BCL9L inhibition on CD8+ T cell cross-priming for enhanced anti-tumor responses.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,"['gastro-esophageal cancer', 'pancreatic cancer', 'hepatobiliary cancer']","['gastroesophageal cancer', 'pancreatic cancer', 'hepatobiliary cancer']",[],[],[],[],[],[],,Low,1
5109,Disparities in receipt of chemotherapy at the end of life among patients with NSCLC.,Care Delivery/Models of Care,Publication Only,['non-small cell lung cancer'],['non-small cell lung cancer'],[],[],[],[],[],[],,Low,1
5110,Second-line therapy following osimertinib in metastatic EGFR-mutated non-small cell lung cancer at an academic medical center.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['second-line metastatic egfr-mutated non-small cell lung cancer'],['egfr inhibitor'],['osimertinib'],[],[],[],"['egfr mutated', 'second-line', 'metastatic']",,Low,1
5111,Effect of KRT3 on colorectal cancer growth through regulation glycolysis via the cebpd-LRRC8A-AKT signaling axis.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['colorectal cancer'],[],[],[],[],[],[],,Low,1
5112,Broadening the gates: Analysis of potentially modifiable screen failures in pancreatic and biliary tract cancer trials.,Quality Care/Health Services Research,Publication Only,"['biliary tract cancer', 'pancreatic cancer']","['biliary tract cancer', 'pancreatic cancer']",[],[],[],[],[],[],,Low,1
5115,The impact of preoperative imaging strategies in EGFR-mutant non-small cell lung cancer (NSCLC): A multi-center retrospective review.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['egfr-mutant non-small cell lung cancer'],[],[],[],[],[],['egfr mutated'],,Low,1
5119,Management of oligoprogressive EGFR+ NSCLC in the age of osimertinib: A single center experience.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['oligoprogressive egfr-positive non-small cell lung cancer'],['egfr inhibitor'],['osimertinib'],[],[],[],['oligoprogressive'],,Low,1
5120,Impact of rurality on patients with synchronous colorectal cancers.,Quality Care/Health Services Research,Publication Only,['colorectal cancer'],['synchronous colorectal cancer'],[],[],[],[],[],[],,Low,1
5126,Sex differences in toxicities among patients receiving regorafenib or trifluridine/tipiracil for refractory metastatic colorectal cancer: A subgroup analysis from the multicenter retrospective ReTrITA study.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['refractory metastatic colorectal cancer'],"['multi kinase inhibitor', 'thymidine phosphorylase inhibitor']","['regorafenib', 'tipiracil/trifluridine']",[],[],[],"['refractory', 'metastatic']",,Low,1
5129,"First-line camrelizumab plus chemotherapy in patients with advanced non-squamous non-small cell lung cancer: A nationwide, retrospective real-world study.",Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-squamous non-small cell lung cancer'],['advanced non-squamous non-small cell lung cancer'],['pd1 targeted therapy'],['camrelizumab'],[],[],['hengrui pharmaceuticals'],['advanced'],,Low,1
5133,Reflex precision oncology consultation to increase comprehensive genomic profiling rates in non-small cell lung cancer.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['non-small cell lung cancer'],[],[],[],[],['illumina'],[],,Low,1
5137,Observation or adjuvant therapy: The optimal regime for patients undergoing neoadjuvant chemoradiotherapy with postoperative yield pathological stage I.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,"['anal cancer', 'colorectal cancer']","['colorectal cancer', 'anal cancer']",[],[],[],[],[],[],,Low,1
151,"Anlotinib versus bevacizumab added to standard first-line chemotherapy among patients with RAS/BRAF wild-type, unresectable metastatic colorectal cancer: A multicenter, prospective, randomised, phase 3 clinical trial (ANCHOR trial).",Gastrointestinal Cancer - Colorectal and Anal,Oral Abstract Session,['colorectal cancer'],['first-line unresectable ras/braf wild type metastatic colorectal cancer'],"['multi kinase inhibitor', 'vegf inhibitor']","['bevacizumab', 'anlotinib']",[],['bevacizumab'],['chia tai tianqing pharmaceutical'],"['first-line', 'braf wild-type', 'unresectable', 'metastatic']",,Medium,1
5143,"Observational study of prevalence, management, and outcomes of synchronous oligometastatic non-small cell lung cancer.",Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['synchronous oligometastatic non-small cell lung cancer'],[],[],[],[],[],['synchronous oligometastatic'],,Low,1
5147,Comprehensive genomic alterations identification and potential shared neoantigens for non-small cell lung cancer immunotherapy.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['non-small cell lung cancer'],[],[],[],[],['runsheng cytomed technology'],[],,Low,1
5149,Colorectal cancer and sepsis mortality among the elderly: Analysis from 1999 to 2020.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,"['colorectal cancer', 'sepsis']","['elderly sepsis', 'elderly colorectal cancer']",[],[],[],[],[],['elderly'],,Low,1
5152,"A single-center, prospective, randomized controlled trial of tislelizumab combined with platinum-containing chemotherapy as first-line treatment for HIV-positive patients with advanced non-small cell lung cancer.",Lung Cancer - Non - Small Cell Metastatic,Publication Only,"['immune deficiency', 'non-small cell lung cancer']",['first-line human immunodeficiency virus-positive advanced non-small cell lung cancer'],"['pd1 inhibitor', 'platinum therapy']",['tislelizumab'],[],[],[],"['advanced', 'first-line']",,Low,1
414,Assessing the predictive role of tumor sidedness in RAS and BRAF wild-type metastatic colorectal cancer (mCRC) treated with first-line doublets + anti-EGFRs/bevacizumab (bev) or triplet + bev: An individual patient data pooled analysis of 10 randomized clinical trials.,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],"['ras wild type metastatic colorectal cancer', 'braf wild type metastatic colorectal cancer']","['vegf inhibitor', 'egfr targeted therapy']",['bevacizumab'],[],[],['takeda'],"['braf wild-type', 'metastatic']",,Medium,1
5161,"Efficacy and safety of Gegen Qinlian tablets in attenuating immune-related adverse events in NSCLC patients: A randomized controlled, multicenter, open-label trial in China.",Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['non-small cell lung cancer'],[],[],[],[],[],[],,Low,1
5163,Pattern of resistance on first-line EGFR-directed therapy in EGFR-positive metastatic non-small cell lung cancer.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['first line egfr-positive metastatic non-small cell lung cancer'],[],[],[],[],[],"['first-line', 'metastatic']",,Low,1
5164,"Regorafenib and nivolumab in refractory microsatellite stable, metastatic colorectal cancer and impact of site of dominant disease.",Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['refractory microsatellite stable metastatic colorectal cancer'],"['pd1 inhibitor', 'multi kinase inhibitor']","['nivolumab', 'regorafenib']",[],[],[],"['refractory', 'microsatellite stable', 'metastatic']",,Low,1
421,Prognostic and predictive impact of the baseline systemic proteome in patients with RAS wild-type metastatic colorectal cancer: Analysis from the randomized phase II PanaMa (AIO KRK0212) trial.,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['ras wild type metastatic colorectal cancer'],[],[],[],[],['amgen'],['metastatic'],,Medium,1
5169,"Survival outcomes in non-small cell lung cancer: Real-world analysis of immunotherapy era vs pre-immunotherapy era, with insights into treatment settings, racial disparities, and socioeconomic impacts.",Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['non-small cell lung cancer'],[],[],[],[],[],[],,Low,1
5175,Clinicogenomic features of non-small cell lung cancer patients with BRAF non-V600 mutations.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['braf non-v600-mutant non-small cell lung cancer'],[],[],[],[],[],[],,Low,1
5176,A phase 2 study of SR-8541A in combination with botensilimab and balstilimab in subjects with refractory metastatic microsatellite stable colorectal cancer (MSS-CRC).,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['refractory metastatic microsatellite stable colorectal cancer'],"['pd1 inhibitor', 'enpp1 inhibitor', 'ctla4 inhibitor']","['botensilimab', 'sr-8541a', 'balstilimab']",[],[],['stingray therapeutics'],"['refractory', 'microsatellite stable', 'metastatic']",,Low,1
5178,Accuracy of MRI in the detection of pathological complete response post neoadjuvant therapy in locally advanced colorectal cancer.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['locally advanced colorectal cancer'],[],[],[],[],[],['locally advanced'],,Low,1
5187,Pharmacoeconomic analysis of perioperative chemo-immunotherapy in resectable stage III non small cell lung cancer (NSCLC): Survival time cost-efficacy based on NADIM 2 trial.,Quality Care/Health Services Research,Publication Only,['non-small cell lung cancer'],['resectable stage iii non small cell lung cancer'],[],[],[],[],[],"['stage iii', 'resectable']",,Low,1
5189,Real-life efficacy and safety data of lorlatinib treatment in ROS-1‚Äìpositive advanced non-small cell lung cancer: Turkish Oncology Group (TOG) study.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['ros-1-positive advanced non-small cell lung cancer'],['alk/ros1 inhibitor'],['lorlatinib'],[],[],[],['advanced'],,Low,1
5191,"Risk factors for early-onset colorectal cancer: A retrospective analysis of 3,369 cases.",Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['early onset colorectal cancer'],[],[],[],[],[],['early onset'],,Low,1
5197,Comparative analysis of immunotherapy treatments in non-small cell lung cancer (NSCLC) using novel causal machine learning approaches.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['non-small cell lung cancer'],[],[],[],[],[],[],,Low,1
5198,Shifts in the landscape of colorectal cancer burden: A systematic analysis using the global burden of disease and SEER databases.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['colorectal cancer'],[],[],[],[],[],[],,Low,1
5205,Trends and gaps in colorectal cancer screening research in the Arab world: A 16-year bibliometric analysis (2007-2023).,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['colorectal cancer'],[],[],[],[],[],[],,Low,1
5206,Actionability landscape and biomarker utility in a colorectal cancer alliance cohort: Initial results from the Know Your Biomarker program.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['colorectal cancer'],[],[],[],[],[],[],,Low,1
5207,Interplatform and cross-cohort meta-analysis of tumor transcriptomics to predict non-small cell lung cancer c-Met protein overexpression.,Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology,Publication Only,['non-small cell lung cancer'],['c-met overexpressing non small cell lung cancer'],[],[],[],[],['abbvie'],['met-overexpressed'],,Low,1
5220,Celecoxib vs placebo in combination with chemotherapy for non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['non-small cell lung cancer'],['cox2 inhibitor'],['celecoxib'],[],[],[],[],,Low,1
5223,Access to new therapies and outcomes in Brazilian patients with metastatic non-small cell lung cancer (mNSCLC).,Quality Care/Health Services Research,Publication Only,['non-small cell lung cancer'],['metastatic non-small cell lung cancer'],[],[],[],[],[],['metastatic'],,Low,1
5224,Colorectal cancer (CRC): Now a disease of young!,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['young colorectal cancer'],[],[],[],[],[],['young'],,Low,1
5227,Risk factors and outcomes of second primary cancers in colorectal cancer patients by primary tumor site.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['second primary colorectal cancer'],[],[],[],[],[],[],,Low,1
5230,Evaluating multiplex immunofluorescence analysis of the tumor microenvironment for predicting immunotherapy efficacy in NSCLC compared to traditional biomarkers.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['non-small cell lung cancer'],[],[],[],[],[],[],,Low,1
5231,Impact of radiomic features on prediction of progression-free survival in patients with non-small cell lung cancer stage IV.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['stage iv non small cell lung cancer'],[],[],[],[],['sanofi'],['metastatic'],,Low,1
5232,Toxicity profile of fruquintinib (Fruq) versus regorafenib (Rego) in refractory metastatic colorectal cancer (mCRC).,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['refractory metastatic colorectal cancer'],['vegfr inhibitor'],['fruquintinib'],[],['regorafenib'],[],"['refractory', 'metastatic']",,Low,1
5236,Diffusing capacity for carbon monoxide (DLCO) change and outcome in advanced non-small cell lung cancer (aNSCLC) treated with immune checkpoint inhibitors (ICIs).,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['advanced non-small cell lung cancer'],['immune checkpoint inhibitor'],[],[],[],[],['advanced'],,Low,1
5237,Prospective observational study to evaluate efficacy and safety of immunotherapy (IO) in elderly (eld) patients (pts) with non-small cell lung cancer (NSCLC) undergoing comprehensive geriatric assessment (CGA).,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['elderly non-small cell lung cancer'],[],[],[],[],[],['elderly'],,Low,1
5241,Rechallenge with epidermal growth factor receptor inhibitors for metastatic colorectal cancer: A systematic review and meta-analysis.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['metastatic colorectal cancer'],['egfr inhibitor'],[],[],[],[],['metastatic'],,Low,1
5244,Trifluridine tipiracil with bevacizumab in refractory metastatic colorectal cancer with a convenient two weekly schedule: An Indian single center experience.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['refractory metastatic colorectal cancer'],"['vegf inhibitor', 'dna synthesis inhibitor']","['bevacizumab', 'tipiracil/trifluridine']",[],[],[],"['refractory', 'metastatic']",,Low,1
5245,Methodology for estimation of progression-free survival in patients with non-small cell lung cancer using real-world data from a French cohort.,Quality Care/Health Services Research,Publication Only,['non-small cell lung cancer'],['non small cell lung cancer'],[],[],[],[],[],[],,Low,1
5249,Colorectal cancer in young adults: What social behavior factors may be responsible?,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['young adult colorectal cancer'],[],[],[],[],[],['young adult'],,Low,1
5251,Investigating the role of ZEB2 upregulation in TAM polarization and immune modulation in EGFR-TKI resistant NSCLC.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['egfr-tki resistant non-small cell lung cancer'],['egfr-tki'],[],[],[],[],[],,Low,1
5252,Pembrolizumab vs chemotherapy in elderly patients with NSCLC: A comparative analysis of survival and adverse effects.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['elderly non-small cell lung cancer'],['pd1 inhibitor'],['pembrolizumab'],[],[],[],['elderly'],,Low,1
5255,Comparative of PD-L1 expression on live single circulating tumor cells with PD-L1 in tumor tissue assessed by immunohistochemistry in advanced NSCLC patients.,Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology,Publication Only,['non-small cell lung cancer'],['advanced non-small cell lung cancer'],[],[],[],[],['onecell dx'],['advanced'],,Low,1
5259,Exploring clonal hematopoiesis (CH) of short variants (SVs) detected in liquid biopsies (LBx) in genes relevant to non-small cell lung cancer (NSCLC).,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['non-small cell lung cancer'],[],[],[],[],['foundation medicine'],[],,Low,1
5262,Retrospective single-institution application of a deep learning‚Äìbased radiomic score in metastatic NSCLC: Potential impact on first-line treatment decisions and outcomes.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['first line metastatic non-small cell lung cancer'],[],[],[],[],['onc.ai'],"['first-line', 'metastatic']",,Low,1
5268,Multigene NGS assay for biomarker identification in 621 colorectal cancer cases.,Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology,Publication Only,['colorectal cancer'],['colorectal cancer'],[],[],[],[],[],[],,Low,1
5273,Genetic characteristics and clinical outcomes of driver mutant oligometastatic non small cell lung cancer treated with combination definitive chemoradiotherapy and targeted systemic therapy.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['driver mutant oligometastatic non small cell lung cancer'],[],[],[],[],[],['oligometastatic'],,Low,1
5288,Effect of branched-chain amino acid metabolic interactions between HIBADH+ tumor cells and BCAT1+ macrophages on immunotherapy response in advanced NSCLC.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['advanced non-small cell lung cancer'],[],[],[],[],[],['advanced'],,Low,1
5289,Circulating tumor cells and clusters exhibiting expression of PD-L1 in colorectal patients.,Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology,Publication Only,['colorectal cancer'],['pd-l1 expressing colorectal tumor'],[],[],[],[],['actorius innovations and research'],['pd-l1 expressing'],,Low,1
5292,Efficacy and safety of combination therapy versus monotherapy in advanced non-small cell lung cancer: A meta-analysis of overall survival and progression-free survival.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['advanced non-small cell lung cancer'],[],[],[],[],[],['advanced'],,Low,1
5303,Accelerating treatment decisions with liquid biopsy NGS in non-small cell lung cancer.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['non-small cell lung cancer'],[],[],[],[],['guardant health'],[],,Low,1
5307,Circulating tumor DNA as a prognostic biomarker for long-term survival in de-novo oligometastatic non-small cell lung cancer.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['de-novo oligometastatic non-small cell lung cancer'],[],[],[],[],[],['oligometastatic'],,Low,1
5308,Five-year survival outcomes in NSCLC patients with concurrent GERD on proton pump inhibitors receiving pembrolizumab or nivolumab: A global study.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,"['gastroesophageal reflux disease', 'non-small cell lung cancer']","['gastroesophageal reflux disease', 'non-small cell lung cancer']",['pd1 inhibitor'],"['nivolumab', 'pembrolizumab']",[],[],[],[],,Low,1
5312,Trends in second primary cancer incidence by primary colorectal cancer location.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['primary colorectal cancer'],[],[],[],[],[],[],,Low,1
5313,Early onset colorectal cancer in Pakistan: Frequency and association with stage and grade.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['early onset colorectal cancer'],[],[],[],[],[],['early onset'],,Low,1
5315,Tumor proportion score (TPS) and response to first-line (1L) anti‚ÄìPD-1/PD-L1 plus chemotherapy for metastatic non-small cell lung cancer (NSCLC): A real-world cohort study.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['first line metastatic non-small cell lung cancer'],['pd1/pdl1 targeted therapy'],[],[],[],['obsidian therapeutics'],"['first-line', 'metastatic']",,Low,1
5317,Real-world experience of fruquintinib in patients with metastatic colorectal cancer: A single-center retrospective study in the United States.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['metastatic colorectal cancer'],['vegfr inhibitor'],['fruquintinib'],[],[],[],['metastatic'],,Low,1
5318,Contemporary trends and survival outcomes in young-onset vs. average-onset metastatic colorectal cancer: A real-world comparison.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['young onset/average onset metastatic colorectal cancer'],[],[],[],[],[],"['young', 'metastatic']",,Low,1
5319,"Genomic predictive biomarkers of anti-EGFR resistance in EGFR-mutated non-small-cell lung cancer: Impact of classical mutations, comutations and secondary CNVs.",Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['egfr-mutated non-small cell lung cancer'],[],[],[],[],[],['egfr mutated'],,Low,1
5326,"Prognostic value of the estrogen receptor alpha, ESR1, and aromatase expression in non-small cell lung cancer: A meta-analysis.",Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['eralpha expressing non-small cell lung cancer'],[],[],[],[],[],[],,Low,1
5329,Real world efficacy of dose-reduced capmatinib and tepotinib for advanced MET exon 14‚Äìskipping+ NSCLC.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['advanced met exon14 skipping positive non-small cell lung cancer'],['met inhibitor'],"['capmatinib', 'tepotinib']",[],[],[],['advanced'],,Low,1
5335,Molecular markers associated with survival in PD-L1‚Äì high non-small cell lung cancer treated with first-line immunotherapy versus chemoimmunotherapy.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['first line pd-l1 high non small cell lung cancer'],['pdl1 targeted therapy'],[],[],[],[],['first-line'],,Low,1
5338,Real-world evidence of fruquintinib (Fruq) efficacy after regorafenib (Rego) and trifluridine‚Äìtipiracil (TAS-102) in refractory metastatic colorectal cancer (mCRC).,Quality Care/Health Services Research,Publication Only,['colorectal cancer'],['refractory metastatic colorectal cancer'],"['vegf inhibitor', 'multi kinase inhibitor', 'dna synthesis inhibitor']","['regorafenib', 'fruquintinib', 'tipiracil/trifluridine']",[],[],[],"['refractory', 'metastatic']",,Low,1
5345,Outcomes of patients with concurrent chronic lymphocytic leukemia and non-small cell lung carcinoma.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,"['non-small cell lung carcinoma', 'chronic lymphocytic leukemia']","['metastatic non-small cell lung carcinoma', 'chronic lymphocytic leukemia']",[],[],[],[],[],['metastatic'],,Low,1
5349,Impact of immune checkpoint inhibitors on unplanned emergency department consultations in mNSCLC: More toxicities or lack of knowledge of their management.,Symptom Science and Palliative Care,Publication Only,['non-small cell lung cancer'],['metastatic non-small cell lung cancer'],['immune checkpoint inhibitor'],[],[],[],[],['metastatic'],,Low,1
5363,Efficacy of targeted therapy versus immunotherapy in metastatic colorectal cancer: A systematic review and meta-analysis.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['metastatic colorectal cancer'],[],[],[],[],[],['metastatic'],,Low,1
437,A multicenter randomized phase II trial assessing the efficacy and safety of mCapOX plus cetuximab and mFOLFOX6 plus cetuximab as first-line treatment for patients with RAS/BRAF wild-type metastatic colorectal cancer: Primary results of the CAPCET study.,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['first line ras/braf wild type metastatic colorectal cancer'],"['nucleoside metabolic inhibitor', 'alkylating agent', 'folic acid analog', 'dna synthesis inhibitor']","['mcapox', 'cetuximab', 'mfolfox6']",[],[],[],"['braf wild-type', 'first-line', 'metastatic']",,Medium,1
5370,Body composition and allostatic load in racially and ethnically diverse patients with metastatic colorectal cancer.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['metastatic colorectal cancer'],[],[],[],[],[],['metastatic'],,Low,1
5371,METscreen: Decision-support tool for metastatic colorectal cancer patients based on organoid drug screening in a clinical research feasibility study.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['metastatic colorectal cancer'],[],[],[],[],[],['metastatic'],,Low,1
5374,Genetic epidemiology of colorectal cancer in Morocco: A systematic review and meta-analysis.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['colorectal cancer'],[],[],[],[],[],[],,Low,1
5375,Incidence of colorectal cancer in the republic of Ireland: Trends and challenges.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['colorectal cancer'],[],[],[],[],[],[],,Low,1
5377,Predictive effectiveness of circulating tumor DNA in recurrent early-stage non-small cell lung cancer: An updated meta-analysis.,Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology,Publication Only,['non-small cell lung cancer'],['recurrent early stage non small cell lung cancer'],[],[],[],[],['geneseeq technology'],"['early-stage', 'recurrent']",,Low,1
5380,Evaluating barriers to timely NSCLC treatment: A northern Nevada perspective.,Quality Care/Health Services Research,Publication Only,['non-small cell lung cancer'],['non-small cell lung cancer'],[],[],[],[],[],[],,Low,1
5384,Enhancing recurrence detection in stage III colorectal cancer patients through molecular residual disease test-guided surveillance: A modeling study.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['recurrent stage iii colorectal cancer'],[],[],[],[],['exact sciences corporation'],"['stage iii', 'recurrent']",,Low,1
505,"OrigAMI-2: A randomized, phase 3 study of amivantamab vs cetuximab, both in combination with FOLFOX or FOLFIRI, as first-line treatment in left-sided RAS/BRAF wild-type metastatic colorectal cancer.",Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['first-line left-sided ras/braf wild type metastatic colorectal cancer'],['egfr targeted therapy'],['amivantamab'],[],"['cetuximab', 'folfiri', 'folfox']",['johnson & johnson'],"['braf wild-type', 'first-line', 'metastatic']",,Medium,1
5386,The prognostic value of acneiform rash grade in metastatic colorectal cancer patients treated with EGFR inhibitors.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['metastatic colorectal cancer'],['egfr inhibitor'],[],[],[],[],['metastatic'],,Low,1
5388,Next generation sequencing (NGS) of malignant effusions and comparison to blood liquid biopsy (ctDNA): A community experience.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['metastatic non small cell lung cancer'],[],[],[],[],[],['metastatic'],,Low,1
507,"OrigAMI-3: A randomized, phase 3 study of amivantamab plus FOLFIRI vs cetuximab or bevacizumab plus FOLFIRI in participants with recurrent, unresectable, or metastatic RAS/BRAF wild-type colorectal cancer.",Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['recurrent unresectable/metastatic ras/braf wild type colorectal cancer'],"['egfr targeted therapy', 'nucleoside metabolic inhibitor', 'folic acid analog', 'top1 inhibitor']","['amivantamab', 'folfiri']",[],"['bevacizumab', 'cetuximab', 'folfiri']",['johnson & johnson'],"['recurrent', 'braf wild-type', 'unresectable', 'metastatic']",,Medium,1
5391,Big data analysis of outcomes in non-small cell lung cancer at a regional cancer institute with a coordinated precision medicine program.,Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology,Publication Only,['non-small cell lung cancer'],['non-small cell lung cancer'],[],[],[],[],[],[],,Low,1
5392,Immunotherapy in patients with early-stage microsatellite instable (MSI-H)/mismatch repair deficient (dMMR) colorectal cancer (CRC) treated in a community setting.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['early stage microsatellite instability/mismatch repair deficient colorectal cancer'],[],[],[],[],[],"['dmmr', 'early-stage', 'microsatellite instability']",,Low,1
5398,Real-world clinical outcomes of patients with metastatic colorectal cancer (mCRC) treated with trifluridine-tipiracil + bevacizumab by performance status.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['metastatic colorectal cancer'],"['vegf targeted therapy', 'nucleoside analog']","['bevacizumab', 'tipiracil/trifluridine']",[],[],"['taiho oncology', 'concertai']",['metastatic'],,Low,1
5399,Drug-eluting transarterial chemoembolization combined with anlotinib for non-small cell lung cancer in the elderly: A multicenter retrospective study.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['elderly non-small cell lung cancer'],['multi kinase inhibitor'],['anlotinib'],[],[],[],['elderly'],,Low,1
5400,Molecular profile and disparity of care in metastatic non small cell lung cancer in a low middle income country: A retrospective analysis.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['metastatic non small cell lung cancer'],[],[],[],[],[],['metastatic'],,Low,1
5401,Investigating clinical and molecular characteristics of BRAF mutated MSS CRC and impact of inflammatory markers on survival outcomes.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['braf-mutant microsatellite stable colorectal cancer'],[],[],[],[],[],"['microsatellite stable', 'braf mutated']",,Low,1
5403,AI-based complete blood count model for colorectal cancer detection.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['colorectal cancer'],[],[],[],[],[],[],,Low,1
5416,Neoadjuvant radio-chemoimmunotherapy versus neoadjuvant chemoimmunotherapy for resectable non-small cell lung cancer: A pooled analysis of prospective studies.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Publication Only,['non-small cell lung cancer'],['resectable non-small cell lung cancer'],[],[],[],[],[],['resectable'],,Low,1
5424,Time from diagnosis to surgery for stage I non-small cell lung cancer among Native Hawaiians and other Pacific Islanders.,Care Delivery/Models of Care,Publication Only,['non-small cell lung cancer'],['stage i non-small cell lung cancer'],[],[],[],[],[],['stage i'],,Low,1
5438,Advancing targeted therapies in oncology: The role of alectinib in managing ALK-positive non-small cell lung cancer.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Publication Only,['non-small cell lung cancer'],['alk-positive non-small cell lung cancer'],['alk inhibitor'],['alectinib'],[],[],[],['alk-positive'],,Low,1
5442,"The HALP score as a prognostic biomarker in non-small cell lung cancer: A comprehensive meta-analysis of over 7,000 patients.",Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Publication Only,['non-small cell lung cancer'],['non small cell lung cancer'],[],[],[],[],[],[],,Low,1
5446,Leveraging AI predictive models to develop thymic tumor‚Äìspecific peptides mimicking COL17A1 alterations.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Publication Only,"['non-small cell lung cancer', 'thoracic cancers']","['non-small cell lung cancer', 'thoracic cancer']",[],[],[],[],[],[],,Low,1
5506,"Meat consumption and colorectal cancer risk: A comprehensive meta-analysis of red, processed, and total meat intake.","Prevention, Risk Reduction, and Genetics",Publication Only,['colorectal cancer'],['colorectal cancer'],[],[],[],[],[],[],,Low,1
5539,Pembrolizumab monotherapy for melanoma or non-small cell lung cancer in India: Results of the phase IV keynote-593 study.,Melanoma/Skin Cancers,Publication Only,"['non-small cell lung cancer', 'melanoma']","['non small cell lung cancer', 'melanoma']",['pd1 inhibitor'],['pembrolizumab'],[],[],['merck'],[],,Low,1
5691,IDOV-Safe: An intravenously deliverable oncolytic vaccinia virus for solid tumors refractory to standard of care‚ÄîPreliminary results from the pMMR/MSS CRC cohort.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,"['colorectal cancer', 'solid tumor']","['refractory solid tumor', 'mismatch repair proficient microsatellite stable colorectal cancer']",['oncolytic virus therapy'],['vaccinia virus'],[],[],"['viromissile', 'longyao biological']","['refractory', 'microsatellite stable']",,Low,1
5693,Improving colorectal cancer screening rates in veterans: A quality improvement initiative.,Quality Care/Health Services Research,Publication Only,['colorectal cancer'],['colorectal cancer'],[],[],[],[],[],[],,Low,1
5694,"Non-small cell lung cancer in women: Experience of the National Institute of Oncology of Rabat, Morocco.",Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['non-small cell lung cancer'],[],[],[],[],[],[],,Low,1
5696,"Triplet therapy with BRAF inhibitor, anti-EGFR agent, and MEK inhibitor in V600E BRAF‚Äìmutant colorectal cancer: A meta-analysis.",Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['v600e braf-mutant colorectal cancer'],"['egfr targeted therapy', 'mek inhibitor', 'braf inhibitor']",[],[],[],[],['braf mutated'],,Low,1
5701,Neutrophil-to-lymphocyte ratio (NLR) as an independent prognostic marker in MUTYH- associated colorectal cancers (MUTYH-CRCs).,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['mutation-associated colorectal cancer'],[],[],[],[],[],[],,Low,1
5704,Racial and socioeconomic disparities in colorectal cancer incidence following bariatric surgery: A retrospective analysis (2009‚Äì2022).,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['colorectal cancer'],[],[],[],[],[],[],,Low,1
5705,Epidemiologic trends in colorectal cancer: Age-related variations and site-specific patterns over two decades.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['colorectal cancer'],[],[],[],[],[],[],,Low,1
5706,"Comparative real-world survival of first-line atezolizumab, nivolumab, and pembrolizumab in older patients with metastatic non‚Äìsmall cell lung cancer.",Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['elderly first line metastatic non small cell lung cancer'],"['pd1 targeted therapy', 'pdl1 targeted therapy']","['nivolumab', 'pembrolizumab', 'atezolizumab']",[],[],[],"['first-line', 'metastatic', 'elderly']",,Low,1
5708,Evaluating the Khorana score in advanced EGFR-mutated NSCLC patients receiving first-line osimertinib.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['advanced egfr-mutated non-small cell lung cancer'],['egfr inhibitor'],['osimertinib'],[],[],[],"['egfr mutated', 'advanced']",,Low,1
5711,Plasma-based next generation sequencing in advanced non-small cell lung cancer (NSCLC): Significance in diagnosis and treatment.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['advanced non-small cell lung cancer'],[],[],[],[],[],['advanced'],,Low,1
5713,Efficacy and safety of nivolumab and ipilimumab in treating metastatic colorectal cancer (mCRC): A systematic review and meta-analysis.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['metastatic colorectal cancer'],"['pd1 inhibitor', 'ctla4 inhibitor']","['nivolumab', 'ipilimumab']",[],[],[],['metastatic'],,Low,1
5714,"Disitamab vedotin combined with fruquintinib in patients with HER2-expressing or HER2 mutation/amplified metastatic colorectal cancer refractory to at least two standard regimens: A prospective, exploratory, single-arm study.",Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['her2 expressing/her2 mutant/amplified refractory metastatic colorectal cancer'],"['vegf inhibitor', 'her2 antibody drug conjugate']","['fruquintinib', 'disitamab vedotin']",[],[],[],"['refractory', 'her2-mutated', 'metastatic']",,Low,1
5715,Deciphering colorectal cancer progression through integrative epigenomic analysis for precision therapeutics.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['progressive colorectal cancer'],[],[],[],[],[],['progressive'],,Low,1
5716,"Trends of colorectal cancer-related mortality among patients with comorbid type 2 diabetes in the United States, 1999‚Äì2020.",Gastrointestinal Cancer - Colorectal and Anal,Publication Only,"['type 2 diabetes', 'colorectal cancer']","['colorectal cancer', 'comorbid type 2 diabetes']",[],[],[],[],[],[],,Low,1
5717,Use of PD-1/PD-L1 inhibitors in non-small cell lung cancer in elderly patients: A meta-analysis.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['elderly non-small cell lung cancer'],"['pd1 inhibitor', 'pdl1 inhibitor']",[],[],[],[],['elderly'],,Low,1
5719,"Efbemalenograstim alfa for the primary/secondary prophylaxis of intermediate-risk febrile neutropenia (FN) chemotherapy regimen with risk factors in patients with non-small cell lung cancer (NSCLC): A randomized, multicenter, exploratory clinical trial.",Lung Cancer - Non - Small Cell Metastatic,Publication Only,"['non-small cell lung cancer', 'febrile neutropenia']","['non-small cell lung cancer', 'intermediate risk febrile neutropenia']",['leukocyte growth factor'],['efbemalenograstim alfa'],[],[],['chia tai tianqing pharmaceutical'],['intermediate-risk'],,Low,1
5722,NGS technologies and metastatic colorectal cancer: Experience and future in Uzbekistan.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['metastatic colorectal cancer'],[],[],[],[],[],['metastatic'],,Low,1
5723,Clinical value of carbon nanoparticle staining in identifying metastatic lymph nodes in colorectal cancer surgery.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['metastatic lymph node colorectal cancer'],[],[],[],[],[],['metastatic'],,Low,1
5726,Exploring potential biomarkers for FOLFIRI plus aflibercept as second-line treatment in patients with metastatic colorectal cancer.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['second line metastatic colorectal cancer'],"['folate analog', 'vegf targeted therapy', 'top inhibitor', 'antimetabolite']","['folfiri', 'aflibercept']",[],[],[],"['second-line', 'metastatic']",,Low,1
509,"Neoadjuvant cetuximab plus tislelizumab combined with chemotherapy in pMMR RAS/BRAF wild-type (wt) locally advanced rectal cancer (LARC): A prospective, multicenter, phase II study.",Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['rectal cancer'],['pmmr ras/braf wild type locally advanced rectal cancer'],"['pd1 targeted therapy', 'egfr targeted therapy']","['cetuximab', 'tislelizumab']",[],[],[],"['braf wild-type', 'locally advanced']",,Medium,1
5732,Performance of a blood-based screening test for the early detection of colorectal cancer.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['early onset colorectal cancer'],[],[],[],[],['natera'],['early onset'],,Low,1
711,Unveiling the differences in tumor immune microenvironment between KRAS-wildtype and KRAS-mutant pancreatic ductal adenocarcinoma.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Poster Session,['pancreatic ductal adenocarcinoma'],['kras wild type/mutant pancreatic ductal adenocarcinoma'],[],[],[],[],['labcorp'],['kras wild-type'],,Medium,1
5735,Return to intended oncologic therapy in patients with metastatic non-small cell lung cancer discharged to a skilled nursing facility.,Quality Care/Health Services Research,Publication Only,['non-small cell lung cancer'],['metastatic non-small cell lung cancer'],[],[],[],[],[],['metastatic'],,Low,1
5736,Comprehensive metabolite profiling of FFPE tissue to analyze metabolic changes in colorectal cancer.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['colorectal cancer'],[],[],[],[],[],[],,Low,1
5737,Evaluating the efficacy of fruquintinib versus regorafenib and trifluridine/tipiracil in treating advanced metastatic colorectal cancer: A match-adjusted indirect comparison.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['advanced metastatic colorectal cancer'],['vegf inhibitor'],['fruquintinib'],[],"['regorafenib', 'tipiracil/trifluridine']",[],"['advanced', 'metastatic']",,Low,1
5742,Identifying key predictors of MSI/MMR status in colorectal cancer: Insights from a real-world clinical dataset.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['colorectal cancer'],[],[],[],[],['panakeia technologies'],[],,Low,1
5748,The expression of human endogenous retrovirus env-gene product as a hallmark of sidedness in operable colorectal cancer.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['operable colorectal cancer'],[],[],[],[],[],['operable'],,Low,1
5750,The preliminary safety results of an observational phase II study of concurrent use of aspirin with dabrafenib and trametinib in BRAF V600 NSCLC.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['braf v600 non-small cell lung cancer'],"['mek inhibitor', 'antiplatelet', 'braf inhibitor']","['aspirin', 'dabrafenib', 'trametinib']",[],[],[],[],,Low,1
5752,"Overall survival based on sequencing of fruquintinib, regorafenib, and TAS-102 with or without bevacizumab in treatment-refractory metastatic colorectal cancer.",Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['treatment refractory metastatic colorectal cancer'],"['vegf inhibitor', 'multi kinase inhibitor', 'thymidine phosphorylase inhibitor']","['regorafenib', 'fruquintinib', 'tas-102']",['bevacizumab'],[],[],"['refractory', 'metastatic']",,Low,1
1722,"Nautilus, a phase 1b/2 trial of combining oral HDAC inhibitor (HDACi) with MEK inhibitor (MEKi) in patients with NRAS-mutated metastatic melanoma (MM).",Melanoma/Skin Cancers,Poster Session,['melanoma'],['nras-mutated metastatic melanoma'],"['hdac inhibitor', 'mek inhibitor']",[],[],[],['onkure'],"['nras-mutated', 'metastatic']",,Medium,1
5754,Predicting colorectal cancer patient response to neoadjuvant chemotherapy using the MicroOrganoSphere (MOS) platform.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['colorectal cancer'],[],[],[],[],['xilis'],[],,Low,1
5761,The prognostic factors for refractory metastatic colorectal cancer treated with trifluridine‚Äìtipiracil.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['refractory metastatic colorectal cancer'],"['thymidine phosphorylase inhibitor', 'nucleoside analog']",['tipiracil/trifluridine'],[],[],[],"['refractory', 'metastatic']",,Low,1
5763,Trend analysis of risk factors for early-onset primary colorectal cancer: A population-based time trend analysis using the SEER database.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['early onset primary colorectal cancer'],[],[],[],[],[],['early onset'],,Low,1
5766,Use of recombinant Newcastle disease virus expressing TRAIL to overcome resistance and enhance apoptosis in colorectal cancer models.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['colorectal cancer'],['oncolytic virus therapy'],['trail expressing recombinant newcastle disease virus'],[],[],['libentech'],[],,Low,1
5767,"Liposomal irinotecan plus bevacizumab in irinotecan-refractory metastatic colorectal cancer: A multicenter, phase I/II trial.",Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['refractory metastatic colorectal cancer'],"['vegf inhibitor', 'top1 inhibitor']","['bevacizumab', 'irinotecan liposome']",[],[],[],"['refractory', 'metastatic']",,Low,1
1969,Association of HIPEC response in ovarian cancer with PI3K/RAS/Notch gene signatures: A whole transcriptomic analysis of U.S. and French HIPEC treated ovarian cancer patients.,Gynecologic Cancer,Poster Session,['ovarian cancer'],['ovarian cancer'],[],[],[],[],[],[],,Medium,1
5772,Machine learning‚Äìbased identification of a metabolic gene prognostic signature (MALMPS) model to investigate the clinical and molecular heterogeneity of stage II/III colorectal cancer.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['stage ii/iii colorectal cancer'],[],[],[],[],[],['stage ii'],,Low,1
5780,Are patients with early-stage non-small cell lung cancer receiving timely testing for the ALK rearrangement?,Quality Care/Health Services Research,Publication Only,['non-small cell lung cancer'],['alk-rearranged early stage non small cell lung cancer'],[],[],[],[],['genentech'],"['early-stage', 'alk rearranged']",,Low,1
5784,"The frequency of driver mutations in non-small cell lung cancer patients: The Turkish nation-wide, observational, Registurk-Lung study (updated analysis).",Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['non-small cell lung cancer'],[],[],[],[],[],[],,Low,1
5787,Comprehensive profiling of immune and stromal alterations in colorectal cancer with diabetes mellitus through single-cell transcriptomics and proteomics.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,"['colorectal cancer', 'diabetes']","['colorectal cancer', 'diabetes mellitus']",[],[],[],[],[],[],,Low,1
5789,Minimal residual disease (MRD) test utilization in the first 6 months after initiating MRD testing in patients with colorectal cancer (CRC).,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['colorectal cancer'],[],[],[],[],[],[],,Low,1
5791,"Envafolimab plus docetaxel in combination with or without trilaciclib versus docetaxel in pretreated advanced or metastatic non-small cell lung cancer (NSCLC): Preliminary analysis of an open-label, randomized, phase II trial.",Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['previously treated advanced/metastatic non-small cell lung cancer'],"['microtubule inhibitor', 'pdl1 inhibitor']","['docetaxel', 'envafolimab']",['trilaciclib'],['docetaxel'],[],"['advanced', 'metastatic', 'previously treated']",,Low,1
5792,Signatera ctDNA in stage II CRC: A retrospective comparison with traditional risk factors for survival and prognostic stratification.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['stage ii colorectal cancer'],[],[],[],[],[],['stage ii'],,Low,1
2095,Upfront modified FOLFOXIRI plus panitumumab (pan) versus FOLFOX/pan for unresectable RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients: Overall survival (OS) results from the phase III TRIPLETE study by GONO.,Gastrointestinal Cancer - Colorectal and Anal,Rapid Oral Abstract Session,['colorectal cancer'],['unresectable ras and braf wild type metastatic colorectal cancer'],"['nucleoside metabolic inhibitor', 'folic acid analog', 'dna synthesis inhibitor', 'top1 inhibitor', 'egfr antagonist']","['mfolfoxiri', 'panitumumab']",[],"['folfox', 'panitumumab']",[],"['braf wild-type', 'metastatic', 'unresectable']",,Medium,1
5796,Prospective observational study of application of multi-target fecal FIT-DNA testing in postoperative follow-up for colorectal cancer patients.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['postoperative colorectal cancer'],[],[],[],[],[],['postoperative'],,Low,1
2096,FIRE-4 (AIO KRK-0114): Randomized study evaluating the efficacy of cetuximab re-challenge in patients with metastatic RAS wild-type colorectal cancer responding to first-line treatment with FOLFIRI plus cetuximab.,Gastrointestinal Cancer - Colorectal and Anal,Rapid Oral Abstract Session,['colorectal cancer'],['first-line metastatic ras wild type colorectal cancer'],"['nucleoside metabolic inhibitor', 'folic acid analog', 'egfr inhibitor', 'top1 inhibitor']","['cetuximab', 'folfiri']",[],[],[],"['first-line', 'metastatic']",,Medium,1
5803,Complete blood count as a prognostic tool for NSCLC patients treated with immune checkpoint inhibitors.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['non-small cell lung cancer'],[],[],[],[],[],[],,Low,1
5804,A retrospective real-world study of first-line PD-(L)1 inhibitor use in patients with metastatic non-small cell lung cancer (mNSCLC).,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['first line metastatic non-small cell lung cancer'],['pdl1 inhibitor'],[],[],[],['incyte'],"['first-line', 'metastatic']",,Low,1
5806,Role of high-dose vitamin C as adjunct treatment in gastric and colorectal cancers: A systematic review.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,"['colorectal cancer', 'gastric cancer']","['colorectal cancer', 'gastric cancer']",['vitamin supplement'],['vitamin c'],[],[],[],[],,Low,1
5807,Real-world baseline characteristics and diagnostic path of Polish patients with ALK-positive NSCLC eligible for brigatinib treatment: Interim results from the ENTIRETY study.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['alk-positive non-small cell lung cancer'],['tyrosine kinase inhibitor'],['brigatinib'],[],[],['takeda'],['alk-positive'],,Low,1
5812,Phase II study of irinotecan liposome combined with 5-FU/LV + bevacizumab as first-line therapy in metastatic colorectal cancer: An early analysis from the study.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['first-line metastatic colorectal cancer'],"['vegf inhibitor', 'thymidylate synthase inhibitor', 'top1 inhibitor']","['bevacizumab', 'leucovorin', 'irinotecan liposomal', '5-fluorouracil']",[],[],[],"['first-line', 'metastatic']",,Low,1
5813,NSCLC in the immunotherapy era: Trends in survival and disparities across demographic and socioeconomic groups.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['metastatic non-small cell lung cancer'],[],[],[],[],[],['metastatic'],,Low,1
5814,HRD status and genomic characteristics of Chinese NSCLC patients.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['hrd-positive non small cell lung cancer'],[],[],[],[],['3dmed'],['hrd-positive'],,Low,1
5815,Biomarker testing in metastatic colorectal cancer (mCRC): 2015-2024 trends in the United States (US) community oncology setting.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['metastatic colorectal cancer'],[],[],[],[],[],['metastatic'],,Low,1
5817,"Clinical-pathological differences in colorectal cancer: Rectum, left colon, and microsatellite instability‚ÄîABDON study.",Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['microsatellite instability colorectal cancer'],[],[],[],[],[],['microsatellite instability'],,Low,1
5819,"Inhibition of transcriptional cyclin-dependent kinases, CDK12/13, as a treatment for colorectal cancer with CDK12 upregulation.",Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['cdk12 upregulated colorectal cancer'],['cdk12/13 inhibitor'],[],[],[],"['carrick therapeutics', 'dragonfly therapeutics']",[],,Low,1
5821,Evaluating the safety and effectiveness of cemiplimab in combination with platinum-doublet chemotherapy by demographic characteristics in first-line treatment of advanced non-small cell lung cancer: An ongoing multi-database real world evidence study in US patients.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['first line advanced non-small cell lung cancer'],['pd1 inhibitor'],['cemiplimab'],[],[],['regeneron pharmaceuticals'],['first-line advanced'],,Low,1
5824,Prognostic biomarkers for colorectal cancer in a Nigerian population.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['colorectal cancer'],[],[],[],[],[],[],,Low,1
5827,Racial and ethnic disparities in the occurrence of second primary malignancies (SPMs) in early onset colorectal cancer (EOCRC).,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['early onset colorectal cancer'],[],[],[],[],[],['early onset'],,Low,1
5830,Trend of non-small cell lung cancer in young people.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['young non small cell lung cancer'],[],[],[],[],[],['young'],,Low,1
5831,Optimizing biomarker testing and targeted therapy integration in early-stage NSCLC: A quality improvement initiative at community oncology clinics.,Quality Care/Health Services Research,Publication Only,['non-small cell lung cancer'],['early stage non-small cell lung cancer'],[],[],[],[],[],['early-stage'],,Low,1
2097,Longitudinal ctDNA monitoring and prediction of anti-EGFR rechallenge outcomes in RAS/BRAF wild-type metastatic colorectal cancer (mCRC): The REMARRY & PURSUIT trials.,Gastrointestinal Cancer - Colorectal and Anal,Rapid Oral Abstract Session,['colorectal cancer'],['ras/braf wild type metastatic colorectal cancer'],['egfr targeted therapy'],[],[],[],[],"['braf wild-type', 'metastatic']",,Medium,1
2099,Panitumumab retreatment followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA (ctDNA): Results of the phase II randomized PARERE trial by GONO.,Gastrointestinal Cancer - Colorectal and Anal,Rapid Oral Abstract Session,['colorectal cancer'],['ras/braf wild type metastatic colorectal cancer'],"['multi kinase inhibitor', 'egfr inhibitor']","['regorafenib', 'panitumumab']",[],[],"['bayer', 'amgen']","['braf wild-type', 'metastatic']",,Medium,1
5839,Global burden and trend of colorectal cancer and its attributable risk factors in Latin America and Caribbean from 1990-2021: A benchmarking secondary analysis.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['colorectal cancer'],[],[],[],[],[],[],,Low,1
5841,Prognostic impact of SMARCA4 deficiency and STK11 co-mutations on non-small cell lung cancer treated with immune checkpoint inhibitors.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,"['non-small cell lung cancer', 'deficiency']","['stk11 co-mutant non-small cell lung cancer', 'smarca4 deficiency']",['immune checkpoint inhibitor'],[],[],[],[],[],,Low,1
5844,Trends in the treatment of stage IIB/C and IIIA colorectal cancer: A National Cancer Database (NCDB) analysis.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['stage iib/iiia colorectal cancer'],[],[],[],[],[],['stage iib'],,Low,1
5845,Oncologists‚Äô preferences for first-line (1L) treatment of ALK-positive metastatic NSCLC in the US: A discrete choice experiment (DCE).,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['first line alk-positive metastatic non-small cell lung cancer'],[],[],[],[],['takeda'],"['first-line', 'alk-positive', 'metastatic']",,Low,1
5847,Impact of pressure-related injury on hospitalized patients with colorectal cancer: A United States population-based cohort study.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['colorectal cancer'],[],[],[],[],[],[],,Low,1
5848,Efficacy and safety of nivolumab plus chemotherapy versus chemotherapy alone for the treatment of advance non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['advanced non-small cell lung cancer'],['pd1 inhibitor'],['nivolumab'],[],[],[],['advanced'],,Low,1
2148,The Excitement and Challenges of Targeting RAS Beyond KRAS G12C,Capturing Unicorns: No Target Is Out of the Realm of Possibility,Education Session,[],[],[],[],[],[],[],[],,Medium,1
5852,"Efficacy and safety of envafolimab plus platinum-based chemotherapy as neoadjuvant therapy in resectable stage IIb-IIIb NSCLC: A single-arm, prospective, exploratory study.",Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['resectable stage iib/iiia non-small cell lung cancer'],"['pd1 inhibitor', 'platinum therapy']",['envafolimab'],[],[],[],"['resectable', 'stage iib']",,Low,1
5859,Evaluation of current programmed death-ligand 1 (PD-L1) testing practices for metastatic non-small cell lung cancer (mNSCLC): Insights from a large network of US community oncology practices.,Quality Care/Health Services Research,Publication Only,['non-small cell lung cancer'],['metastatic non-small cell lung cancer'],[],[],[],[],['regeneron pharmaceuticals'],['metastatic'],,Low,1
5861,The utility of one-step nucleic acid amplification in detecting sentinel lymph node metastases in colorectal cancer: A systematic review and meta-analysis.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,"['anal cancer', 'colorectal cancer']","['synchronous colorectal cancer', 'sentinel lymph node metastases', 'anal cancer']",[],[],[],[],[],[],,Low,1
5862,The addition of monoclonal antibodies to chemotherapy in metastatic early-onset colorectal cancer: A comparative effectiveness study using real-world data.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['metastatic early onset colorectal cancer'],[],[],[],[],[],"['early onset', 'metastatic']",,Low,1
5865,Real-world data on efficacy and safety of trifluridine-tipiracil and bevacizumabin refractory metastatic colorectal cancer.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['refractory metastatic colorectal cancer'],"['vegf inhibitor', 'pyrimidine analog', 'thymidine phosphorylase inhibitor']","['bevacizumab', 'tipiracil/trifluridine']",[],[],[],"['refractory', 'metastatic']",,Low,1
5868,Predictive value of the triglyceride-glucose index for the efficacy of immunotherapy in patients with advanced NSCLC: A retrospective study.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['advanced non-small cell lung cancer'],[],[],[],[],[],['advanced'],,Low,1
5871,Association of rurality with guideline-concordant survivorship care receipt among Medicare beneficiaries with colorectal cancer.,Quality Care/Health Services Research,Publication Only,['colorectal cancer'],['colorectal cancer'],[],[],[],[],[],[],,Low,1
5872,Utility of plasma cell-free DNA and tissue next generation sequencing (NGS) in detecting genetic mutations in non-small cell lung cancer (NSCLC).,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['genetic mutant non-small cell lung cancer'],[],[],[],[],[],[],,Low,1
5875,Use of aspirin for chemoprevention in Lynch syndrome: A systematic review and meta-analysis.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,"['gastrointestinal cancer', 'colorectal cancer', 'lynch syndrome', 'anal cancer']","['gastrointestinal cancer', 'colorectal cancer', 'lynch syndrome', 'anal cancer']",['cyclooxygenase inhibitor'],['aspirin'],[],[],[],[],,Low,1
2286,"A first-in-human phase I/II study of GFH375, a highly selective and potent oral KRAS G12D inhibitor in patients with KRAS G12D mutant advanced solid tumors.",Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology,Rapid Oral Abstract Session,['solid tumor'],['kras g12d mutant advanced solid tumor'],['kras g12d inhibitor'],['gfh-375'],[],[],['genfleet therapeutics'],"['kras g12d-mutant', 'advanced']",,Medium,1
5878,Identifying barriers and effective strategies to improve biomarker testing rates in non-small cell lung cancer.,Quality Care/Health Services Research,Publication Only,['non-small cell lung cancer'],['non small cell lung cancer'],[],[],[],[],[],[],,Low,1
5882,Real-world data analysis of clinical characteristics and survival outcomes in Russian patients with NSCLC harboring EGFR mutations.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['egfr-mutant non-small cell lung cancer'],[],[],[],[],[],['egfr mutated'],,Low,1
5883,Real-world retrospective analysis of the mutation and co-mutation landscape of ERBB2 in advanced NSCLC.,Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology,Publication Only,['non-small cell lung cancer'],['advanced non-small cell lung cancer'],[],[],[],[],[],['advanced'],,Low,1
5884,Clinical outcomes of first-line osimertinib in NSCLC patients with EGFR mutations.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['egfr-mutant non-small cell lung cancer'],['egfr inhibitor'],['osimertinib'],[],[],[],['egfr mutated'],,Low,1
3399,"A phase I study of AFNT-211, autologous CD4+ and CD8+ T cells engineered to express a high avidity HLA-A*11:01-restricted, KRAS G12V-specific transgenic TCR; CD8Œ±/Œ≤ coreceptor; and FAS-41BB switch receptor in patients with advanced or metastatic solid tumors.",Developmental Therapeutics - Immunotherapy,Poster Session,['solid tumor'],['advanced/metastatic solid tumor'],['t lymphocyte replacement'],['afnt-211'],[],[],['affini-t therapeutics'],"['advanced', 'metastatic']",,Medium,1
5887,Phase II study of disitamab vedotin (RC48) in combination with tislelizumab and bevacizumab in patients (Pts) with HER2 alterations locally advanced or metastatic NSCLC: Primary analysis results of RESOLUTION.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['her2 altered locally advanced/metastatic non-small cell lung cancer'],"['pd1 inhibitor', 'vegf inhibitor', 'her2 antibody drug conjugate']","['bevacizumab', 'tislelizumab', 'disitamab vedotin']",[],[],[],"['metastatic', 'locally advanced']",,Low,1
5888,Targeting the PYGL with chicoric acid to normalize glucose metabolism to inhibit progress in NSCLC.,Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology,Publication Only,['non-small cell lung cancer'],['non-small cell lung cancer'],['pygl inhibitor'],['chicoric acid'],[],[],[],[],,Low,1
5889,Lobaplatin-based chemotherapy with immunotherapy as first-line treatment in patients with advanced NSCLC: A real-world bidirectional cohort study.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['first-line advanced non-small cell lung cancer'],['alkylating agent'],['lobaplatin'],[],[],[],['first-line advanced'],,Low,1
5892,Correlation between the number of circulating epithelial tumor cells (CETCs/CTCs) and circulating tumor DNA (ctDNA) in patients with colorectal cancer.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,"['anal cancer', 'colorectal cancer']","['colorectal cancer', 'anal cancer']",[],[],[],[],[],[],,Low,1
5893,Over a decade of insights into genomic profiling in metastatic colorectal cancer from a phase I setting.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['metastatic colorectal cancer'],[],[],[],[],[],['metastatic'],,Low,1
5899,Overall survival with fruquintinib versus placebo after adjusting for subsequent anticancer therapy in patients with refractory metastatic colorectal cancer in the FRESCO-2 study.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['refractory metastatic colorectal cancer'],['vegfr inhibitor'],['fruquintinib'],[],[],"['takeda', 'hutchmed']","['refractory', 'metastatic']",,Low,1
5904,Verification of a novel plasma eight-protein signature predicting long-term efficacy of first-line chemoimmunotherapy for advanced non-small cell lung cancer.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['first-line advanced non-small cell lung cancer'],[],[],[],[],['amoy diagnostics'],['first-line advanced'],,Low,1
5907,The impact of surgical resection in early onset colorectal cancer patients with liver limited disease.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['early onset colorectal cancer'],[],[],[],[],[],['early onset'],,Low,1
5910,The correlation of two SNPs in the DRACH motif with gefitinib-induced hepatotoxicity in patients with non-small cell lung cancer.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],"['non small cell lung cancer', 'hepatotoxicity']",[],[],[],[],[],[],,Low,1
3517,Discovery of potent degraders of pan-KRAS based on a novel KRAS binder.,Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology,Poster Session,['tumors'],['tumor'],['kras degrader'],[],[],[],[],[],,Medium,1
5914,"Bevacizumab, TAS-102, and irinotecan in oxaliplatin and fluoropyrimidine pre-treated metastatic colorectal cancer (BEV-TASIRI): A single-arm, prospective, multicenter study and comparison with BEV-FOLFIRI/XELIRI using inverse probability of treatment weighting.",Gastrointestinal Cancer - Colorectal and Anal,Publication Only,"['colorectal cancer', 'anal cancer']","['pre-treatment metastatic colorectal cancer', 'anal cancer']","['nucleoside metabolic inhibitor', 'fluoropyrimidine', 'dna synthesis inhibitor', 'top1 inhibitor', 'vegf inhibitor']","['oxaliplatin', 'tas-102', 'bevacizumab', 'irinotecan']",[],"['xeliri', 'bevacizumab', 'folfiri']",[],['metastatic'],,Low,1
5915,Clinical and molecular features of concomitant EGFR and SMARCA4 mutations in an East Asian cohort.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],"['smarca4-mutant non-small cell lung cancer', 'egfr-mutant non-small cell lung cancer']",[],[],[],[],[],"['egfr mutated', 'smarca4-mutant']",,Low,1
4085,Targeting focal adhesion kinase to mitigate hepatotoxicity induced by PD-1 inhibition with or without KRAS G12C suppression.,Developmental Therapeutics - Immunotherapy,Publication Only,[],['hepatotoxicity'],[],[],[],[],['inxmed'],[],,Medium,1
5923,Correlation of clinical benefit from immune checkpoints and baseline radiomic signature in inoperable NSCLC without activating mutations.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['inoperable non-small cell lung cancer'],[],[],[],[],[],['inoperable'],,Low,1
5924,Real-world treatment patterns and outcomes among patients with advanced NSCLC treated with amivantamab.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['advanced non-small cell lung cancer'],['egfr/met bispecific antibody'],['amivantamab'],[],[],['johnson & johnson'],['advanced'],,Low,1
5925,A multimodal analysis of CT radiomics and clinical variables in predicting immunotherapy response for NSCLC.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['non-small cell lung cancer'],[],[],[],[],['ge healthcare'],[],,Low,1
5926,An innovative evidence-based laboratory medicine (EBLM) test to help doctors in the basic assessment of colorectal cancer.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,"['anal cancer', 'colorectal cancer']","['colorectal cancer', 'anal cancer']",[],[],[],[],[],[],,Low,1
5929,Real-world outcomes of neoadjuvant immunotherapy for mismatch repair-deficient colorectal cancer: A single center experience in Russia.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['mismatch repair deficiency colorectal cancer'],[],[],[],[],[],['dmmr'],,Low,1
5930,FFPE RNA-based ddPCR assay: An effective and efficient confirmation for MET exon 14 skipping in NSCLC.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['non small cell lung cancer'],[],[],[],[],[],[],,Low,1
5932,Increasing mortality burden in patients with hypertension and colorectal cancer in the United States from 1999 to 2020.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,"['anal cancer', 'colorectal cancer', 'hypertension']","['colorectal cancer', 'hypertension', 'anal cancer']",[],[],[],[],[],[],,Low,1
4183,"Sintilimab in combination with cetuximab and chemotherapy as first-line treatment for RAS/BRAF wild-type advanced colorectal cancer (CALLIOPSIS): An open-label, non-comparative, phase 1b/2 dose escalation and expansion trial.",Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['first-line ras/braf wild type advanced colorectal cancer'],"['egfr targeted therapy', 'pdl1 targeted therapy']","['cetuximab', 'sintilimab']",[],[],[],"['braf wild-type', 'advanced', 'first-line']",,Medium,1
5934,Understanding the clinical and molecular phenotype of cancer of unknown primary (CUP) with a lung cancer profile.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['metastatic non small cell lung cancer'],[],[],[],[],[],['metastatic'],,Low,1
5936,Long-term oncologic outcomes in elderly patients with localized anal cancer.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,"['colorectal cancer', 'anal cancer']","['colorectal cancer', 'elderly localized anal cancer']",[],[],[],[],[],"['elderly', 'localized']",,Low,1
5937,Risk factors for immune checkpoint inhibitor‚Äìrelated adverse events in the geriatric lung cancer population.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['geriatric non-small cell lung cancer'],[],[],[],[],[],[],,Low,1
5942,Efficacy and safety of trastuzumab deruxtecan in gastrointestinal malignancies: A systemic review and meta-analysis.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['cancer'],"['pancreatic malignancy', 'hepatobiliary malignancy', 'gastroesophageal malignancy']",['her2 antibody drug conjugate'],['trastuzumab deruxtecan'],[],[],[],[],,Low,Should be not relevant (pancreatic malginancy incorrectly mentioned under indication column)
5960,Octreotide scintigraphy versus DOTATOC PET: Concordance of Krenning scores and implications on PRRT treatment eligibility.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,"['gastro-esophageal cancer', 'pancreatic cancer', 'hepatobiliary cancer']","['gastroesophageal cancer', 'pancreatic cancer', 'hepatobiliary cancer']",['somatostatin analog'],['octreotide'],[],['dotatoc'],[],[],,Low,1
5961,Gastric cancer incidence in Mongolia: A clinical and molecular pathological study.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,"['gastro-esophageal cancer', 'pancreatic cancer', 'hepatobiliary cancer']","['gastroesophageal cancer', 'pancreatic cancer', 'hepatobiliary cancer']",[],[],[],[],[],[],,Low,1
4238,The cancer fusionome and overexpressed druggable oncogenic signals in K-RAS wild-type pancreatic cancer.,Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology,Publication Only,['pancreatic cancer'],['k-ras wild type pancreatic cancer'],[],[],[],[],['neogenomics laboratories'],[],,Medium,1
5982,"Barriers, facilitators, and practice patterns for next-generation sequencing testing use for non-small cell lung cancer patients.",Quality Care/Health Services Research,Publication Only,['non-small cell lung cancer'],['non small cell lung cancer'],[],[],[],[],[],[],,Low,1
5985,Long-term survival analysis comparison of radical antegrade modular pancreatectomy (RAMPS) and standard retrograde pancreatectomy (SPRS): Based on LASSO Cox regression prediction model.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,"['gastro-esophageal cancer', 'pancreatic cancer', 'hepatobiliary cancer']","['gastroesophageal cancer', 'pancreatic cancer', 'hepatobiliary cancer']",[],[],[],[],[],[],,Low,1
5140,RAS/BRAF testing of circulating cell-free DNA (cfDNA) in RAS/BRAF wild-type (RAS/BRAFWT) metastatic colorectal cancer (mCRC) patients: Preliminary results of the phase III LIBImAb study.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['metastatic colorectal cancer'],[],[],[],[],[],['metastatic'],,Medium,1
6001,Effect of EGR1-mediated glutamine metabolic reprogramming through mTOR signaling pathway on pancreatic stellate cell activation and pancreatic cancer liver metastasis.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic cancer'],"['pancreatic cancer', 'liver metastasis']",[],[],[],[],[],['metastatic'],,Low,1
6024,"Trends and persistent disparities in incidence, mortality, and survival of pancreatic cancer: A Surveillance, Epidemiology, and End Results program‚Äìbased retrospective cohort study (2000‚Äì2021).","Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic cancer'],['pancreatic cancer'],[],[],[],[],[],[],,Low,1
6047,Postoperative adjuvant donafenib combined with PD-1 checkpoint inhibitor for patients at high risk of recurrence.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,"['pancreatic cancer', 'hepatobiliary cancer', 'gastric cancer']","['high risk recurrent gastric cancer', 'high risk recurrent pancreatic cancer', 'high risk recurrent hepatobiliary cancer']","['multi kinase inhibitor', 'pd1 checkpoint inhibitor']",['donafenib'],[],[],[],"['high-risk', 'recurrent']",,Low,1
6059,LAPNet1: Phase 1b study investigating the association of NP137 with mFOLFIRINOX in locally advanced pancreatic ductal adenocarcinoma.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic ductal adenocarcinoma'],['locally advanced pancreatic ductal adenocarcinoma'],"['thymidylate synthetase inhibitor', 'ntn1 targeted therapy', 'nucleoside metabolic inhibitor', 'dna synthesis inhibitor', 'top1 inhibitor']","['mfolfirinox', 'np-137']",[],[],[],['locally advanced'],,Low,1
6060,"A prospective, single-arm, phase II study of surufatinib in combination with gemcitabine and nab-paclitaxel for the neoadjuvant treatment of resectable and borderline resectable pancreatic cancer.","Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic cancer'],['resectable/borderline resectable pancreatic cancer'],"['nucleoside metabolic inhibitor', 'vegf inhibitor', 'microtubule inhibitor']","['gemcitabine', 'surufatinib', 'nab-paclitaxel']",[],[],[],"['resectable', 'borderline resectable']",,Low,1
6087,"A prospective, single-arm clinical study of icaritin in combination with gemcitabine and nab-pacitaxel in patients with advanced pancreatic ductal adenocarcinoma not received prior systemic therapy.","Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic ductal adenocarcinoma'],['advanced pancreatic ductal adenocarcinoma'],"['nucleoside metabolic inhibitor', 'microtubule inhibitor', 'akt/pi3k pathway activator']","['gemcitabine', 'icaritin', 'nab-paclitaxel']",[],[],[],['advanced'],,Low,1
6099,"Efficacy of adebrelimab with chidamide, gemcitabine, and S-1 in locally advanced or metastatic pancreatic cancer: A phase II study.","Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic cancer'],['locally advanced/metastatic pancreatic cancer'],"['fluoropyrimidine derivative', 'nucleoside metabolic inhibitor', 'pd1 targeted therapy', 'hdac inhibitor']","['gemcitabine', 'adebrelimab', 'chidamide', 's-1']",[],[],[],"['metastatic', 'locally advanced']",,Low,1
6102,Clinical trial access in patients with pancreatic cancer (PC): A Pancreatic Cancer Action Network (PanCAN) patient survey.,Quality Care/Health Services Research,Publication Only,['pancreatic cancer'],['pancreatic cancer'],[],[],[],[],[],[],,Low,1
6108,"Serum MUC5AC as a dynamic biomarker for tumor response, prognosis, and risk stratification in resected pancreatic ductal adenocarcinoma.","Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic ductal adenocarcinoma'],['resectable pancreatic ductal adenocarcinoma'],[],[],[],[],[],['resectable'],,Low,1
6116,Mechanism of DEPTOR in promoting gemcitabine resistance in pancreatic cancer.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic cancer'],['pancreatic cancer'],['nucleoside analog'],['gemcitabine'],[],[],[],[],,Low,1
6118,Evaluation of pancreatic cancer fibrosis based on CT images and its association with chemotherapy efficacy: A multicenter study.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,"['pancreatic cancer', 'fibrosis']","['pancreatic cancer', 'fibrosis']",[],[],[],[],[],[],,Low,1
6122,Preclinical study of safety and efficacy in vivo of a yttrium-90 resin microspheres glue formulation in a large animal model of pancreatic cancer.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic cancer'],['pancreatic cancer'],['radiation therapy'],['yttrium-90 resin microsphere'],[],[],['betaglue therapeutics'],[],,Low,1
6131,Epidemiology and outcomes of disseminated intravascular coagulation in pancreatic cancer patients admitted with sepsis: Insights from a national database.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,"['disseminated intravascular coagulation', 'pancreatic cancer']","['disseminated intravascular coagulation', 'pancreatic cancer']",[],[],[],[],[],[],,Low,1
6142,Chemotherapy and supportive care practice patterns among older adults with metastatic pancreatic cancer.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic cancer'],['older adult metastatic pancreatic cancer'],[],[],[],[],[],"['metastatic', 'elderly']",,Low,1
6147,Duration and de-escalation of FOLFIRINOX as first-line chemotherapy in advanced pancreatic adenocarcinoma.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic adenocarcinoma'],['first-line advanced pancreatic adenocarcinoma'],"['thymidylate synthetase inhibitor', 'nucleoside metabolic inhibitor', 'dna synthesis inhibitor', 'top1 inhibitor']",['folfirinox'],[],[],[],['first-line advanced'],,Low,1
6148,MUC5AC profiling as a biomarker for predicting post-recurrence outcomes and guiding precision therapy in pancreatic ductal adenocarcinoma (PDA).,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic ductal adenocarcinoma'],['recurrent pancreatic ductal adenocarcinoma'],[],[],[],[],[],['recurrent'],,Low,1
6151,First-in-human phase 1/2a study of PBP1510 (anti-PAUF mAb) in advanced/metastatic pancreatic adenocarcinoma: Safety results from early combination cohorts.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic adenocarcinoma'],['advanced/metastatic pancreatic adenocarcinoma'],['pauf targeted antibody'],['pbp1510'],[],[],['prestige biopharma'],"['advanced', 'metastatic']",,Low,1
6156,Combining novel miRNA biomarkers with CA19-9 to enhance early detection of pancreatic ductal adenocarcinoma.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic ductal adenocarcinoma'],['pancreatic ductal adenocarcinoma'],[],[],[],[],['pharus diagnostics'],[],,Low,1
6157,Diagnostic performance of artificial intelligence‚Äìbased computed tomography methods in detecting pancreatic cancer: A systematic review and meta-analysis.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic cancer'],['pancreatic cancer'],[],[],[],[],[],[],,Low,1
6163,Impact of treatment patterns on clinical outcomes in patients of advanced pancreatic cancer treated with chemotherapy: A large-scale data analysis from real world practice.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic cancer'],['advanced pancreatic cancer'],[],[],[],[],[],['advanced'],,Low,1
6171,A multimodal deep learning model for early prediction of pancreatic cancer progression.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic cancer'],['pancreatic cancer'],[],[],[],[],[],[],,Low,1
6184,Value of tumor mutational burden as a prognostic factor in patients with non-small cell lung carcinoma.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Publication Only,['non-small cell lung carcinoma'],['non small cell lung carcinoma'],[],[],[],[],[],[],,Low,1
6199,Real world outcomes of EGFR-mutated non small cell lung cancer treated with surgery EXERPOS 02 GFPC study.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Publication Only,['non-small cell lung cancer'],['egfr-mutant non small cell lung cancer'],[],[],[],[],[],['egfr mutated'],,Low,1
6207,Qingre huoxue formula and its key active components as associated with multi-targeted effects on human pancreatic cancer cells.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic cancer'],['pancreatic cancer'],[],[],[],[],[],[],,Low,1
6208,"Efficacy and safety of second-line therapy by envafolimab combined with anlotinib and S-1 in pancreatic cancer patients: A single-arm, phase II clinical trial.","Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic cancer'],['second line pancreatic cancer'],"['pdl1 inhibitor', 'fluoropyrimidine', 'oprt inhibitor', 'vegf inhibitor', 'dihydropyrimidine dehydrogenase inhibitor']","['s-1', 'envafolimab', 'anlotinib']",[],[],[],['second-line'],,Low,1
6232,Impact of palliative care on the management and outcomes of elderly pancreatic cancer patients following admissions for acute pulmonary embolism.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,"['pancreatic cancer', 'pulmonary embolism']","['elderly acute pulmonary embolism', 'elderly pancreatic cancer']",[],[],[],[],[],['elderly'],,Low,1
6234,Trends in pancreatic cancer mortality in older adults with diabetes mellitus in the United States (1999‚Äì2023).,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,"['diabetes', 'pancreatic cancer']","['pancreatic cancer', 'elderly diabetes mellitus']",[],[],[],[],[],['elderly'],,Low,1
5168,Impact of the Q61H mutational subtype on the response to standard first line treatment in patients with colon adenocarcinoma with KRAS mutation.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colon adenocarcinoma'],['first line kras-mutant colon adenocarcinoma'],[],[],[],[],[],"['first-line', 'kras mutant']",,Medium,1
6291,Molecular profiling in NSCLC: Uncovering disparities and advancing health equity.,"Prevention, Risk Reduction, and Genetics",Publication Only,['non-small cell lung cancer'],['non-small cell lung cancer'],[],[],[],[],[],[],,Low,1
6342,Global trends in prevalence and incidence of pancreatic cancer among adults aged 70 and older: A comprehensive analysis of the Global Burden of Disease study (1990‚Äì2021).,"Prevention, Risk Reduction, and Genetics",Publication Only,['pancreatic cancer'],['adult pancreatic cancer'],[],[],[],[],[],['adult'],,Low,1
6353,National trends in disability-adjusted life years (DALYs) of pancreatic cancer among individuals aged 70 and older across 204 countries (1990-2021): A global burden of disease study.,"Prevention, Risk Reduction, and Genetics",Publication Only,['pancreatic cancer'],['elderly pancreatic cancer'],[],[],[],[],[],['elderly'],,Low,1
6355,Prevalence of obesity/overweight and its relationship with incidence of pancreatic cancer in the US states using BRFSS and CDC WONDER database of 2021.,"Prevention, Risk Reduction, and Genetics",Publication Only,['pancreatic cancer'],['pancreatic cancer'],[],[],[],[],[],[],,Low,1
6381,Trends and disparities in cerebrovascular disease‚Äìrelated mortality in older adults with colorectal cancer: A nationwide retrospective analysis.,"Prevention, Risk Reduction, and Genetics",Publication Only,"['colorectal cancer', 'cerebrovascular disease']","['elderly cerebrovascular disease', 'elderly colorectal cancer']",[],[],[],[],[],['elderly'],,Low,1
6397,The role of the Colorectal Cancer Alliance‚Äôs digital screening quiz in advancing CRC screening.,"Prevention, Risk Reduction, and Genetics",Publication Only,['colorectal cancer'],['colorectal cancer'],[],[],[],[],[],[],,Low,1
6399,Individual participant data meta-analysis comparing neoadjuvant to perioperative chemoimmunotherapy in early-stage non-small cell lung cancer according to PD-L1 status.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Publication Only,['non-small cell lung cancer'],['early stage non small cell lung cancer'],[],[],[],[],[],['early-stage'],,Low,1
6400,Exploration on perioperative treatment strategies of driver gene‚Äìpositive resectable non-small cell lung cancer.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Publication Only,['non-small cell lung cancer'],['resectable non-small cell lung cancer'],[],[],[],[],[],['resectable'],,Low,1
6409,"Real world analysis comparing chemoradiation with durvalumab vs chemoradiation alone in locally advanced, unresectable, stage III non-small cell lung cancer.",Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Publication Only,['non-small cell lung cancer'],['locally advanced unresectable stage iii non-small cell lung cancer'],['pdl1 inhibitor'],['durvalumab'],[],[],[],"['stage iii', 'locally advanced', 'unresectable']",,Low,1
6418,"PD-1/PD-L1 inhibitors as neoadjuvant therapies in resectable non-small cell lung cancer, including their effects in various PD-1 expression subtypes: A meta-analysis.",Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Publication Only,['non-small cell lung cancer'],['resectable non-small cell lung cancer'],"['pd1 inhibitor', 'pdl1 inhibitor']",[],[],[],[],['resectable'],,Low,1
6423,A phase II study of atezolizumab combined with cisplatin and vinorelbine as adjuvant therapy for completely resected non-small cell lung cancer with EGFR mutation (WJOG11719L: ADJUST study).,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Publication Only,['non-small cell lung cancer'],['resectable non-small cell lung cancer'],"['pdl1 inhibitor', 'microtubule inhibitor', 'alkylating agent']","['atezolizumab', 'vinorelbine', 'cisplatin']",[],[],[],['resectable'],,Low,1
6425,Comparison of induction chemoimmunotherapy with surgery and concurrent chemoradiation followed by immunotherapy for potentially resectable stage III non-small-cell lung cancer: A retrospective study.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Publication Only,['non-small cell lung cancer'],['resectable stage iii non-small cell lung cancer'],[],[],[],[],[],"['stage iii', 'resectable']",,Low,1
6432,Survival outcomes in locally advanced inoperable NSCLC patients converted to resectable disease by neoadjuvant therapy.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Publication Only,"['non-small cell lung cancer', 'thoracic cancers']","['locally advanced non-small cell lung cancer', 'resectable thoracic cancer']",[],[],[],[],[],"['resectable', 'locally advanced']",,Low,1
6433,Real-world treatment patterns in stage III ALK+ NSCLC patients in China: A multicenter retrospective study.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Publication Only,['non-small cell lung cancer'],['stage iii alk-positive non-small cell lung cancer'],[],[],[],[],[],"['stage iii', 'alk-positive']",,Low,1
6435,Prevalence of EGFR mutations in non-small cell lung cancer in Hawaii: A multi-center epidemiology study.,"Prevention, Risk Reduction, and Genetics",Publication Only,['non-small cell lung cancer'],['egfr-mutant non-small cell lung cancer'],[],[],[],[],[],['egfr mutated'],,Low,1
6436,Transforming data management in clinical trials: Uncovering CRC pain points through user research.,Medical Education and Professional Development,Publication Only,['colorectal cancer'],['colorectal cancer'],[],[],[],[],[],[],,Low,1
6437,Evaluating inflammatory biomarkers as predictors of outcomes and immune-related adverse events (irAE) in the Big Ten Cancer Research Consortium (BTCRC) LUN16-081 phase II clinical trial.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Publication Only,"['lung cancer', 'non-small cell lung cancer', 'thoracic cancers']","['lung cancer', 'non-small cell lung cancer', 'thoracic cancer']",[],[],[],[],['bristol-myers squibb'],[],,Low,1
6439,Magnetic resonance imaging‚Äìbased deep learning for predicting EGFR mutations in metastatic non-small cell lung cancer: A systematic review and meta-analysis.,Central Nervous System Tumors,Publication Only,['non-small cell lung cancer'],['egfr-mutant metastatic non-small cell lung cancer'],[],[],[],[],[],"['egfr mutated', 'metastatic']",,Low,1
5369,"Real-world evaluation of a ‚Äúhyperselection‚Äù predictive biomarker for anti-EGFR therapy benefit in patients with RAS/RAF wild-type, MMRp/MSS mCRC.",Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['ras/raf wild type mismatch repair proficient microsatellite stable metastatic colorectal cancer'],['egfr targeted therapy'],[],[],[],[],"['raf wild-type', 'microsatellite stable', 'metastatic']",,Medium,1
6476,"Mortality trends in metabolic syndrome and colorectal, endometrial, and breast cancers in the US (1999‚Äì2020).",Care Delivery/Models of Care,Publication Only,"['colorectal cancer', 'metabolic syndrome', 'endometrial cancer']","['colorectal cancer', 'metabolic syndrome', 'endometrial cancer']",[],[],[],[],[],[],,Low,1
5385,Prevalence and characteristics of KRAS-G12D mutations in patients with solid malignancies.,Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology,Publication Only,['cancer'],['kras-g12d mutated solid malignancy'],[],[],[],[],[],[],,Medium,1
5753,"Preliminary results of fruquintinib in combination with FOLFIRI as second-line treatment for RAS-mutant metastatic colorectal cancer: A prospective, single-center phase 2 study.",Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['second-line ras-mutant metastatic colorectal cancer'],"['nucleoside metabolic inhibitor', 'folic acid analog', 'top1 inhibitor', 'vegf inhibitor']","['fruquintinib', 'folfiri ']",[],[],['hutchison medipharma'],"['second-line', 'ras-mutated', 'metastatic']",,Medium,1
6567,Diagnostic and prognostic applications of blood cadherin-17 (CA17) and CA19.9 on pancreatic cancer.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic cancer'],['pancreatic cancer'],[],[],[],[],[],[],,Low,1
6568,Clinical and molecular outcomes of gastrointestinal malignancies treated with early phase studies: A retrospective single-center experience.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,"['gastro-esophageal cancer', 'pancreatic cancer', 'hepatobiliary cancer']","['gastroesophageal cancer', 'pancreatic cancer', 'hepatobiliary cancer']",[],[],[],[],[],[],,Low,1
6580,The association of obesity in hospitalized pancreatic cancer patients: A nationwide analysis.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,"['pancreatic cancer', 'hepatobiliary cancer', 'obesity']","['pancreatic cancer', 'hepatobiliary cancer', 'obesity']",[],[],[],[],[],[],,Low,1
6585,Racial disparities in major adverse cardiovascular and cerebrovascular events and healthcare resource utilization in patients with pancreatic cancer.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic cancer'],['pancreatic cancer'],[],[],[],[],[],[],,Low,1
6610,"The role of LYCAT in EGFR-TKI resistance, NSCLC progression, and smoking-induced lung cancer.",Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Publication Only,"['non-small cell lung carcinoma', 'lung cancer']","['progressive non-small cell lung carcinoma', 'smoking induced lung cancer']",[],[],[],[],[],['progressive'],,Low,1
6613,Paraneoplastic syndromes in non-small cell lung carcinoma: A systematic review of case reports and case series.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Publication Only,"['non-small cell lung carcinoma', 'paraneoplastic syndrome']","['non small cell lung carcinoma', 'paraneoplastic syndrome']",[],[],[],[],[],[],,Low,1
6618,Use of STAMP-seq to enable spatial transcriptomics through single-nucleus in situ tagging and exploration of relationship of dynamic plasma cell modules and immunotherapy response in non-small cell lung cancer..,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Publication Only,['non-small cell lung cancer'],['non small cell lung cancer'],[],[],[],[],['seekgene biosciences'],[],,Low,1
6628,Concurrent chemoradiotherapy in locally advanced lung cancer with cisplatin-etoposide or carboplatin-paclitaxel: An institutional analysis.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Publication Only,"['non-small cell lung cancer', 'thoracic cancers']","['locally advanced non small cell lung cancer', 'thoracic cancer']","['top2 inhibitor', 'microtubule inhibitor', 'alkylating agent']","['paclitaxel', 'cisplatin', 'carboplatin', 'etoposide']",[],[],[],['locally advanced'],,Low,1
6630,A quality initiative focused on biomarker testing in stage IB-IIIA resected and stage IV non-small cell lung cancer patients.,Care Delivery/Models of Care,Publication Only,['non-small cell lung cancer'],['stage ib-iiia resectable stage iv non-small cell lung cancer'],[],[],[],[],[],"['resectable', 'metastatic', 'stage ib']",,Low,1
5850,Impact of KRAS mutation status on outcomes in peritoneal metastatic mucinous adenocarcinoma of the colon and appendix following CRS-HIPEC: A retrospective analysis.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,"['adenocarcinoma', 'colorectal adenocarcinoma']","['kras-mutant peritoneal metastatic colorectal adenocarcinoma', 'kras-mutant peritoneal metastatic appendice adenocarcinoma']",[],[],[],[],[],"['kras mutant', 'metastatic']",,Medium,1
5921,Prevalence of PD-L1 expression and RAS mutations and association with overall survival in metastatic colorectal cancer patients.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['metastatic colorectal cancer'],[],[],[],[],['merck'],['metastatic'],,Medium,1
6673,Effectiveness and safety of the amivantamab to lazertinib versus lazertinib alone in EGFR mutant metastatic non-small-cell lung cancer: Systematic review and meta-analysis.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['egfr-mutated metastatic non-small cell lung cancer'],"['egfr inhibitor', 'egfr/met bispecific antibody']","['amivantamab', 'lazertinib']",[],['lazertinib'],[],"['egfr mutated', 'metastatic']",,Low,1
6675,The EGFR-TKIs treatment challenge in NSCLC: Changes in survival after COVID-19 infection.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,"['non-small cell lung cancer', 'coronavirus infection']","['covid-19', 'non-small cell lung cancer']",['egfr tyrosine kinase inhibitor'],[],[],[],[],[],,Low,1
6684,Evaluating the impact of COPD exacerbations on survival outcomes in non-small cell lung cancer patients receiving immunotherapy: A retrospective cohort analysis.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,"['non-small cell lung cancer', 'pulmonary disease']","['chronic obstructive pulmonary disorder', 'metastatic non-small cell lung cancer']",[],[],[],[],[],['metastatic'],,Low,1
6689,Exploring molecular resistance mechanisms in therapy na√Øve NSCLC patients: A retrospective 2 year Indian study.,Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology,Publication Only,['non-small cell lung cancer'],['naive non-small cell lung cancer'],[],[],[],[],[],[],,Low,1
6697,Lorlatinib in TKI-na√Øve patients with advanced ALK-positive non-small cell lung cancer (NSCLC) from India.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['advanced alk-positive non-small cell lung cancer'],['alk/ros1 inhibitor'],['lorlatinib'],[],[],['pfizer'],"['advanced', 'alk-positive']",,Low,1
6701,Dynamic combined monitoring of SII and PNI in evaluating the prognostic impact on advanced driver gene‚Äìnegative NSCLC patients receiving immunotherapy.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['advanced driver gene negative non-small cell lung cancer'],[],[],[],[],[],['advanced'],,Low,1
6710,NTRK1-3 point mutations in non-small cell lung cancer: Molecular profiling.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['ntrk1-3 point-mutant non-small cell lung cancer'],[],[],[],[],[],[],,Low,1
6714,Quantifying clinical harm and financial waste from failure to deploy personalized medicine for patients with metastatic non-small cell lung cancer in the United States.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['metastatic non-small cell lung cancer'],[],[],[],[],"['illumina', 'thermo fisher']",['metastatic'],,Low,1
6718,"A phase 2 study of CBDCA + PEM + pembrolizumab in elderly (‚â•75 yrs) patients with advanced non-Sq, NSCLC.",Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['elderly advanced non-small cell lung cancer'],"['pd1 inhibitor', 'nucleic acid biosynthesis inhibitor', 'alkylating agent']","['pembrolizumab', 'pemetrexed', 'carboplatin']",[],[],[],"['advanced', 'elderly']",,Low,1
6720,Seasonal impact of anti‚ÄìPD-1 treatment initiation in non-small cell lung cancer patients.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['metastatic non-small cell lung cancer'],['pd1 inhibitor'],[],[],[],[],['metastatic'],,Low,1
6724,Bridging the gap: Palliative care outcomes in academic versus community centers for advanced non-small cell lung cancer patients.,Quality Care/Health Services Research,Publication Only,['non-small cell lung cancer'],['advanced non small cell lung cancer'],[],[],[],[],[],['advanced'],,Low,1
6725,Real-world data on the management of potentially resectable stage IB-IIIA non-small cell lung cancer (NSCLC) in the United Kingdom (UK) in 2023: Early adoption of immune checkpoint inhibitors (ICIs).,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['resectable stage ib/iiia non-small cell lung cancer'],['immune checkpoint inhibitor'],[],[],[],[],"['resectable', 'stage ib']",,Low,1
6730,Co-mutations in non small cell lung cancer: Real-world data and clinical insights from a tertiary care centre in western India.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['metastatic non small cell lung cancer'],[],[],[],[],[],['metastatic'],,Low,1
6733,Efficacy and safety of nivolumab and docetaxel combination therapy versus nivolumab monotherapy for the treatment of advanced non-small cell lung cancer: A systematic review and meta-analysis.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['advanced non-small cell lung cancer'],"['pd1 inhibitor', 'taxane']","['nivolumab', 'docetaxel']",[],['nivolumab'],[],['advanced'],,Low,1
6736,A retrospective observational analysis examining liquid biopsies with tissue biopsies in patients with advanced non-small cell lung cancer.,Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology,Publication Only,['non-small cell lung cancer'],['advanced non small cell lung cancer'],[],[],[],[],[],['advanced'],,Low,1
6737,Genomic profiles and treatment outcomes in young adults with stage IV non-small cell lung cancer (NSCLC): Insights from the Middle East.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['young adult stage iv non-small cell lung cancer'],[],[],[],[],[],"['young adult', 'metastatic']",,Low,1
5933,NGS testing for patient selection in left-sided RAS/BRAF wild-type metastatic colorectal cancer receiving anti-EGFR therapy.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,"['colorectal cancer', 'anal cancer']","['ras/braf wild type metastatic colorectal cancer', 'anal cancer']",['egfr targeted therapy'],[],[],[],[],"['braf wild-type', 'metastatic']",,Medium,1
6742,Design of a phase 1 trial of Listeria monocytogenes 11-T856-1313 tetanus toxoid (Lm-LLO-TT) for pancreatic ductal adenocarcinoma (PDAC).,Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology,Publication Only,['pancreatic ductal adenocarcinoma'],['pancreatic ductal adenocarcinoma'],['listeria monocytogenes 11 t856 1313 tetanus toxoid therapy'],[],[],[],['loki therapeutics'],[],,Low,1
6743,Elucidating contributions to burden of disease in CNS progression for EGFR+ NSCLC.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],"['central nervous system progression', 'egfr-positive non-small cell lung cancer']",[],[],[],[],[],[],,Low,1
6744,Obesity paradox in non-small cell lung cancer (NSCLC) patients on immune checkpoint inhibitors: Real-world evidence using the global collaborative network database.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['non small cell lung cancer'],[],[],[],[],[],[],,Low,1
6745,Molecular characteristics of non-small cell lung cancer in Venezuela: A multicenter study.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['metastatic non-small cell lung cancer'],[],[],[],[],[],['metastatic'],,Low,1
6753,Real-world survival data analysis in EGFR-mutated NSCLC patients.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['egfr-mutant non-small cell lung cancer'],[],[],[],[],[],['egfr mutated'],,Low,1
6757,Intra/intertumoral heterogeneity assessed by blood-based next generation sequencing (NGS) to predict inferior survival outcome compared to intratumoral heterogeneity assessed by tissue-based NGS in advanced stage non-small cell lung cancer (NSCLC).,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['advanced stage non-small cell lung cancer'],[],[],[],[],[],['advanced'],,Low,1
6760,Effects of the COVID-19 pandemic on staging and treatment patterns in non-small cell lung cancer: A large national study.,Quality Care/Health Services Research,Publication Only,"['non-small cell lung cancer', 'coronavirus infection']","['covid-19', 'non-small cell lung cancer']",[],[],[],[],[],[],,Low,1
6762,Differential patterns of cell surface marker expression in clinically relevant subgroups of non-small cell lung cancer.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['metastatic non-small cell lung cancer'],[],[],[],[],[],['metastatic'],,Low,1
6763,Patterns of second-line treatment in patients with NSCLC and targetable mutations.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['second line non-small cell lung cancer'],[],[],[],[],[],['second-line'],,Low,1
6766,The impact of obesity on survival in non-small cell lung cancer patients receiving immune checkpoint inhibitor therapy: A retrospective multi-institutional US cohort study.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['non-small cell lung cancer'],[],[],[],[],[],[],,Low,1
6768,Enhancing team efficiency for genetic risk assessment: Medical oncology-led germline testing for pancreatic cancer.,Quality Care/Health Services Research,Publication Only,['pancreatic cancer'],['pancreatic cancer'],[],[],[],[],[],[],,Low,1
6769,Molecular and clonal evolution of primary lesions vs brain metastasis of EGFR-mutated NSCLC: A retrospective cohort study.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,"['secondary brain cancer', 'non-small cell lung cancer']","['brain metastasis', 'egfr-mutant non-small cell lung cancer']",[],[],[],[],[],['egfr mutated'],,Low,1
6770,Efficacy and safety of durvalumab plus tremelimumab versus standard chemotherapy for non-small cell lung cancer: A systematic review and meta-analysis of phase III randomized controlled trials.,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['metastatic non-small cell lung cancer'],"['ctla4 inhibitor', 'pdl1 inhibitor']","['durvalumab', 'tremelimumab']",[],[],[],['metastatic'],,Low,1
5964,Outcomes with targeted therapy for NRAS-mutated melanoma: A systematic review and meta-analysis.,Melanoma/Skin Cancers,Publication Only,['melanoma'],['nras-mutated melanoma'],[],[],[],[],[],['nras-mutated'],,Medium,1
6778,Impact of periodontal microbiome on response to immunotherapy in patients with advanced non-small cell lung cancer (NSCLC).,Lung Cancer - Non - Small Cell Metastatic,Publication Only,['non-small cell lung cancer'],['advanced non-small cell lung cancer'],[],[],[],[],[],['advanced'],,Low,1
6794,Real-life use of G-CSF in non-small cell lung cancer (NSCLC): Secondary data analysis from the French national cohorts KBP-ESCAP-2020-CPHG.,Symptom Science and Palliative Care,Publication Only,['non-small cell lung cancer'],['non-small cell lung cancer'],['leukocyte growth factor'],['granulocyte colony-stimulating factor'],[],[],['chugai pharma'],[],,Low,1
6502,Frequency of RAS family gene mutations in metastatic solid tumors in Venezuela: Experience at a large academic center.,Care Delivery/Models of Care,Publication Only,['solid tumor'],['ras family gene-mutant metastatic solid tumor'],[],[],[],[],[],['metastatic'],,Medium,1
6656,Survival outcomes and therapy response in RAS-mutated myeloid malignancies.,"Hematologic Malignancies - Leukemia, Myelodysplastic Syndromes, and Allotransplant",Publication Only,['myeloid malignancy'],['ras-mutated myeloid malignancy'],[],[],[],[],[],['ras-mutated'],,Medium,1
6826,"Clinical characteristics, molecular landscape and survival outcomes of metastatic pancreatic cancer from western India.","Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic cancer'],['metastatic pancreatic cancer'],[],[],[],[],[],['metastatic'],,Low,1
6857,Socioeconomic disparities in pancreatic cancer treatment: The role of pre-diagnosis healthcare utilization.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic cancer'],['pancreatic cancer'],[],[],[],[],[],[],,Low,1
6865,Trends in cardiovascular disease mortality among pancreatic cancer patients in the US (1999‚Äì2023): Uncovering hidden comorbidities and their impact.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,"['pancreatic cancer', 'cardiovascular disease']","['pancreatic cancer', 'cardiovascular disease']",[],[],[],[],[],[],,Low,1
6879,Clinical and molecular features of early-onset metastatic pancreatic cancer and their impact on therapeutic sequences: A multicenter study.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic cancer'],['early onset metastatic pancreatic cancer'],[],[],[],[],[],"['early onset', 'metastatic']",,Low,1
6881,Hypertension and VEGF-A level correlation in cancer patients starting VEGF inhibitors: A prospective study.,Genitourinary Cancer - Kidney and Bladder,Publication Only,"['bladder cancer', 'hypertension', 'colorectal cancer']","['bladder cancer', 'hypertension', 'colorectal cancer']",['vegf inhibitor'],[],[],[],[],[],,Low,1
6899,National trends in incidence of pancreatic cancer among adults aged 70 and older across 204 nations: A global burden of disease study (1990‚Äì2021).,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic cancer'],['adult pancreatic cancer'],[],[],[],[],[],['adult'],,Low,1
6936,Tislelizumab with anlotinib and chemotherapy for second-line treatment of pancreatic ductal adenocarcinoma: A phase II clinical trial.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic ductal adenocarcinoma'],['second-line pancreatic ductal adenocarcinoma'],"['pd1 inhibitor', 'vegfr inhibitor']","['tislelizumab', 'anlotinib']",[],[],[],['second-line'],,Low,1
6956,Accuracy of early detection of pancreatic cancer using cfDNA methylation marker ZFP30.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic cancer'],['pancreatic cancer'],[],[],[],[],[],[],,Low,1
6960,National trends in mortality of pancreatic cancer in adults aged 70 and older across 204 nations: A global burden of disease analysis (1990‚Äì2021).,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Publication Only,['pancreatic cancer'],['adult pancreatic cancer'],[],[],[],[],[],['adult'],,Low,1
6961,Clinical characteristics and treatment outcomes of colorectal cancer in a resource-restricted country.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,"['anal cancer', 'colorectal cancer']","['colorectal cancer', 'anal cancer']",[],[],[],[],[],[],,Low,1
6962,Trends in colorectal cancer and iron deficiency anemia‚Äìrelated mortality in the United States: A nationwide retrospective analysis over 24 years.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,"['colorectal cancer', 'iron deficiency anemia']","['colorectal cancer', 'analytic iron deficiency anemia']",[],[],[],[],[],[],,Low,1
6966,Prediction of sotorasib response duration and identification of clinically actionable resistance mechanisms using an RNA- and machine learning‚Äìbased patient classifier.,Care Delivery/Models of Care,Publication Only,['cancer'],['cancer'],['kras g12c inhibitor'],['sotorasib'],[],[],"['tempus', 'genialis']",[],,Medium,1
6968,Diagnostic value of septin-9 methylation assay in the diagnosis of early-stage colorectal cancer and high-grade intraepithelial neoplasia: A systematic review and meta-analysis.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,"['cancer', 'colorectal cancer']","['high grade intraepithelial neoplasia', 'early stage colorectal cancer']",[],[],[],[],[],"['early-stage', 'high-grade']",,Low,1
6978,Outcomes of patients with technically resectable stage III non-small cell lung cancer treated with concurrent chemoradiation followed by durvalumab consolidation.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Publication Only,['non-small cell lung cancer'],['resectable stage iii non-small cell lung cancer'],['pdl1 inhibitor'],['durvalumab'],[],[],[],"['stage iii', 'resectable']",,Low,1
6979,Trends in small cell lung cancer incidence and projections of future burden through 2050.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Publication Only,"['non-small cell lung cancer', 'small-cell lung cancer']","['non small cell lung cancer', 'small-cell lung cancer']",[],[],[],[],[],[],,Low,1
6981,Optimizing chemotherapy decisions in low-resource settings with deep learning: A novel approach for unresectable NSCLC.,Care Delivery/Models of Care,Publication Only,['non-small cell lung cancer'],['unresectable non-small cell lung cancer'],[],[],[],[],[],['unresectable'],,Low,1
6999,Effect of carotuximab (ENV105)-mediated CD105 blockade on osimertinib sensitivity in EGFR-mutant non-small cell lung cancer persister cells.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Publication Only,['non-small cell lung cancer'],['egfr-mutant non-small cell lung cancer'],"['egfr inhibitor', 'endoglin targeted antibody', 'cd105 inhibitor']","['osimertinib', 'carotuximab']",[],[],[],['egfr mutated'],,Low,1
7057,Evaluating artificial intelligence (AI) as a clinical decision support tool for lung cancer treatment recommendations.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Publication Only,"['non-small cell lung cancer', 'small-cell lung cancer']","['local non small cell lung cancer', 'regional non small cell lung cancer', 'small cell lung cancer']",[],[],[],[],[],[],,Low,1
7058,Targeting HER3 in NSCLC: Leveraging continuing education to bridge the gaps between evidence and practice.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Publication Only,['non-small cell lung cancer'],"['non-small cell lung cancer', 'her3 non-small cell lung cancer']",['her3 targeted agent'],[],[],[],[],[],,Low,1
7062,Postoperative radiotherapy and survival outcomes in pN2 non-small-cell lung cancer with positive surgical margins: An updated review of the National Cancer Database.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Publication Only,['non-small cell lung cancer'],['pn2 non-small cell lung cancer'],[],[],[],[],[],[],,Low,1
7078,What's weight got to do with it? In-hospital outcomes in colorectal cancer patients with and without obesity: An NIS analysis.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,"['anal cancer', 'colorectal cancer', 'obesity']","['colorectal cancer', 'obesity', 'anal cancer']",[],[],[],[],[],[],,Low,1
7084,Overcoming barriers to colorectal cancer screening and research enrollment by minoritized and underinsured populations.,Care Delivery/Models of Care,Publication Only,['colorectal cancer'],['colorectal cancer'],[],[],[],[],[],[],,Low,1
7088,Efficacy of trastuzumab and trastuzumab adjunct chemotherapy HER2 amplified colorectal cancer: A systematic review and meta-analysis.,Gastrointestinal Cancer - Colorectal and Anal,Publication Only,['colorectal cancer'],['her2 amplified colorectal cancer'],['her2 targeted therapy'],['trastuzumab'],[],[],[],['her2-amplified'],,Low,1
7101,Impact of inflammatory bowel disease on outcomes of colorectal cancer patients undergoing open resection.,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,"['colorectal cancer', 'inflammatory bowel disease']","['colorectal cancer', 'inflammatory bowel disease']",[],[],[],[],[],[],,Low,1
7103,A phase II study of encorafenib and cetuximab (EC) beyond progression in combination with FOLFIRI in BRAF V600E-mutated metastatic colorectal cancer (mCRC).,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['braf v600e-mutated metastatic colorectal cancer'],"['nucleoside metabolic inhibitor', 'braf inhibitor', 'egfr inhibitor', 'folic acid analog', 'top1 inhibitor']","['cetuximab', 'folfiri', 'encorafenib']",[],[],[],"['braf v600e-mutant', 'metastatic']",,Low,1
7109,Machine learning‚Äìinformed navigation of patients in persistent poverty zip codes to improve colorectal cancer screening: A prospective controlled study.,"Prevention, Risk Reduction, and Genetics",Poster Session,['colorectal cancer'],['colorectal cancer'],[],[],[],[],[],[],,Low,1
7113,Initial treatment and survival outcomes for early-stage NSCLC in Veterans: Insights from cancer cube data.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Poster Session,['small-cell lung cancer'],['early-stage non-small-cell lung cancer'],[],[],[],[],[],['early-stage'],,Low,1
7114,Survival of induction aumolertinib followed by aumolertinib and concurrent radiotherapy (RT) in unresectable EGFR-mutated stage III NSCLC: Final analysis of the phase III ADVANCE trial and real-world data.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Poster Session,['small-cell lung cancer'],['egfr-mutated stage iii non-small-cell lung cancer'],"['radiotherapy', 'egfr inhibitor']",['aumolertinib'],[],[],[],"['egfr mutated', 'stage iii']",,Low,1
7119,"A global phase 2/3, randomized, open-label trial of BNT327/PM8002 in combination with chemotherapy (chemo) in first-line (1L) non-small cell lung cancer (NSCLC).",Lung Cancer - Non - Small Cell Metastatic,Poster Session,['small-cell lung cancer'],['first-line non-small-cell lung cancer'],['pdl1/vegf alpha bispecific antibody'],['pm8002/bnt327'],[],[],['biontech'],['first-line'],,Low,1
7140,Acoustic biomarkers and AI: Transforming NSCLC detection and personalized care.,Care Delivery/Models of Care,Poster Session,['small-cell lung cancer'],['non-small-cell lung cancer'],[],[],[],[],[],[],,Low,1
7142,Real world treatment patterns and outcomes in metastatic EGFR mutation‚Äìpositive NSCLC patients: A retrospective study from a tertiary care cancer center in India.,Care Delivery/Models of Care,Poster Session,['small-cell lung cancer'],['egfr mutation‚Äìpositive non-small-cell lung cancer'],[],[],[],[],[],['egfr mutated'],,Low,1
7163,Claudin18.2 (CLDN18.2) expression and efficacy in pancreatic ductal adenocarcinoma (PDAC): Results from a phase I dose expansion cohort evaluating IBI343.,"Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Rapid Oral Abstract Session,['pancreatic ductal adenocarcinoma'],['pancreatic ductal adenocarcinoma'],['claudin18.2 antibody drug conjugate'],['ibi343'],[],[],['innovent biologics'],[],,Low,1
7183,MODULE 1: Evolving First-Line Treatment for Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer (NSCLC),Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Clinical Care of Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer,Ancillary Educational Events,['non-small cell lung cancer'],['first-line metastatic egfr mutated-positive non-small cell lung cancer'],[],[],[],[],[],"['egfr mutated', 'first-line', 'metastatic']",,Low,1
7184,MODULE 2: EGFR-Targeted Approaches for Relapsed EGFR-Mutant NSCLC; Strategies to Facilitate Delivery of Recently Approved Agents,Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Clinical Care of Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer,Ancillary Educational Events,['non-small cell lung cancer'],['relapsed egfr-mutated non-small cell lung cancer'],['egfr targeted therapy'],[],[],[],[],"['egfr mutated', 'relapsed']",,Low,1
7185,MODULE 6: Emerging Role of HER3-Targeted Therapy in the Management of EGFR-Mutant NSCLC,Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Clinical Care of Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer,Ancillary Educational Events,['non-small cell lung cancer'],['egfr-mutated non-small cell lung cancer'],['her3 targeted therapy'],[],[],[],[],['egfr mutated'],,Low,1
7186,MODULE 3: Potential Utility of TROP2-Targeted Therapy in the Management of EGFR-Mutant NSCLC,Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Clinical Care of Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer,Ancillary Educational Events,['non-small cell lung cancer'],['egfr-mutated non-small cell lung cancer'],['trop2 targeted therapy'],[],[],[],[],['egfr mutated'],,Low,1
7187,MODULE 4: Contemporary Care for Patients with Nonmetastatic EGFR-Mutant NSCLC,Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Clinical Care of Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer,Ancillary Educational Events,['non-small cell lung cancer'],['non-metastatic egfr-mutated non-small cell lung cancer'],[],[],[],[],[],"['non-metastatic', 'egfr mutated']",,Low,1
7188,MODULE 5: Current and Future Management of EGFR Exon 20 Mutation-Positive NSCLC,Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Clinical Care of Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer,Ancillary Educational Events,['non-small cell lung cancer'],['egfr exon 20 mutated-positive non-small cell lung cancer'],[],[],[],[],[],['egfr exon 20 mutated'],,Low,1
7192,Reprogramming the Tumor Microenvironment for Pancreatic Cancer Immunotherapy: Challenges and Opportunities,Advances in Cancer Immunotherapy: Translating Discoveries into Clinical Applications,Ancillary Educational Events,['pancreatic cancer'],['pancreatic cancer'],[],[],[],[],[],[],,Low,1
7205,MODULE 1: Role of Circulating Tumor DNA (ctDNA) Evaluation in Nonmetastatic Colorectal Cancer,Cases from the Community: Investigators Discuss Available Research Guiding the Care of Patients with Colorectal Cancer,Ancillary Educational Events,['colorectal cancer'],['non-metastatic colorectal cancer'],[],[],[],[],[],['non-metastatic'],,Low,1
7206,MODULE 2: Role of Immune Checkpoint Inhibitors in the Management of Nonmetastatic Microsatellite Instability-High (MSI-H) CRC,Cases from the Community: Investigators Discuss Available Research Guiding the Care of Patients with Colorectal Cancer,Ancillary Educational Events,['colorectal cancer'],['non-metastatic msi-high colorectal cancer'],['immune checkpoint inhibitor'],[],[],[],[],"['non-metastatic', 'msi-h']",,Low,1
7207,MODULE 3: Management of Oligometastatic Disease and Hepatic-Only Metastases in CRC; Role of ctDNA Evaluation in Metastatic Disease,Cases from the Community: Investigators Discuss Available Research Guiding the Care of Patients with Colorectal Cancer,Ancillary Educational Events,['colorectal cancer'],"['colorectal cancer', 'hepatic-only metastases', 'oligometastatic disease']",[],[],[],[],[],['oligometastatic'],,Low,1
7208,MODULE 4: Role of Immune Checkpoint Inhibitors in the Management of MSI-H Metastatic CRC (mCRC),Cases from the Community: Investigators Discuss Available Research Guiding the Care of Patients with Colorectal Cancer,Ancillary Educational Events,['colorectal cancer'],['msi-high metastatic colorectal cancer'],['immune checkpoint inhibitor'],[],[],[],[],"['msi-h', 'metastatic']",,Low,1
7209,MODULE 5: Identification and Care of Patients with mCRC and Actionable Genomic Alterations,Cases from the Community: Investigators Discuss Available Research Guiding the Care of Patients with Colorectal Cancer,Ancillary Educational Events,['colorectal cancer'],['metastatic colorectal cancer'],[],[],[],[],[],['metastatic'],,Low,1
7210,Later-Line Treatment for mCRC,Cases from the Community: Investigators Discuss Available Research Guiding the Care of Patients with Colorectal Cancer,Ancillary Educational Events,['colorectal cancer'],['later-line metastatic colorectal cancer'],[],[],[],[],[],['metastatic'],,Low,1
7232,Precision Medicine in mCRC: Mastering the Application of Testing to Personalize Treatments for Better Patient Outcomes,Med Learning Group,Ancillary Educational Events,['colorectal cancer'],['metastatic colorectal cancer'],[],[],[],[],[],['metastatic'],,Low,1
7244,Hypofraction radiotherapy followed by immune checkpoint inhibitors for locally advanced non-small cell lung cancer: A phase I/II trial.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Poster Session,['non-small cell lung cancer'],['locally advanced non-small cell lung cancer'],['immune checkpoint inhibitor'],[],[],[],[],['locally advanced'],,Low,1
7245,Clinical outcomes with definitive surgery or radiotherapy after neoadjuvant immunochemotherapy in stage II-III NSCLC: Full cohort pragmatic analysis.,Lung Cancer - Non - Small Cell Local - Regional/Small Cell/Other Thoracic Cancers,Poster Session,['non-small cell lung cancer'],['stage ii/iii non-small cell lung cancer'],[],[],[],[],[],['stage ii'],,Low,1
7248,Analysis of genomic and immune microenvironment differences in Chinese populations: Revealing potential mechanisms of poor immunotherapy outcomes in patients with EGFR mutation and ALK fusion non-small cell lung cancer.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],"['egfr mutated non-small cell lung cancer', 'alk fusion non-small cell lung cancer']",[],[],[],[],[],['egfr mutated'],,Low,1
7249,RC108 in combination with furmonertinib in patients with locally advanced or metastatic EGFR-mutated non-small-cell lung cancer (NSCLC) with MET overexpression: Results from a phase Ib/II trial.,Lung Cancer - Non - Small Cell Metastatic,Poster Session,['non-small cell lung cancer'],['met overexpressing locally advanced or metastatic egfr-mutated non-small cell lung cancer'],"['cmet antiody drug conjugate', 'egfr inhibitor']","['furmonertinib', 'rc108']",[],[],['remegen'],"['met-overexpressed', 'egfr mutated', 'locally advanced', 'metastatic']",,Low,1
7266,Tumour microbiome and immune dysregulation in early-onset colorectal cancer.,Gastrointestinal Cancer - Colorectal and Anal,Poster Session,['colorectal cancer'],['early-onset colorectal cancer'],[],[],[],[],[],['early onset'],,Low,1
7272,"Preliminary result of a phase Ib study: Efficacy and safety of FG-M108 plus gemcitabine and nab-paclitaxel in patients with Claudin18.2-positive, locally advanced, unresectable, or metastatic pancreatic cancer.","Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Poster Session,['pancreatic cancer'],['claudin18.2-positive locally advanced unresectable metastatic pancreatic cancer'],"['cldn18.2 targeted monoclonal antibody', 'microtubule inhibitor', 'nucleoside metabolic inhibitor']","['gemcitabine', 'fg-m108', 'nab-paclitaxel']",[],[],['futuregen biopharmaceutical'],"['locally advanced', 'metastatic', 'unresectable']",,Low,1
7274,"ALTER-PA001: A multicenter, randomized study of anlotinib and benmelstobart in combination with AG chemotherapy vs. AG as first-line treatment for metastatic pancreatic cancer.","Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary",Poster Session,['pancreatic cancer'],['first line metastatic pancreatic cancer'],"['pdl1 inhibitor', 'nucleoside metabolic inhibitor', 'tyrosine kinase inhibitor', 'microtubule inhibitor']","['gemcitabine', 'benmelstobart', 'anlotinib', 'nab-paclitaxel']",[],"['gemcitabine', 'nab-paclitaxel']",['chia tai tianqing pharmaceutical'],"['first-line', 'metastatic']",,Low,1
7292,Evaluation of longitudinal image-derived AI prognostication as a predictor of overall survival (OS) in a phase 3 advanced non-small cell lung cancer (aNSCLC) trial.,Care Delivery/Models of Care,Poster Session,['non-small cell lung cancer'],['advanced non-small cell lung cancer'],[],[],[],[],['bayer pharmaceuticals'],['advanced'],,Low,1
7321,Biological determinants of immune exclusion in non-small cell lung cancer: An analysis of the precision medicine BIP study.,Developmental Therapeutics - Immunotherapy,Poster Session,['non-small cell lung cancer'],['non-small cell lung cancer'],[],[],[],[],"['gsk', 'immusmol']",[],,Low,1
7333,Impact of sample characteristics on RNA-based next-generation sequencing (NGS) for fusion gene detection in non-small cell lung cancer (NSCLC).,Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology,Poster Session,['non-small cell lung cancer'],['non-small cell lung cancer'],[],[],[],[],['3dmed'],[],,Low,1
7337,MODULE 1: Role of Immune Checkpoint Inhibitors in Metastatic Non-Small Cell Lung Cancer (NSCLC) without a Targetable Tumor Mutation,Research To Practice ‚Äì Group Listing - Data + Perspectives: Clinical Investigators Discuss the Current and Future Role of Immunotherapy and Antibody-Drug Conjugates in Lung Cancer,Ancillary Educational Events,['non-small cell lung cancer'],['metastatic non-small cell lung cancer'],['immune checkpoint inhibitor'],[],[],[],[],['metastatic'],,Low,1
7338,MODULE 2: Targeted and Other Novel Therapeutic Strategies for Relapsed Metastatic NSCLC,Research To Practice ‚Äì Group Listing - Data + Perspectives: Clinical Investigators Discuss the Current and Future Role of Immunotherapy and Antibody-Drug Conjugates in Lung Cancer,Ancillary Educational Events,['non-small cell lung cancer'],['relapsed metastatic non-small cell lung cancer'],[],[],[],[],[],"['relapsed', 'metastatic']",,Low,1
7339,MODULE 3: Potential Role of TROP2-Targeted Antibody-Drug Conjugates in Advanced NSCLC,Research To Practice ‚Äì Group Listing - Data + Perspectives: Clinical Investigators Discuss the Current and Future Role of Immunotherapy and Antibody-Drug Conjugates in Lung Cancer,Ancillary Educational Events,['non-small cell lung cancer'],['advanced non-small cell lung cancer'],['trop2 antibody drug conjugate'],[],[],[],[],['advanced'],,Low,1
7340,MODULE 4: Evolving Role of Immune Checkpoint Inhibitors in the Care of Patients with Nonmetastatic NSCLC,Research To Practice ‚Äì Group Listing - Data + Perspectives: Clinical Investigators Discuss the Current and Future Role of Immunotherapy and Antibody-Drug Conjugates in Lung Cancer,Ancillary Educational Events,['non-small cell lung cancer'],['non-metastatic non-small cell lung cancer'],['immune checkpoint inhibitor'],[],[],[],[],['non-metastatic'],,Low,1
7358,MODULE 3: Colorectal Cancer,Research To Practice ‚Äì Group Listing - Data + Perspectives: Clinical Investigators Discuss the Current and Future Clinical Care of Patients with HER2-Positive Gastrointestinal Cancers,Ancillary Educational Events,['colorectal cancer'],['colorectal cancer'],[],[],[],[],[],[],,Low,1
7391,"PRAGMATICA-LUNG (SWOG S2302): A prospective, randomized study of ramucirumab plus pembrolizumab versus standard of care for participants previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer.",Lung Cancer - Non-Small Cell Metastatic,Rapid Oral Abstract Session,['non-small cell lung cancer'],"['stage iv non-small cell lung cancer', 'recurrent non-small cell lung cancer']","['vegfr2-inhibitor', 'pd1-inhibitor']","['ramucirumab', 'pembrolizumab']",[],[],"['eli lilly and company', 'merck']","['recurrent', 'metastatic']",,Low,1
